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Ischemic preconditioning (IPC) was initially developed as a protective technique 
against ischemia/reperfusion injuries, however it has since been employed as an 
ergogenic aid. Existing literature has demonstrated that IPC can elicit small ergogenic 
effects, which have been attributed to improved skeletal muscle oxygen delivery and 
extraction. However, recent studies have also suggested that IPC may augment neural 
drive, evidenced by improved surface electromyography (sEMG) signal parameters 
recorded concomitant to improved exercise performance. However, inferences made 
from sEMG measures warrant further investigation with more accurate assessments 
(i.e. interpolated twitch technique) in order to substantiate notions of augmented neural 
drive. Therefore, this thesis investigated the capacity of IPC to augment neural drive 
via central and peripheral mechanisms associated with sustaining neuromuscular 
function during exercise. 
 
Study 1 attempted to define any changes in neural drive that IPC may elicit following 
a sustained maximal isometric contraction. Whilst IPC improved skeletal muscle 
oxygen delivery and extraction, central and peripheral fatigue development remained 
unaffected. The use of an isometric exercise protocol in Study 1 may have inhibited any 
neural effects by preventing adequate muscle perfusion. Therefore, Study 2 utilised a 
maximal dynamic exercise protocol to assess the effect of IPC on neural drive. The 
addition of a dynamic exercise protocol made no impact on the capacity of IPC to 
augment neural drive. Furthermore, no benefits to oxygen delivery or extraction were 
observed throughout the exercise, suggesting the humoral benefits conferred by IPC 
may be more related to the impairment of tissue oxygenation imposed by the exercise. 
The final study (Study 3) of this thesis combined both dynamic exercise and tissue 
oxygenation deprivation (via hypoxia) in an attempt to create optimal conditions for 
observing an effect of IPC on neural drive. The use of hypoxia successfully 
demonstrated a relationship between impaired tissue oxygenation and the humoral 
benefits of IPC, however as previously observed, the capacity for IPC to elicit any 




This thesis suggests that IPC is unable to influence parameters of neural drive during 
and following maximal single limb isometric and dynamic exercise. However, the 
findings suggest a task-dependant relationship between the humoral benefits of IPC and 
the level of tissue deoxygenation imposed by the exercise. Overall, the cumulative body 
of work in this thesis provides novel insights into the relationship between IPC and 











Ischemic preconditioning (IPC) is a concept that has emerged from cardioprotective 
medicine into high performance sport science. It is characterised by the application of 
repeat cycles of ischemia and reperfusion (IR) prior to a subsequent prolonged ischemic 
episode. The transient repeat IR cycles enact a multitude of pro-survival effects within 
the targeted cells that work to defend the tissue against IR injury. Recently it has been 
found that these same pro-survival effects may also be utilised to benefit exercise 
performance.  
 
The IPC technique was initially recognized as a novel form of cardio-protection in 
Murry, Jennings, and Reimer (1986). Transient cycles of IR prior to a global ischemic 
event were found to enhance the tolerance of myocardial cells to subsequent ischemic 
events. In this study, canine myocardium were preconditioned with four 5-min IR 
periods before being subjected to 40 min of unimpeded ischemia. The preconditioned 
myocardium exhibited a ~75% reduction in post-ischemia cell infarction size compared 
to that untreated hearts. This technique demonstrated potential utility as a protective 
pre-surgical procedure. However, in its early stages, the invasive surgery required to 
perform arterial cross clamping was an impractical means of inducing the IR cycles. 
Fortunately, rapid technical and methodological advancement enabled the development 
of a less invasive strategy of remote IPC (RIPC) activation via the inflation of blood 
pressure cuffs around a limb (Birnbaum, Hale, & Kloner, 1997; Gho, Schoemaker, van 
den Doel, Duncker, & Verdouw, 1996; Kharbanda et al., 2001; Oxman, Arad, Klein, 
Avazov, & Rabinowitz, 1997; Przyklenk, Bauer, Ovize, Kloner, & Whittaker, 1993; 
Yellon, Alkhulaifi, & Pugsley, 1993). This has permitted a vast increase in the 
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possibilities for IPC research to be carried out in healthy human populations, both in 
clinical and exercise performance contexts. 
 
Initially the factor identified as the key to the protection of myocardial cells was the 
preservation of ATP content during the prolonged ischemic episodes (Murry et al., 
1986; Murry, Richard, Reimer, & Jennings, 1990). This was found to be crucial in 
avoiding the pathways leading to cell programmable cell death (apoptosis) and the 
disruption to endothelial function common in ischemic and reperfusion injuries 
respectively (Iliodromitis, Lazou, & Kremastinos, 2007).  In the years following Murry 
et al. (1986), the pathways leading to ATP preservation became the focal point of 
mechanistic research. Significant headway has since been made in elucidating the 
triggers, signal transduction pathways, mediators and end effectors that comprise the 
molecular mechanisms of IPC (Ertracht, Malka, Atar, & Binah, 2014). From this 
mechanism a number of pro-survival effects defending the targeted tissue against IR 
injury have been identified (D. J. Hausenloy & Yellon, 2016). These effects included 
reducing cellular energy demand, preserving mitochondrial respiration and better 
maintaining electrolyte homeostasis to attenuate ischemic injuries (Pasupathy & 
Homer-Vanniasinkam, 2005). Furthermore, IPC was also found to improve defence 
against reperfusion injuries via vasodilation induced by upregulated nitric oxide (NO), 
reductions in oxidative stress and reduced endothelial inflammation (Pasupathy & 
Homer-Vanniasinkam, 2005).  
 
In 2010 the potential for IPC to benefit exercise performance was investigated for the 
first time. The premise of the initial performance study of de Groot, Thijssen, Sanchez, 
Ellenkamp, and Hopman (2010) was based on the potential for IPC to enhance the 
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delivery of oxygen and metabolic substrates to the muscle in order to increase exercise 
capacity. A practical IPC protocol was improvised using blood pressure cuffs placed 
around the left and right thigh to induce three 5 min cycles of IR alternating between 
each leg for a total of 30 min (Bushell et al., 2002; Kharbanda et al., 2002; Saita, 
Yokoyama, Nakamura, & Itoman, 2002). When participants underwent this IPC 
procedure prior to the maximal incremental cycling test, maximal aerobic power and 
VO2max were improved by 1.6% and 2.6% respectively. At this time, de Groot et al. 
(2010) demonstrated the first successful use of IPC to enhance maximal exercise 
performance and in doing so, provided a methodological blueprint to be used in all 
subsequent IPC performance studies.  
 
Ischemic preconditioning has since been observed to elicit mainly small-moderate 
ergogenic effects across numerous exercise modalities (running, rowing, cycling, 
swimming, resistance exercise and speed skating) (Caru, Levesque, Lalonde, & 
Curnier, 2019; Salvador et al., 2016). The exercise protocols have ranged over vast time 
domains (<1 min to 140 min) and also intensities (sub-maximal, sustained high intensity 
and all-out effort) (Salvador et al., 2016). However, the body of performance research 
has shown significant variability in ergogenic effects. This variability seems to arise 
from a number of factors relating to both the subject cohort and the exercise protocols. 
Exercise intensity, duration, objectives, IPC protocol (timing), environmental factors 
and participant characteristics all appear to influence the efficacy of the procedure (Caru 
et al., 2019; Salvador et al., 2016). Ultimately, the variability of IPC efficacy can serve 
to highlight how current mechanistic understanding of IPC within a sporting context 
limits its applicability.  
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The observation of the physiological responses to IPC occurring concomitant to 
exercise enhancement have developed the understanding of how to best harness the pro-
survival effects of IPC for the benefit exercise performance. An array of humoral 
physiological responses has been documented thus far. Humoral physiological 
responses include improved vascular function (increased endothelial dilation, 
microvascular perfusion, reductions in endothelial inflammation) and metabolism 
(increased oxidative phosphorylation, lactate recycling, reduced oxidative stress, 
increased skeletal muscle oxygen extraction) (Andreas et al., 2011; Bailey, Birk, et al., 
2012; Barbosa et al., 2014; Jeffries, Waldron, Pattison, & Patterson, 2018; Kido et al., 
2015; Angus Lindsay et al., 2017; Paradis-Deschenes, Joanisse, & Billaut, 2016; 
Tanaka et al., 2016). Furthermore, there have also been observations of improved 
neuromuscular function, leading to inferences that IPC may also elicit neurally 
mediated ergogenic benefits (Cruz, de Aguiar, Turnes, Pereira, & Caputo, 2015).  
 
The neurally mediated ergogenic benefit is proposed to occur via an increase in muscle 
activation (Cruz et al., 2015; Cruz, de Aguiar, Turnes, Salvador, & Caputo, 2016; 
Durand et al., 2019; A. Hyngstrom, Schmit, Gutterman, & Durand, 2016; A. S. 
Hyngstrom et al., 2018). The molecular mechanism of IPC is known to utilise neural 
pathways in the signal transduction and triggering phases fatigue (Aulakh, Randhawa, 
Singh, & Jaggi, 2017; Endres-Becker et al., 2007; Light et al., 2008; Y. Liu, Sato, 
O'Rourke, & Marban, 1998; Luo, Liu, Dai, Yang, & Peng, 2013; Patel, Moore, Hsu, & 
Gross, 2002; Schultz, Hsu, & Gross, 1997a, 1997b). Metabolically sensitive group III 
and IV afferent fibres contribute to the triggering of IPC when they are stimulated by 
IR metabolites (Endres-Becker et al., 2007; Light et al., 2008; Luo et al., 2013). 
Subsequently, this interaction has been proposed to prolong neuromuscular function in 
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the severe exercise intensity domain via the alteration of afferent fibre sensitivity (Cruz, 
Pereira, Lisboa, & Caputo, 2017). The discharge of group III and IV afferents provides 
feedback to the CNS to help to regulate exercise intensity (Amann, 2011). The afferent 
signalling of metabolic perturbations to the CNS signals reductions in nervous output 
(neural drive) to the alpha motor neuron pools of the muscle to reduce muscle 
activation, a process known as centrally mediated (Gandevia, 2001; Gandevia, Allen, 
Butler, & Taylor, 1996). Thus, IPC-mediated reductions in afferent sensitivity would 
result in reduced afferent feedback, attenuating the development of central fatigue 
development (Hureau et al., 2019). This effect would then permit an “overshoot” in 
neural drive to the muscle, prolonging muscle activation throughout severe intensity 
exercise (Amann, Proctor, Sebranek, Pegelow, & Dempsey, 2009). However, this could 
then be at the cost of exacerbated peripheral fatigue development due to increased 
biochemical changes that inhibit muscle contractility (Nordlund, Thorstensson, & 
Cresswell, 2004). 
 
Increases in IPC-mediated muscle activation have been evidenced in increases in 
surface electromyography (sEMG) signal amplitudes during enhanced performances of 
maximal intensity cycling efforts (Cruz et al., 2015; Cruz et al., 2016; Cruz et al., 2017). 
Moreover, increased sEMG activity and muscular force output concomitant with 
lowered motor unit recruitment thresholds have also been observed during strength 
exercises (Durand et al., 2019; A. Hyngstrom et al., 2016; A. S. Hyngstrom et al., 2018). 
However, sEMG signals can provide only an estimation of gross motor output 
(Dimitrova & Dimitrov, 2003; Farina, 2006). Furthermore, among other issues 
affecting the composition of the signal, sEMG measures are unable to characterise 
changes in neural drive (De Luca, Gilmore, Kuznetsov, & Roy, 2010; Dimitrova & 
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Dimitrov, 2003; Farina, 2006; Farina, Holobar, Merletti, & Enoka, 2010). Although the 
neural pathway of IPC may be able to elicit ergogenic benefits by increasing muscle 
activation during intense exercise, current evidence requires validation from more 
accurate measures.  
 
The interpolated twitch technique can be used to observe the development of central 
fatigue without the fallacies associated with sEMG measures (Gandevia, 2001). By 
delivering a supramaximal electrical stimulus to the axons of the alpha motor neurons 
that innervate the muscle during a maximal effort, the voluntary activation (VA) of the 
muscle can be calculated (Merton, 1954; Strojnik & Komi, 1998). Reductions in 
muscular strength concomitant with declines in VA can then identify fatigue developing 
through central mechanisms (Doguet et al., 2016; Gandevia, 2001). The technique can 
also assess peripheral fatigue development through the assessing the contractile 
characteristics of an electrically evoked twitch at rest (Gandevia, 2001). Therefore, the 
use of the interpolated twitch technique can provide support to existing sEMG evidence 
of IPC-mediated increases in muscle activation by further characterising changes in 





Statement of the problem 
The use of IPC as an ergogenic aid is limited by the lack of mechanistic understanding 
restricting its effective application. A number of physiological responses relating to 
improved skeletal muscle oxygen delivery and extraction have been recorded 
concomitant to enhanced performance. However, the overall contributions of these 
physiological responses to performance enhancement is not well understood. 
Additionally, the potential for IPC to increase muscle activation may further complicate 
attempts to understand the mechanisms related to performance enhancement. 
 
The neural pathway of IPC has been proposed to prolong muscle activation throughout 
the severe intensity exercise domain. However, the current sEMG evidence is restricted 
from providing accurate insights into the nature of the neuromuscular modulation. As 
such, the capacity for IPC to increase muscle activation requires further validation by a 
more accurate means of assessment.  
 
Therefore, the primary focus of this research was to utilise the interpolated twitch 
technique to investigate the capacity for IPC to augment muscle activation during 
exercise by assessing parameters of central and peripheral fatigue development. By 
devising exercise models to exacerbate central and peripheral fatigue development, the 




General aims of the project 
The aim of this project was to investigate the capacity for IPC to elicit changes in 
nervous system output in the form of voluntary activation and muscle activation leading 
to ergogenic benefits. In this project, neuromuscular responses to IPC were assessed 
via the use of the interpolated twitch method as well as traditional methods such as 
sEMG and dynamometry measures. It is envisaged that this project would improve the 
understanding of the contribution that the neural pathway of IPC makes towards its 
ergogenic effects, thus improving its utility as an ergogenic aid. 
 
Specific aims of the project 
Study 1 (Chapter 3) 
Use the interpolated twitch technique in conjunction with sEMG alongside measures of 
tissue oxygenation to investigate the influence of IPC on the development of central 
and peripheral fatigue during sustained maximal isometric exercise. 
It was hypothesized that IPC could affect mechanisms associated with centrally 
mediated fatigue after a maximally fatiguing protocol. 
Study 2 (Chapter 4) 
Use the interpolated twitch technique in conjunction with sEMG alongside measures of 
tissue oxygenation to investigate the effect of IPC on the development of central and 
peripheral fatigue development during a dynamic exercise task designed to optimise 
oxygen delivery to skeletal muscle. 
It was hypothesised that the IPC-mediated increases in muscle oxygenation during a 
dynamic exercise task could subsequently attenuate exercise-induced centrally 
mediated fatigue. 
Study 3 (Chapter 5) 
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Use the interpolated twitch technique in conjunction with sEMG alongside measures of 
tissue and blood oxygenation to investigate the effect of exercising tissue oxygenation 
(modulated by changes in inspired oxygen fractions) on the capacity of IPC to influence 
mechanisms of central and peripheral fatigue. 
It was hypothesised that IPC would attenuate the magnitude of exercise-induced 
centrally mediated fatigue in both normoxic and hypoxic exercise, with the magnitude 




Structure of Thesis 
The research chapters of this thesis are comprised of three progressive experiments with 
each one informing the direction of the ensuing. All experiments have been published 
in peer-reviewed journals with the final articles and respective publication information 
included in the appendices of this document. However, the content of each research 
chapter represents the sole work of the student prior to co-author collaboration. 
 
List of Publications 
 
Halley, S. L., Marshall, P., & Siegler, J. C. (2018). The effect of IPC on central and 
peripheral fatiguing mechanisms in humans following sustained maximal isometric 
exercise. Exp Physiol. doi:10.1113/ep086981 
 
Halley, S. L., Marshall, P., & Siegler, J. C. (2019). The effect of IPC on central and 
peripheral fatiguing mechanisms in humans following maximal single limb isokinetic 
exercise. Physiological Reports, 7(8), e14063. doi:10.14814/phy2.14063 
 
Halley, S. L., Marshall, P., & Siegler, J. C. (2019). Effect of ischemic preconditioning 
and changing inspired O2 fractions on neuromuscular function during intense exercise. 











Ischemic preconditioning has been proposed to prolong muscle activation during 
maximal intensity exercise via an inhibition of central fatigue development. Therefore, 
the aim of study 1 was to define any changes in central fatigue development that IPC 
may elicit pre- and post- an exercise protocol. To do this, we selected a 2 min MVC 
exercise protocol to induce metabolic stress likely to result in high degrees of central 
fatigue. The use of an isometric contraction also implicated high degrees of 
intramuscular pressure and helped to distinguish neuromuscular modulations from 
known humoral responses. Then, using the interpolated twitch technique in association 
with sEMG and force output measures, we assessed the critical variables of voluntary 
activation and potentiated twitch torque. These variables gave us insight into the effect 
of IPC on the development of central fatigue. 
 
The results of study 1 showed that IPC failed to influence changes in both central and 
peripheral fatigue development following an isometric protocol. However, IPC did 
improve skeletal muscle O2 delivery and extraction, albeit without enhancing 
performance. Prior research reporting increased muscle activation did so using dynamic 
exercise protocols. As such, prior use of an isometric protocol may have limited the 
ergogenic potential of increased muscle oxygenation, potentially inhibiting the 
engagement of a neuromuscular modulation leading to increased muscle activation. 
Therefore, study 2 aimed to utilise an exercise protocol with consistent perfusion to 
maximise the benefits of any humoral adaptations in the attempt to elicit concomitant 
neuromuscular benefits. Accordingly, the exercise protocol was adapted into 135 (3 
min) dynamic isokinetic knee extensions. Using identical neuromuscular assessment 
methods as the previous chapter, this dynamic protocol with increased exercising tissue 
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perfusion was expected to enact the proposed increases in muscle activation associated 
with IPC. Furthermore, the humoral benefits observed in study 1 were expected to 
translate into ergogenic benefits with the progression from isometric to dynamic 
exercise. 
 
The findings of study 1 & 2 show that IPC failed to influence the development of 
central or peripheral fatigue in both isometric and dynamic exercise protocols. 
Interestingly though, IPC only elicited humoral benefits in the isometric protocol, 
suggestive of a task-dependant preference for exercises with greater localised tissue 
deoxygenation. As such, to combine both severe localised tissue deoxygenation and 
dynamic contractions, study 3 examined the addition of hypoxia to a dynamic exercise 
protocol. As part of this, the exercise protocol was modified to resemble repeated 
anaerobic efforts with limited recovery periods. This permitted a greater degree of 
localised muscle deoxygenation and created a dependence on aerobic energy systems 
to recover anaerobic energy stores between sets. Furthermore, this gave the opportunity 
for any enacted humoral benefits to increase between-set recovery capacity, potentially 










Part 1 of this literature review aims to characterise the origins of IPC prior to 
investigating its molecular mechanisms. It begins with a brief detailing of 
ischemia/reperfusion injury and highlights the triggers necessary for IPC to evade to 
mitigate cell death. With this concept in mind, the technical development of IPC is 
elaborated as it evolved into a valid tool for cardioprotection. From here, the molecular 
mechanisms underpinning the technique are then explored by following the progression 
of the initial signalling into the actions of the end effectors. By delving into the 
mechanisms of IPC in depth, it can be seen that physiological responses to IPC 
promoting cell survival also involve key factors central to the regulation of exercise 
performance. Part 2 of the review focusses on the transition of IPC into sport science. 
Existing performance research is then summarised, with the factors contributing to 
outcome variability expounded. Ensuring this, the physiological responses observed 
alongside enhanced performance are elucidated by proposing end effectors of the 
molecular mechanism that could be responsible. The conclusion of this section probes 
the lesser researched physiological responses to IPC that could also contribute to 





Part 1: The Use of Ischemic Preconditioning for Cardioprotection 
Mechanisms of Ischemia Reperfusion Injury 
The primary purpose of IPC is to enact protective effects against ischemia/reperfusion 
injuries. Ischemic injury is incurred when tissue is deprived of oxygen for a sustained 
period of time. This oxygen deprivation results in the impairment of ATP production 
which, left unresolved, leads to cellular acidosis, lethal ROS production (above redox 
signalling concentrations) and the failure of Ca+2 and Na+ pumps within the 
mitochondria (Jennings et al., 1978; Jennings & Reimer, 1991; Jennings, Reimer, & 
Steenbergen, 1991; Kübler & Spieckermann, 1970; Piper, Meuter, & Schafer, 2003) 
(Dekker et al., 1996; Murphy, Perlman, London, & Steenbergen, 1991; Ten Hove, Van 
Emous, & Van Echteld, 2003). These factors promote the opening of the mitochondrial 
permeability transition pore (MPTP), a non-selective channel of the inner mitochondrial 
membrane. It’s opening collapses the mitochondrial membrane potential, disabling the 
electron transport chain (ETC) ceasing all cellular respiration (D. J. Hausenloy, Ong, & 
Yellon, 2009). Furthermore, it’s opening results in uncontrolled matrix swelling leading 
to the rupturing of the membrane, releasing toxic substances (cytochrome c) into the 
cytosol and initiating programmable cell death (apoptosis) (Brookes, Yoon, Robotham, 
Anders, & Sheu, 2004).  
 
Following ischemic injury, cytotoxic metabolites released from damaged cells into the 
blood circulate throughout the body, inducing reperfusion injuries. Specifically, lethal 
concentrations of ROS and tumour necrotic factor alpha (TNFα) increase leukocyte 
activity and adhesion molecule expression, invoking inflammatory responses within the 
endothelium. (Kharbanda et al., 2001; Kozakowska, Pietraszek-Gremplewicz, 
Jozkowicz, & Dulak, 2015; Shimizu et al., 2010). This results in endothelial 
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dysfunction, amplifying the damage of the ischemia reperfusion injury by further 
restricting the supply of oxygen to tissue (Wu et al., 2018).  
 
The Origins and Technical Development of Ischemic Preconditioning  
As outlined above, the preservation of ATP levels within the cell is of utmost 
importance when avoiding the progressions of ischemia/reperfusion. Accordingly, this 
facet became the focal point for the origins of IPC research. The research group of 
Murry and colleagues began their IPC investigations upon two observations they had 
noted in prior research. The first, repeated periods of ischemia did not have cumulative 
deleterious effects (magnitude of cell death) as would have been expected from a single 
block of ischemia, matched for time. The second observation was that four 10 min 
occlusion periods produced no more ATP depletion than a single 40 min occlusion. 
From these base observations, it was then proposed that multiple brief episodes of 
ischemia could theoretically slow the rate of ATP depletion during a subsequent 
prolonged ischemic period, thereby reducing cellular death size during the following 
episode. To investigate this hypothesis, four 5 min periods of arterial occlusion were 
employed within canine hearts prior to a 40 min global ischemia period. It was found 
that the pre-treatment resulted in a 75% reduction of cell infarction size compared to 
the control group (Murry et al., 1986). Although unconfirmed at the time, this was 
presumed to be permitted by a preservation of ATP content. A subsequent replication 
study confirmed that indeed, a preservation of ATP and also an attenuation in lactate 
accumulation accompanied the reduced infarction size (Murry et al., 1990). These 
initial studies of Murry and colleagues served as the basis of IPC research and provided 
a novel approach to affording protection against IR injuries. After several more years 
confirming the phenomenon in other species, the technique was utilised successfully in 
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human trials by Yellon et al. (1993). Patients undergoing a 10 min cardiopulmonary 
bypass surgery procedure underwent a prior preconditioning treatment (two 3 min 
periods of arterial cross clamping interspaced with 2 min of reperfusion). Muscle 
biopsies taken following the surgery found in treated tissue, ATP content increased by 
76% relative to controls. Although an important progression into realising the potential 
for IPC treatments within human participants, the invasiveness of the procedure 
remained an obstacle for further human research. A major development in this respect 
was the discovery of a remote form of IPC activation. Previously it was thought that 
IPC protected only the cells involved in the initial procedure. However, Przyklenk et 
al. (1993) determined that protection could be translated from tissue adjacent to the area 
of intervention. The technique of applying IPC treatment to remote organs in order to 
protect the myocardium thus became known as remote IPC or RIPC. A series of 
progressions within this realm soon followed, culminating in the technical development 
of the use of non-invasive limb occlusion to induce IR cycles (Birnbaum et al., 1997; 
Gho et al., 1996; Oxman et al., 1997; Whittaker & Przyklenk, 1994). However, it wasn’t 
until 2001 when this method took hold in human trials. This method utilised inflations 
of blood pressure cuffs around the forearm to induce the IR cycles (three 5 minute 
cycles at 200 mmHg), providing systemic protection against markers of IR injury 
(Kharbanda et al., 2001). This permitted greater control for research quality and comfort 
for the participants.  Furthermore, this methodological advancement continued in the 
following year when the same method was replicated with the systemic protection 
observed this time in the contralateral limb (Kharbanda et al., 2002). This advancement 
provided the means to practically and effectively investigate the potential of IPC 
mediated cardioprotection within humans with a technique that has remained 




The Molecular Mechanism of Ischemic Preconditioning 
The initial link established between ATP preservation and reduced MI size formed the 
basis of the molecular mechanism of IPC (Murry et al., 1986).Although the exact 
process is yet to be defined, there is a general consensus that there are three main phases 
of IPC; triggering, mediation and end effectors (Fig. 2.1). Triggering refers to the 
generation of signalling molecules by ischemic tissue. These molecules are then 
Mediated by their respective metabolic pathways. Once the signal reaches the desired 
target, End Effectors make conformational changes leading to increased tolerance. This 
process is pertaining to traditional IPC where the treated tissue is also the targeted tissue 
for protection. However, in the instance of remote activation of IPC, where the treated 
tissue is not target tissue, an additional step is required. Here, Signal Transduction is 




Figure 2-1 The potential mechanistic pathway underlying both traditional (treated tissue is target tissue) IPC and 
remote (treated tissue is distal to target tissue) IPC. Within remote IPC, the signal is transduced via either humoral 
or neural pathways. Within the humoral pathway, triggers are produced within the ischemic tissue and then washed 
out into the blood stream to activate extracellular receptors within the target tissue. Within the neural pathway, the 
ischemic tissue triggers the local afferent neural pathway, stimulating an efferent pathway into the target tissue, 
activating extracellular receptor pathways. The resulting pathways RISK (receptor dependant triggering) and SAFE 







Triggering and Mediation 
Receptor Dependant Triggering and Mediation 
The triggers of IPC are released during the initial IR phases of the IPC treatment and 
carry the signals for protection against ischemic injury. These triggers are released as a 
response to the transient IR cycles and activate downstream messaging pathways to 
enact their effects. The primary signalling molecules identified in traditional 
preconditioning are a group of receptor dependant autacoids including adenosine (Carr 
et al., 1997; G. J. Gross & Auchampach, 1992; Kuno et al., 2007; Lancaster, Jefferson, 
& Korzick, 2011; Liang & Jacobson, 1999; G. S. Liu et al., 1991; Y. Liu & Downey, 
1992; Simkhovich, Przyklenk, & Kloner, 2013; Wolfrum et al., 2002), bradykinin 
(Morris & Yellon, 1997; Schulz, Post, Vahlhaus, & Heusch, 1998) and opioids (Patel 
et al., 2002; Schultz et al., 1997a, 1997b; Wall, Sheehy, & Hartman, 1994). Receptor 
dependant triggers operate via trans-membranal G protein coupled receptors (GPCR), 
which respond to extracellular signals by producing secondary intracellular messengers 
that command the actions of end effectors downstream (Luttrell, 2006). All receptor 
dependant triggers follow independent, parallel pathways to a convergence point upon 
protein kinase c epsilon (PKCε). (Lancaster et al., 2011; Speechly-Dick, Grover, & 
Yellon, 1995; Wolfrum et al., 2002; Zaha et al., 2016). Following the PKCε activation, 
the IPC signal is then mediated via the reperfusion injury salvation kinase (RISK) 
pathway which results in the phosphorylation of glycogen synthase kinase 3 beta (GSK-
3β) (Gross Eric, Hsu Anna, & Gross Garrett, 2004; Tong, Imahashi, Steenbergen, & 
Murphy, 2002). In this context, GSK-3β essentially governs the opening of the MPTP 
and represents the end of the receptor dependant mediation pathway (D. J. Hausenloy 
& Yellon, 2007; Juhaszova et al., 2009).  
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The robustness of the IPC mechanism is demonstrated when the antagonism of one of 
the specific trigger receptor fails to fully abrogate the protective effects of IPC. Rather, 
the blockage of one trigger purely increases the threshold of activation required for the 
other triggers, meaning a greater IR dosage (more cycles) is required to sufficiently 
accumulate the other triggers to compensate (Goto et al., 1995).  
 
A number of intermediate triggers are also involved within the IPC process which are 
produced throughout the mediation pathways of the receptor dependant triggers. Nitric 
oxide (NO), produced via endothelial nitric oxide synthase (eNOS), serves as an 
intermediate trigger in the bradykinin and opioid pathways (Dimmeler et al., 1999; 
Huang et al., 1995; S. P. Jones et al., 1999). Its production then serves to activate the 
mitochondrial ATP sensitive potassium channels (mKATP channels) (D. J. Hausenloy & 
Yellon, 2007), which then releases sub-lethal signalling ROS as a secondary 
intermediate trigger, which participates to activate PKCε (Bell et al., 2005; Costa & 
Garlid, 2008; Forbes Robert, Steenbergen, & Murphy, 2001; Kalogeris, Bao, & 
Korthuis, 2014; Tingyang Zhou, Chuang, & Zuo, 2015; T. Zhou, Prather, Garrison, & 
Zuo, 2018; X. Zhou, Zhai, & Ashraf, 1996). Whilst participating as signalling 
molecules in the preliminary stages of the mechanism, each intermediate later 
contributes in their own right as part of the actions of the end effectors. 
 
Non-receptor dependant triggering and Mediation 
Non-receptor dependant triggering occurs outside of the activation of GPCRs and the 
RISK pathway and instead operate via the survival activating factor enhancement 
(SAFE) pathway. Sphingonsine-1 phosphate (S1P), tumour necrosis factor alpha 
(TNFα) and interleukin 6 (IL6) are known triggers of the SAFE pathway, and the 
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phosphorylation of signal transducer and activator of transcription 3 (STAT3) is the 
known end point (Deuchar, Opie, & Lecour, 2007; Muller et al., 2014; Somers, Frias, 
Lacerda, Opie, & Lecour, 2012). The phosphorylation of STAT3 permits regulation of 
ROS levels through modified ETC activity, thus leading to MPTP opening inhibition 
(Kerstin Boengler, Hilfiker-Kleiner, Heusch, & Schulz, 2010; Kerstin, Elvira, Gerd, & 
Rainer, 2013).  
 
Signal Transduction 
In traditional forms of IPC (where the treated tissue is also the target tissue), the 
production of triggering autacoids immediately initiates mediation pathways. However, 
in the case of remote IPC (where the treated tissue is not the target tissue), a pathway 
of signal transduction is required to deliver the signal to the target tissue. Signal 
transduction takes form in either/both a neural and humoral pathway. The humoral 
pathway specifies the metabolites produced within the tissue under the IR cycles and is 
flushed through the system during reperfusion, thus leading to localised signal 
transduction within the target tissue. Conversely, the neural pathway suggests that the 
detection of the initial IR stimuli is signalled to the central nervous system (CNS) by 
metabolically sensitive afferent fibres and then relayed to the target tissue by efferent 
signalling. Initial research portrayed these pathways as competing, although they are 




It was initially hypothesised that the remote activation of IPC required the wash-out of 
an endogenous signalling molecule from the treated tissue into the heart in order to 
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confer cardio-protection (Gho et al., 1996). This hypothesis formed when it was found 
that the permanent occlusion of the mesenteric artery of mice prior to a 60 min 
occlusion of the aortic artery did not confer any expected protective benefits. This 
suggested that an unknown humoral factor was required to be washed out of the treated 
tissue to be delivered to the target area. Based off this, Dickson et al. (1999) used a 
Langendorff model to successfully precondition a virgin rabbit heart by perfusing it 
with the preconditioned blood of a donor rabbit, demonstrating the presence of a 
humorally mediated factor. Donor rabbit myocardium were preconditioned before the 
coronary effluent was extracted and transferred to receiving virgin hearts before being 
subjected to 40 min of ischemia and then 60 min of reperfusion. Mean infarct size was 
reduced (9% in RIPC hearts vs 34-36% in control hearts) when the receiving heart was 
perfused with the preconditioned effluent. The subsequent demonstration of the 
successful preconditioning of a de-innervated transplanted heart further implicated the 
involvement of such a humoral factor by bypassing neural pathways (Konstantinov, Li, 
et al., 2005). If a sole neural transduction pathway existed within IPC, this would have 
been impossible within the de-innervated heart. Yet, this provided evidence that a factor 
within the blood itself contributes to the preconditioning effect. However, the specific 
molecule responsible for the protection remained unidentified and this search continues 
today (Lang et al., 2006; Serejo, Rodrigues, da Silva Tavares, de Carvalho, & 
Nascimento, 2007). Regardless, it is clear that a humoral pathway is in action during 
IPC, with or without the assistance of a neural pathway. 
 
Neural Pathway  
Intact peripheral sensory fibres have been shown to be a requirement for successful 
preconditioning, providing evidence of a neural pathway for a neural pathway of remote 
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IPC signal transduction. Specifically, the inhibition of afferent signalling pathways 
innervating the treated tissue has been shown to abrogate all protective effects of IPC. 
Multiple studies have been able to demonstrate this by either pharmacological blockade 
or the transection of afferent nerves (Donato et al., 2013; Gho et al., 1996; Lim, Yellon, 
& Hausenloy, 2010; Loukogeorgakis et al., 2005; Schoemaker & van Heijningen, 2000; 
Wolfrum et al., 2002). This has implicated the intact afferent nerve fibres as an 
important component to the mechanism. Whilst Donato and colleagues contributed to 
existing findings regarding afferent nerve function and IPC signal transduction, they 
also uncovered the role of efferent nerve contributions Donato et al. (2013). The 
severance of the vagal nerve was also found to abolish cardioprotection afforded from 
hind limb preconditioning, however the electrical stimulation of the proximal end of 
the severed vagal nerve was sufficient to reproduce the cardioprotective effects. This 
highlighted the importance of intact sensory fibres between both the treated and the 
target tissue. Further work has identified some of the specific receptors with the afferent 
fibres that are responsible for the initiation of the IPC signal transduction. The 
nonselective cation channel, transient receptor potential cation channel subfamily 
member 1 (TRPV1) is the specific receptor responsible for pain stimulus. It is located 
within both type III and IV afferent fibres and is directly activated by pain stimuli and 
also capsaicin (Tang, Dai, Li, & Deng, 1999). Whilst both pain and capsaicin 
application have been found to replicate IPC cardioprotective effects, the application of 
nerve blockers (hexamethonium) prior to treatment can abolish the protection (W. K. 
Jones et al., 2009; Redington et al., 2012).  
 
Research investigating remote IPC has attempted to define the exact pathway of 
responsible for signal transduction. Both humoral and neural pathways have been 
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implicated within the pathway and have even been shown to successfully elicit 
cardioprotection independent of each other. As such, it currently remains unknown as 
to how the two pathways interact in order to proceed the remote IPC signals to engage 
the end effectors responsible for promoting cell survival. (D. Hausenloy, 2013; D. J. 
Hausenloy et al., 2016) 
 
End effectors  
The end effectors of IPC are the final stage of the metabolic cascade and carry out the 
physiological changes required to increase tolerance to ischemic conditions. The 
actions of end effectors include prevention of immediate cell death, (primarily by the 
inhibition of MPTP opening), mitigation of reperfusion injury (inhibition of 
inflammation and endothelial dysfunction) and adaptive responses negating future 
reoccurrences (gene transcriptional adaptations). The gene transcriptional adaptations 
responses will not be explored in detail in this review but can be found in the work of 
D. J. Hausenloy and Yellon (2016). 
 
Prevention of Immediate Cell Death 
The primary function of end effectors preventing immediate cell death is essentially to 
prevent the opening of the MPTP. There are two proposed mechanisms of MPTP 
inhibition, indirect and direct (D. J. Hausenloy et al., 2009). Direct inhibition refers to 
the complex signal transduction pathways (RISK and SAFE) leading to the 
phosphorylation of GSK3β. Indirect inhibition refers to the inhibition of MPTP 
activation factors that occur outside of GSK3β phosphorylation. These activation 
factors include calcium overload, increased oxidative stress, depleted ATP stores and 





Ischemic preconditioning is thought to improve calcium handling via pathways that 
utilise H+/K+ exchangers, Na+/K+ exchangers and the Ca+2/Na+ exchangers. Evidence 
has shown that the opening of the mKATP channel can serve to both facilitate the efflux 
of Ca+2 ions from the mitochondrial matrix and also to increase mitochondrial the 
tolerance to Ca+2 accumulation (Murata, Akao, O'Rourke, & Marban, 2001). Whilst the 
mechanism behind the increase in Ca+2 is unclear, a reduction in the driving force of 
the voltage dependant Ca+2 uniporter appears to reduce Ca+2 influx (Crestanello et al., 
2002; Murata et al., 2001). Nitric oxide has also been shown to impact calcium overload 
in the mitochondria by reversible attachment (S-NO) to a component of the of L-type 
Ca+2 channels, inhibiting calcium importing (J. Sun et al., 2006). Thus, the ability for 
these effects to mitigate the accumulation of Ca+2 within the mitochondria presents a 
valuable tool in preventing the opening of the MPTP.  
 
Oxidative Stress 
In low concentrations, ROS serve to carry out redox signalling, however at larger 
concentrations they present a danger to cell DNA structure and in this context, provide 
triggering for the opening of the MPTP. Reactive oxidative species production arises 
through the ischemic damage to complexes 1 and 3 of the ETC (Borutaite & Brown, 
2006; Nadtochiy, Burwell, & Brookes, 2007). The S-NO of complex 1 and 3 elicits 
structural changes that prevent this increase in ROS production (Ertracht et al., 2014; J. 
Sun et al., 2015; Junhui Sun, Steenbergen, & Murphy, 2006). Furthermore, S-NO 
reactions also inhibit respiration at cytochrome c oxidase, restricting oxygen entry into 
the damaged ETC to be converted to ROS (Nadtochiy, Baker, Freeman, & Brookes, 
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2009; Prime et al., 2009). Additionally, the reduction of Ca+2 intake prevents the 
upregulation of pyruvate dehydrogenase, further reducing electron flux through the 
damaged ETC (Brookes et al., 2004).  
 
ATP Preservation 
ATP is preserved throughout ischemia via both a reduction in usage and also a 
maintenance of supply. The reduction of ATP usage occurs through the inhibition of 
the ATP hydrolysis enacted by the reversal of ATP synthase function (Grover et al., 
2004; Jennings et al., 1991). During ischemia, the mitochondrial membrane potential is 
reduced due impaired ETC function, stimulating ATP synthase hydrolyse ATP to 
reconstitute lost membrane potential (Kobara et al., 1996; Rouslin, 1983). However 
conformational changes induced by IPC inhibit this reversal, thus sparing ATP 
(Rouslin, 1983; Rouslin, Erickson, & Solaro, 1986). Furthermore, the swelling of the 
mitochondrial matrix, enabled by the activation of the mKATP channel, 
compartmentalises the reservoir of ATP available to be hydrolysed to within the matrix. 
The swelling lowers the permeability of the inner mitochondrial membrane to adenine 
nucleotides, preventing the surplus usage of ATP from cytosol sources (Schlattner & 
Wallimann, 2000; Wallimann et al., 1998). This swelling also then facilitates energy 
export from the matrix by improving the rates of phosphocreatine resynthesis (Garlid, 
Dos Santos, Xie, Costa, & Paucek, 2003; V. Saks, Dos Santos, Gellerich, & Diolez, 
1998; V. A. Saks, Khuchua, Kuznetsov, Veksler, & Sharov, 1986; V. A. Saks, Khuchua, 
Vasilyeva, Belikova, & Kuznetsov, 1994).  
Moreover, the IPC mediated-downregulation of anaerobic glycolysis prevents the 
lowering of pH during ischemia. This prevents the inhibition of the pH sensitive 
glycolysis rate controlling enzyme phosphofructokinase 1 (PFK1) during ischemia, 
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accelerating recovery during reperfusion. (Takeo & Nasa, 1999; Yabe, Nasa, Sato, 
Iijima, & Takeo, 1997). 
 
Acidification  
Ischemic preconditioning works to prevent acidosis by inhibiting the compensatory 
upregulation of anaerobic glycolysis during ischemia (Murry et al., 1990; Steenbergen, 
Perlman, London, & Murphy, 1993). Although initially thought to be the result of 
inhibition of glycogenolysis, IPC impairs glycolytic flux via the inhibition of a range 
of glycolytic enzymes (Masoud, Abo Al-Rob, Yang, Lopaschuk, & Clanachan, 2015; 
Vogt et al., 2002; Weiss, Albuquerque, Vandegaer, Chacko, & Gerstenblith, 1996). 
This aversion to matrix acidification serves additional benefits in preventing ATP loss 
to the function ion pumps regulating pH and also the subsequent Ca+2 overload. 
 
Reperfusion Injury Prevention 
The reperfusion injuries occur when the toxic by-products of ischemia are permitted to 
circulate throughout the body. Endothelial cells are particularly vulnerable to injuries 
associated with oedema, neutrophil and platelet aggregation and micro thrombosis. 
These symptoms of reperfusion injuries work to reduce endothelial dilation and impede 
blood flow to tissue, further exacerbating ischemic injuries. The key to avoiding these 
symptoms is nitric oxide dependant vasodilation. Early in the IR cycles, NO content is 
increased as part of signalling mechanism (Cai et al., 2011; Deuchar et al., 2007; D. J. 
Hausenloy & Yellon, 2007). Implicated as an intermediate of the RISK and SAFE 
pathways, adenosine receptor, mKATP and TPRV1 activation have also been shown to 
lead to increases in NO content and subsequently NO mediated dilation (Ay & Tuncer, 
2004; Belardinelli et al., 1998; Jerome, Akimitsu, Gute, & Korthuis, 1995; Sato et al., 
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2005). The ensuing adaptations of IPC (reduced ROS production, increased antioxidant 
defence) then allow NO to maintain its function in facilitating vessel dilation and 
inhibiting inflammation (Akimitsu, Gute, & Korthuis, 1996; M. Chen et al., 2015; 
Garrett J. Gross, Auchampach, Maruyama, Warltier, & Pieper, 1992; Gryglewski, 
Palmer, & Moncada, 1986; Holley, Bakthavatchalu, Velez-Roman, & St Clair, 2011; 
Müller & Dhalla, 2010; Parajuli & MacMillan-Crow, 2013; Park, Chun, Kim, Kim, & 
Kim, 1997; Pieper & Gross, 1992; Rubanyi & Vanhoutte, 1986; Thiagarajan, Winn, & 
Harlan, 1997). The opening of the mKATP channel compliments the anti-inflammatory 
properties of NO by restricting cellular swelling via the prevention of Na+ influx 
required to induce cellular swelling (Mazzoni, Intaglietta, Cragoe, & Arfors, 1992). 
Moreover, IPC has been shown to reduce the immune responses to inflammatory 
stimuli, further sustaining endothelial function and promoting oxygen delivery to the 
required tissue during the recovery from ischemic insults (Kharbanda et al., 2002; 
Kharbanda et al., 2001; Konstantinov et al., 2004; Konstantinov, Arab, et al., 2005).  
 
Summary of Ischemic Preconditioning for Cardioprotection 
Ischemic preconditioning represents an effective strategy to limit the damage of IR 
injuries. The technical developments enabling the use of non-invasive and practical 
transient limb IR cycles has facilitated its transition from pre-clinical to clinical research 
and permitted a greater understanding of the molecular mechanism. Via both neural and 
humoral signal transduction, the technique has been seen to both directly and indirectly 
prevent programmable cell death (via opening of MPTP). Direct inhibition of MPTP 
opening occurs through as a consequence of the RISK and SAFE pathways whereas 
indirect inhibition occurs via the end effects resulting from the mediation of the IPC 
signal. These end effects also provide longer lasting benefits to protect against 
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endothelial dysfunction and stimulate genetic adaptations to protect against future 








Part 2: The Use of Ischemic Preconditioning for Performance Enhancement 
The Transition from Cardioprotection to Sport Science 
The potential for IPC pro-survival end effects to improve parameters of exercise 
performance has facilitated its transfer into sport science settings. The individual 
physiological responses induced by the end effectors of IPC to improve cell function 
during ischemia have also shown potential to benefit parameters of exercise 
performance e.g. vasodilation improving skeletal muscle oxygen delivery (Kimura et 
al., 2007), reduced oxidative stress improving mitochondrial oxidative capacity 
(Quarrie et al., 2011) or the preservation of cellular pH improving glycolytic enzyme 
function (Weiss et al., 1996). Furthermore, these individual physiological responses 
could then complementarily combine to produce compounded benefits to exercise 
capacity (e.g. improved mitochondrial oxygen utilisation supplemented with increased 
of increased oxygen delivery). 
 
This potential was first explored by de Groot et al. (2010) where it was proposed that 
IPC-mediated increases in NO expression alongside the activation of mKATP channels 
could improve exercise capacity (Kimura et al., 2007; Lawson & Downey, 1993; Pang 
et al., 1997). Theoretically, these two physiological responses would increase 
vasodilation and metabolic substrate delivery, offering benefits to maximal aerobic 
exercise capacity. To test this theory, an improvised IPC procedure utilising inflated 
blood pressure cuffs (220mmHg) to induce the IR cycles was performed prior to a 
maximal incremental cycling test (Bushell et al., 2002; Kooijman et al., 2008). The 
findings showed that IPC significantly (p < 0.05) increased maximal aerobic power 
output increased by 1.6%, although this produced only a small (0.1) Cohen’s D effect 
size (Cohen, 1969). Nonetheless, this study revealed for the first time that the pro-
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survival physiological responses to IPC could also be adapted to increase maximal 
exercise capacity.  
The ensuing swimming performance study of Jean-St-Michel et al. (2011) 
demonstrated a more specific transfer of IPC into sports performance. It was speculated 
that the similarities between mild ischemic insults and maximal exercise enabled the 
transfer of pro-survival physiological responses to increase performance. More 
specifically, the use of a swimming exercise task would facilitate this transfer by 
naturally increasing exercise-induced tissue hypoxemia via the imposition of breathing 
restrictions (Noakes, 2000; Wells, Plyley, Thomas, Goodman, & Duffin, 2005). The 
results showed that 100 m sprint performance of highly trained athletes was 
significantly (p < 0.05) increased by 1.1%, with a small effect size (0.12). Although 
only a small effect size, the low degree of variability in highly trained swimmers (within 
subject coefficient of variation: 0.4% (Pyne, Trewin, & Hopkins, 2004)) suggested that 
this was a worthwhile increase in performance. Thus, the work of Jean-St-Michel et al. 
(2011) expanded upon the work of de Groot and colleagues by identifying a specific 
strategy of using IPC to enhance performance. These two studies formed the basis of 
exercise performance IPC research from which all subsequent research has built upon. 
 
The Efficacy of IPC in Sport 
The following section focuses on the efficacy of the use of IPC to enhance exercise 
performance. The existing body of research has been summarised within separate tables 
as defined by the objective of the exercise task (incremental exercise tasks, fixed 
endpoint tasks, time trials, time to failure). Each performance has been characterised by 
participant gender/training status, IPC protocol pressure/duration, exercise 
description/modality and a performance outcome. The performances have been listed 
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by three variables (Caru et al., 2019; Marocolo et al., 2019); the timing of the IPC 
protocol prior to performance (shortest to largest), the primary energy system of the 
task (alactic anaerobic to aerobic) and lastly, the training status of the participants 
(lowest training status to highest). Performance outcomes have been denoted with 
directional symbols (↑: increased, ↓: decreased, ↔: indifferent) and percentage 
increases accompanied by Cohens d effect sizes (ES) where possible (Cohen, 1969). 
The use of an effect size has been used to improve the contextual utility of each 
performance outcome given the issues of small sample sizes associated with exercise 
performance research (Will G Hopkins, 2003, 2006, 2015). The magnitude of effect 
sizes for each change was defined as small > 0.2, moderate > 0.5 and large > 0.8 (Cohen, 
1969). Additionally, performance increases without statistical significance have been 
included, but have been denoted with markers of non-significance (NS) (Will G 





Table 2.1 Summary of the effect of IPC on Incremental Exercise Tasks 
Author Subjects Cycles (Pressure) Preconditioned Limb Timing Description 
Energy 
System Modality Performance Outcome (ES) 
(Crisafulli et al., 
2011) 
17 healthy people  
(40 ml/min/kg) 
3x5 
Systolic + 50/Submaximal 
exercise-circulatory occlusion 
Thigh (Bilateral) <20 min 
Continuous graded maximal 
cycling test Aerobic Cycling 
↑3% (0.23) 
Max aerobic power 
(de Groot et al., 2010) 
12 moderately trained males 




220/None Thigh (Bilateral) 
<20 
min 
Continuous graded maximal 
cycling test Aerobic Cycling 
↑1.6 % (0 1) 
Max aerobic power 
(James, Willmott, 
Richardson, Watt, & 
Maxwell, 2016) 








Continuous graded maximal 
running incline test in heat Aerobic Running 
↑9.2% (0.58) (NS) 
Max aerobic power 
(Tomschi, Niemann, 
Bloch, Predel, & 
Grau, 2018) 
10 moderately trained males 
(MAP ~200W) 
4x5 
200/120 Right arm (unilateral) 
<20 
min 
Continuous graded maximal 
cycling test Aerobic Cycling ↔ 
(Sabino-Carvalho et 
al., 2017) 
14 highly trained males  and 
4  + highly trained females  
m: (66 ml/kg/min) 
f: (57 ml/kg/min) 
4x5 




maximal running speed test Aerobic Running ↔ 
(Kilding, M. 
Sequeira, & Wood, 
2018) 
9 highly trained males  
(4.4 L/min) 
4x5 
200/50 Thigh (Bilateral) 
<20 
min 
Continuous graded maximal 
cycling test Aerobic Cycling ↔ 
(Slysz & Burr, 2018) 12 healthy males (48 ml/kg/min) 
3x5 
220 + EMS or 220 + 
Walking/Con 
Thighs (Bilateral) >20 min 
Continuous graded maximal 
cycling test Aerobic Cycling 
↔ IPC 
↑ 3.7% (0.27) IPC + EMS 
↑5.1% (0.38) IPC + Walking 
Max aerobic power 
(Yoon & Jae, 2018) 17 healthy males  (37 ml/kg/min) 
6x5 
180/20 Thighs (Bilateral) 
>20 
min 
Continuous graded maximal 
cycling test Aerobic Cycling 
↑11.5% (0.8) 
Max aerobic power 
(Bailey, Birk, et al , 
2012; Bailey, Jones, 
et al., 2012) 
13 moderately trained males 
(51 ml/kg/min) 
4x5 
200/20 Thigh (Bilateral) 
>20 
min 
Continuous graded maximal 
running speed test Aerobic Running ↔ 







Continuous graded maximal 
running speed test Aerobic Running ↔ 
(Hittinger et al., 
2015) 
15 highly trained males  
(61 ml/kg/min) 
4x5 
Systolic + 10/20 Thigh (Bilateral) 
>20 
min 
Continuous graded maximal 
cycling test Aerobic Cycling 
↑1.9% (NA) (NS) Normoxia 
↑ 4.7% (NA) (NS) in 
hypoxia 
Max aerobic power 
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Author Subjects Cycles (Pressure) Preconditioned Limb Timing Description 
Energy 
System Modality Performance Outcome (ES) 
(Angus Lindsay et 
al., 2017) 
13 healthy males and 5 
healthy females 
(39 ml/kg/min) 




Continuous graded maximal 
cycling test Aerobic Cycling 
↑18.5% (0.46) 
Max aerobic power 
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Table 2.2 Summary of the effect of IPC on Fixed Endpoint Tasks 
Author Subjects Cycles (Pressure) Preconditioned Limb Timing Description Energy System Modality Performance Outcome (ES) 
(Beaven, Cook, Kilduff, 
Drawer, & Gill, 2012) 




220/15 Thigh (Bilateral) <20 min 
Six 40 m sprint departing 
every 30 s 
Alactic 
Anaerobic Running ↔ 
(A. Hyngstrom et al., 
2016) 











(Beaven et al., 2012) 










↑9.0 cm (0.61) 
Jump height 
(Paradis-Deschenes et al., 
2016) 




220/20 Thigh (Unilateral) <20 min 
Five sets of 5 repetitions 









Ferth, Spriet, & Burr, 
2018) 
10 highly trained males 




220/20 Thigh (Unilateral) <20 min 10m and 20m sprints 
Alactic 
Anaerobic Running ↔ 
(Kraus et al., 2015) 




NA/10 Upper Arm (Bilateral) <20 min 
Four repeat Wingates with 2 
min rest between 
Lactic 
Anaerobic Cycling 
↑1.3% (0.05)  
Mean power Wingate 1 
(Kraus et al., 2015) 






(Unilateral) <20 min 
Four repeat Wingates with 2 
min rest between 
Lactic 
Anaerobic Cycling ↔ 
(Slysz & Burr, 2018) 12 healthy males (48 ml/kg/min) 
3x5 
220 + EMS 
or 220 + 
Walking/Con 
Thighs (Bilateral) <20 min Single Wingate Lactic Anaerobic Cycling ↔ 
(N. Gibson, Mahony, 
Tracey, Fawkner, & 
Murray, 2015) 
7 moderately trained males 






(Unilateral) <20 min 
Five 6s sprints against 7.5% 
body mass with 24 s recovery 
Lactic 
Anaerobic Cycling ↔ 
(Lalonde & Curnier, 
2015) 
8 moderately trained males 






Right arm (unilateral) <20 min 
A 6 s alactic anaerobic test 
followed by a Wingates test 
at 0.8 Nm/kg body mass  
Lactic 
Anaerobic Cycling 
↑1.7% (NA) (NS) 
Mean power 
(Paixão, da Mota, & 
Marocolo, 2014) 






(Unilateral) <20 min 
Three repeat Wingate with 




Mean power all Wingates 
(Griffin, Ferguson, 
Gissane, Bailey, & 
Patterson, 2017) 









Author Subjects Cycles (Pressure) Preconditioned Limb Timing Description Energy System Modality Performance Outcome (ES) 
(Paradis-Deschênes, 
Joanisse, & Billaut, 2017) 
9 moderately trained males 




220/20 Thigh (Unilateral) >20 min 
Five sets of 5 repetitions 






↑13% (0.64) in males 
↑10.4% (0.40) in females 
Mean force 
(Patterson, Bezodis, 
Glaister, & Pattison, 2015) 
14 healthy males 
(NA) 
4x5 
220/20 Thigh (Bilateral) >20 min 
Twelve 6 s repeat sprints 




Mean power sprints 1, 2, 3 
(Cruz et al., 2016) 




220/20 Thigh (Bilateral) >20 min 
1 min Maximal cycling 
performance Aerobic Cycling 
↑2.1% (NA) 
Mean Power 
(Durand et al., 2019) 




of 5x5 every 
second day 
225/10 
Thigh (Unilateral) Chronic MVC Alactic Anaerobic 
Knee 
Extension ↔ 
(A. S. Hyngstrom et al., 
2018) 











(Angus Lindsay et al., 
2017) 
13 healthy males and 5 
healthy females 
(39 ml/kg/min) 





Four Wingate tests 
simulating a Keirin event  
Lactic 
Anaerobic Cycling 
↑3.2% (NA) Wingate 3 





Table 2.3 Summary of the effect of IPC on Time Trial Tasks 
Author Subjects Cycles (Pressure) 
Preconditioned 
Limb Timing Description Energy System Modality Performance Outcome (ES) 
(Neil Gibson, White, Neish, & 
Murray, 2013) 
16 moderately trained males 




220/50 Thigh (Bilateral) 
<20 
min 
Three Repeat 30m 
sprints with 1 min 
recovery between 
Alactic Anaerobic Running ↓NA% (NA) Time 
(Griffin, Hughes, Gissane, & 
Patterson, 2019) 
12 moderately trained males  







Three blocks of 6 x 15 
+ 15m shuttle sprints 
with 20s recovery 
between sprints and 
120s between blocks 
Lactic Anaerobic Running ↑0.4% (0.13) Total time 
(Cocking, Landman, et al., 
2017) 








min 1 h TT Aerobic Cycling 
↑2.2% (0.08) (NS) 
Mean power 
(Marocolo, da Mota, 
Pelegrini, & Appell 
Coriolano, 2015) 
15 moderately trained people 
(NA) 
4x5 
220/20 Arm (Bilateral) 
<20 
min 100m swim TT Aerobic Swimming ↔ 









min 16.1 km TT  Aerobic Cycling ↔ 
(Kilding et al., 2018) 9 highly trained males  (4.4 L/min) 
4x5 
200/50 Thigh (Bilateral) 
<20 
min 4km TT Aerobic Cycling 
↑2.2% (0.18) 
Time 





Thigh (Bilateral) <20 min Self-paced 5km TT  Aerobic Running ↔ 
(Zinner, Born, & Sperlich, 
2017) 
7 moderately trained males 











Sixteen 30m all out 
sprints (15s rest) with 
multidirectional COD 
movements on a 
speed-court 
Alactic Anaerobic Running ↔ 
(Ferreira et al., 2016) 
8 moderately trained males 
and 7 moderately trained 
females 
(NA) 
3 days of 3x5 
220/220 (3 
days of 3x1) 
Thigh (Bilateral) >20 min 
Six 50m swims every 
3 min Lactic Anaerobic Swimming 
↑1.2% (0.54) 
Total time of all swims 
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Author Subjects Cycles (Pressure) 
Preconditioned 
Limb Timing Description Energy System Modality Performance Outcome (ES) 








Three successive 50m 
trials at 1 h, 2 h and 8 
h post IPC  
Lactic Anaerobic Swimming 
↔ (NA) 1h 
↑1% (NA) 2 h  
↑1.2% (NA) 8 h  
Time 












min 357 Kj TT Aerobic Cycling 
↑17 s (NA) 
Time 
(Bailey, Birk, et al., 2012; 
Bailey, Jones, et al., 2012) 
13 moderately trained males 
(51 ml/kg/min) 
4x5  
200/20 Thigh (Bilateral) 
>20 
min 5km TT Aerobic Running 
↑2.2% (0.09) 
Time 
(Foster, Giri, Rogers, Larson, 
& Anholm, 2014) 
6 moderately trained males 










100KJ Cycling TT  
(Hypoxia/Normoxia) Aerobic Cycling 
↔ Normoxia 
↑2.2% (0.07) (NS) Hypoxia 
Time 






min 600m TT Aerobic 
Speed 
Skating ↔ 
(Kjeld, Rasmussen, Jattu, 
Nielsen, & Secher, 2014) 









min 1000m TT Aerobic Rowing 
↑0.4% (0.23) 
Time 
(Jean-St-Michel et al., 2011) 
8 highly trained males and 8 









& Billaut, 2018) 








min 5km TT Aerobic Cycling 
↑ 1.1% (0 22) low hypoxia 
↑ 1.5% (0.38) moderate 
hypoxia  
Time 
(Richard & Billaut, 2018b) 
7 highly trained males and 2 









min 1000m TT Aerobic 
Speed 
Skating ↔ 







min 2000m TT Aerobic Rowing ↔ 
(Wiggins, Constantini, Paris, 
Mickleborough, & Chapman, 
2019) 













↑0.9% (0.14) Normoxia 
↔ Hypoxia 
Time 
(Williams, Russell, Cook, & 
Kilduff, 2018) 
14 highly trained males and 6 








Self-selected 100m or 
200m swim TT Aerobic Swimming 
↑2% (0.25) (NS) 200m 
↔ 100m 
Time 
(Foster et al., 2014) 
11 moderately trained males 
and 1 moderately trained 
female 
(NA) 




12.8km Run in 
increasing altitude 
(from 3560m to 
4343m) 
Aerobic Running ↑7.5% (0.33) Time 
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Author Subjects Cycles (Pressure) 
Preconditioned 
Limb Timing Description Energy System Modality Performance Outcome (ES) 
(Seeger et al., 2017) 
10 moderately trained males 







Self-paced 5km TT  
(20 min/24 h post 
IPC) 
Aerobic Running 
↑1.4% (0.18) 20 min 







Table 2.4 Summary of the effect of IPC on Time to Fatigue tasks 
Author Subjects Cycles (Pressure) 
Preconditioned 






et al., 2016) 










Four sets of maximal repetitions 






Willardson, et al., 
2016) 




220/20 Thighs (Bilateral) 
<20 
min 
Three sets of maximum repetitions 






& Kushnick, 2012) 
10 healthy males 
(NA) 
3x5 
220/Con Thigh (Bilateral) 
<20 
min TTF at 90% max power Aerobic Cycling ↔ 
(Kido et al., 2015) 15 healthy males (3.19 L/min) 
3x5 
300/Con Thigh (Bilateral) 
<20 
min 
Severe intensity (70% of the difference 
between the GET and VO2 peak) until 
exhaustion 
Aerobic Cycling ↑~15% (~2.62) Time 
(Tanaka et al., 2016) 12 healthy males (NA) 
3x5 
300/Con Thigh (Unilateral) 
<20 














(Valenzuela et al., 
2019) 









Two reps  at 30%, 50%, 70% body mass 
force-velocity assessment before a 1RM 
test and 3 sets to failure at 60% 1RM 
Alactic 
Anaerobic Bench Press ↔ 
(Kjeld et al., 2014) 

















(Carvalho & Barroso, 
2019) 




250/10 Thigh (Bilateral) 
>20 







(Barbosa et al., 2014) 13 healthy males (NA) 
4x5 
220/10 Thigh (Bilateral) 
>20 
min Rhythmic 45% MVC to fatigue Aerobic Handgrip 
↑11.2% (0.29) 
Time 
(Cruz et al., 2015) 




220/20 Thigh (Bilateral) 
>20 





Author Subjects Cycles (Pressure) 
Preconditioned 





(L. Smith, P Van 
Guilder, Buchanan, & 
Dalleck, 2018) 
7 moderately trained 
males and 5 moderately 
trained females  
m: (53 ml/kg/min) 
f: (46 ml/kg/min) 
4x5 
220/40 Thighs (Bilateral) 
>20 
min Two AOD tests separated by 20 min Aerobic Cycling ↔ 
(Durand et al., 2019) 
3 post-stroke males and 
7 post-stroke females 
(NA) 
Two weeks of 5x5 every 
second day 
225/10 






Variables Influencing the Efficacy of IPC in Sport 
Participant Characteristics 
Training Status 
The basis of using IPC in a sporting context is to use the physiological responses 
induced by IPC to benefit exercise performance. The fundamental action of IPC itself 
is to use IR cycles to enhance the ischemic tolerance of the body for subsequent threats 
of deoxygenation. Maximal exercise is thought to benefit from IPC due to metabolic 
similarities between mild levels of ischemia and that of maximal intensity exercise 
(Noakes, 2000; Noakes, Peltonen, & Rusko, 2001). However, this reasoning may prove 
less effective in highly conditioned populations. Highly conditioned athletes may 
already be regularly exposing themselves to an alternative form of preconditioning via 
their own high intensity training (Alleman, Stewart, Tsang, & Brown, 2015; Marongiu 
& Crisafulli, 2014). As such, the benefits that IPC can confer to an individual may 
already be well developed in a highly trained athlete, thus reducing the efficacy of the 
treatment (A. Lindsay, Petersen, Ferguson, Blackwell, & Rickerby, 2018; Seeger et al., 
2015). A recent meta-analysis investigating the influence of participant training status 
on the efficacy of IPC found that within existing IPC performance literature, when the 




Gender also plays a role in the efficacy of IPC. Paradis-Deschênes et al. (2017) (Table 
2.2). found that IPC prior to strength exercises increased average force production in 
males by 13% (0.64), but only by 2.3% (0.1) in females. Furthermore, where skeletal 
muscle oxygen extraction was enhanced in males during a number of exercise sets, this 
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effect was absent in females. This study demonstrated greater levels of oxygen 
extraction and strength enhancement in males than females, when exposed to identical 
preconditioning protocols. It was proposed gender differences in the responsiveness to 
endogenous vasodilators could be responsible for this effect (Dietz, 1999; Levenson, 
Pessana, Gariepy, Armentano, & Simon, 2001). However, it was also suggested that 
the greater proportion of type II muscle fibres present within male knee extensor 
muscles relative to female counterparts could have accounted for increases in muscle 
oxygen extraction (Staron et al., 2000). Regardless of how the differences arose, clearly 
gender may influence the efficacy of IPC. 
 
Age 
Age has been shown to influence the efficacy of IPC. van den Munckhof et al. (2013) 
found that in young (20-25 years old), but not old (69-77 years old) men, IPC prevented 
a decrease in endothelial function after a single IR cycle (20 min ischemia, 15 min 
reperfusion). This difference was reasoned to be due to age related reductions in 
signalling molecules key to the metabolic cascades of IPC (K. Boengler, Schulz, & 
Heusch, 2009). The only population within the performance literature comparable to 
the older men of van den Munckhof et al. (2013) is the chronic stroke survivors (mean 
age of ~57 years old) of Hyngstrom and colleagues, which found IPC to be effective in 
improving performance (Durand et al., 2019; A. Hyngstrom et al., 2016; A. S. 
Hyngstrom et al., 2018) (Table 2.2, 2.4). As most of the participants within IPC 
performance literature fall between ~20 to ~ 40 years old and with IPC efficacy evenly 
distributed across all ages, the impact of age within IPC research relevant to high 




Methods of IPC Application 
Dosage 
The dosage of IPC treatment may vary in terms of the mass of ischemic tissue 
(unilateral or bilateral), location (remote or local application) and/or the time under 
ischemia (number of cycles and length of cycles). Cocking, Wilson, et al. (2017) (Table 
2.3) directly assessed the influence of each one of these variables on the efficacy of an 
IPC treatment prior to a 375 kJ cycling time trial. Here, it was shown that a greater 
ischemic mass (bilateral vs unilateral application) produced greater ergogenic effects, 
supporting the existing findings from Kraus et al. (2015) (Table 2.2). Time under 
ischemia (eight 5 min cycles vs four) was found to be a negligible factor which 
concurred with subsequent research from Turnes et al. (2018) (Table 2.3). Similarly, 
the location of application (remote application (arm) vs local (thigh)) was also shown 
to be a negligible factor. Other studies have attempted to replicate these investigations 
but confounding variables within the exercises protocols may have interfered with 
expected outcomes with null effects shown (Table 2.3) (Griffin et al., 2019; Zinner et 
al., 2017). The influence of the magnitude of ischemia (level of blood flow restriction 
and additional deoxygenating factors) has also been investigated. Whilst it has been 
shown that arterial occlusion pressure may vary between individuals, all performance 
studies have utilised pressures (~220mmHg) very likely to eclipse the threshold of any 
individual (Brown et al., 2018).  
 
Timing 
The effect of timing of the IPC stimulus is not fully understood within a sporting 
context. There is yet to be a performance based study manipulating IPC timing prior to 
performance, solely within an acute timeframe (immediate to 1 h). Lisboa et al. (2017) 
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(Table 2.3) did investigate longer term variations of the time period between treatment 
and performance (1, 2 and 8 h post IPC). The results suggested that a longer timeframe 
between treatment and performance would increase the efficacy of IPC, although the 
time scale of this experiment eclipses most performance studies. Nevertheless, the 
results of Lisboa and colleagues concur with the Salvador et al. (2016) meta-analysis 
showing evidence that smaller time domains may be detrimental to anaerobic exercise 
tasks. Smaller time periods between IPC and performances (<20 min) may negatively 
affect anaerobic performances specifically by restricting the recovery of high energy 
phosphates depleted during the IR cycles (Takeo & Sakanashi, 1983). Similarly, a small 
timeframe between treatment and performance could also impair the efficacy of IPC 
within aerobic performances by limiting the physiological adaptations to IPC (Belaiba 
et al., 2007; Calvani, Comito, Giannoni, & Chiarugi, 2012; Fox, Walsh, & Mulhall, 
2018). The variable of timing presents significant potential to influence the mechanism 




Positive effects have been noted in a range of exercise modalities, however, outside of 
swimming performances (to be explored in the following section), there is currently no 
evidence to suggest that the effects of IPC are more prominent in one exercise modality 
over another.  
Environment 
Jean-St-Michel et al. (2011) (Table 2.3) initially proposed that IPC could be effective 
in improving swimming performances because maximal swimming efforts could 
produce metabolic conditions comparable to mild ischemic insults. The positive 
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findings of this experiment has since been backed by nearly all other swimming studies 
showing similar performance improvements (Table 2.3) (Ferreira et al., 2016; Lisboa 
et al., 2017; Williams et al., 2018). Marocolo et al. (2015) found IPC to be indifferent 
to a sham procedure, although the timing of the protocol may have confounded the 
results. The improvements of the studies reporting positive effects are of particular 
interest as most swimming performances have been between ~25 s to ~ 1min in 
duration, implying that the tasks are highly anaerobic. This is in spite of the trend within 
the body of literature showing IPC to be less likely to show beneficial effects in tasks 
of a high anaerobic energy contribution. Consequently, the findings of swimming 
studies advocate a positive relationship between the restriction of oxygen availability 
and the efficacy of IPC.  
The nature of this relationship has been further explored by studies using hypoxia 
(Table 2.2, 2.3) (Foster et al., 2014; Foster, Westerdahl, Foster, Hsu, & Anholm, 2011; 
Hittinger et al., 2015; Paradis-Deschenes et al., 2018; Wiggins et al., 2019). Using 
incremental increases in hypoxia, it was found that the efficacy of IPC is improved 
concomitant with increases in hypoxic severity (Hittinger et al., 2015; Paradis-
Deschenes et al., 2018). Specifically, Paradis-Deschenes et al. (2018) (Table 2.3) found 
IPC to improve the performance of a 5km time trial by 1.1% (0.22) in mild hypoxia 
(FIO2: 18%), yet the ergogenic effects increased to 1.5% (0.38) in more severe hypoxia 
(FIO2: 15.6%) (even in highly trained athletes).  
The effect of heat on the efficacy of IPC has also been investigated in a limited capacity. 
James et al. (2016) (Table 2.1) found that IPC increased performance in a graded 
maximal running test performed in heat (32 °C, 62 % RH). Alongside performance, 
IPC reduced core temperature, although skin temperature remained unaffected. Despite 
the positive effect, as there was no control condition investigating the effects of IPC in 
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normal heat/humidity, the effect of heat on the ergogenic capacity of IPC cannot be 
truly surmised.  
 
Ergogenic Physiological Responses to IPC  
Ischemic preconditioning has demonstrated efficacy as an ergogenic aid. However, it 
is unclear which end effectors of IPC are responsible for enhancing performance. This 
section will explore the physiological responses observed within performance studies 
and expound upon them with the known end effectors of IPC.  
 
Oxygen Consumption 
Ischemic preconditioning has been shown to enhance parameters of oxygen 
consumption (Fig.2.2). This effect appears to be most prominent within the exercising 
tissue, rather than providing a systemic effect throughout the whole body. Supporting 
this are conflicting reports of increased whole body oxygen consumption, whereas 








Figure 2-2 The potential humoral pathway underlying the transfer of the pro-survival end effectors of IPC to the 
betterment of exercise performance. Within the humoral pathway, triggers are produced within the ischemic tissue 
and then washed out into the blood stream to activate extracellular receptors within the target tissue. This induces a 
number of physiological responses which have been observed concomitant to increases (and decreases) in exercise 
performance. A number of end effectors can contribute to these physiological responses and have been listed 
accordingly next to each physiological response. 
 
 
The reported effect of IPC on whole body oxygen consumption are very inconsistent. 
A number of studies have reported increases in systemic maximal oxygen consumption 
(VO2peak) during maximal intensity exercise (Cruz et al., 2015; de Groot et al., 2010; 
Angus Lindsay et al., 2017; Yoon & Jae, 2018). However, this is countered by a similar 
amount null findings (Bailey, Birk, et al., 2012; Crisafulli et al., 2011; H. Jones et al., 
2014; Helen Jones et al., 2015; L. Smith et al., 2018; Tocco et al., 2015). Similarly, 
slow component VO2 amplitudes have been reported to be both increased and decreased 
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by IPC (Cruz et al., 2015; Cruz et al., 2016; Kilding et al., 2018). Further contributing 
to conflictions  are assorted reports of affected/unaffected running economies (James et 
al., 2016; Kaur, Binger, Evans, Trachte, & Van Guilder, 2017; Kilding et al., 2018). 
Although the exact source of such variability are unknown, it’s likely the variables of 
participant conditioning status and also IPC protocol timing are culpable. This is 
because no studies utilising a highly conditioned population for a maximal incremental 
exercise task found IPC to increase any parameters of oxygen utilisation (Hittinger et 
al., 2015; Kilding et al., 2018; Sabino-Carvalho et al., 2017). Furthermore, in the 
incremental exercise tasks that did show an increase in oxygen utilisation, the effects 
appeared to improve as the time duration between the treatment and test increased (de 
Groot et al., 2010; Angus Lindsay et al., 2017; Yoon & Jae, 2018). 
Regardless of confounding factors, a number of IPC end effectors can plausibly 
increase the consumption of oxygen during exercise. One such effect is the reduction 
of oxidative stress (Bentley, Ackerman, Clifford, & Slattery, 2015). Ischemic 
preconditioning is known to reduce ROS production and increase antioxidant defence 
(Holley et al., 2011; Müller & Dhalla, 2010; Quarrie et al., 2011; Quarrie et al., 2012). 
This effect can support mitochondrial respiration during high exercise intensities by 
facilitating ETC function (Bernhard Kadenbach, Ramzan, & Vogt, 2013; Bernhard 
Kadenbach, Ramzan, Wen, & Vogt, 2010; Shiva et al., 2007). Just one performance 
study has measured oxidative stress levels during exercise. Here, biomarkers of 
oxidative stress (neopterin and biopterin) were reduced, coinciding with large increases 
in maximal aerobic power output and maximal oxygen consumptions (Angus Lindsay 
et al., 2017). A number of end effectors could be responsible for increased performance 
resulting from reductions in oxidative stress. In shorter term studies (5-60 min), 
reductions in oxidative stress may have been achieved through acute end effector 
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responses such as the S-NO of ETC compounds (Babot, Birch, Labarbuta, & Galkin, 
2014; Gorenkova, Robinson, Grieve, & Galkin, 2013; B. Kadenbach, 2003; Shiva et 
al., 2007). The S-Nitrosylation of complex 1 elicits a structural change of the cysteine 
39 subunit of complex 1 of the ETC, decreasing the production of ROS (Ertracht et al., 
2014). Further S-NO reactions within the ETC can also occur within at cytochrome c 
oxidase, which optimises the efficiency of respiration within hypoxic cells and reduces 
excessive ROS production (Nadtochiy et al., 2009; Prime et al., 2009). An additional 
the acute response to activated mKATP channels can then also reduce mitochondrial Ca+2 
intake, thereby preventing the upregulation of pyruvate dehydrogenase and reducing 
electron flux through a damaged ETC, thereby preventing excessive ROS production 
(Brookes et al., 2004).  
In longer term studies (>60 min), genetic adaptations can play a part in reducing 
oxidative stress (Belaiba et al., 2007; Calvani et al., 2012; G. L. Semenza, 2011). One 
such adaptation may be an increase in manganese superoxide dismutase (MnSOD) 
content (M. Chen et al., 2015; Holley et al., 2011; Müller & Dhalla, 2010; Parajuli & 
MacMillan-Crow, 2013; Park et al., 1997; Yuan et al., 2012; X. Zhou et al., 1996). 
MnSOD is an antioxidant located primarily within the mitochondria and it is essential 
for the removal of ROS generated by the ETC (Xu et al., 2015). Ischemic 
preconditioning has notable increased MnSOD content in as little as 60 min following 
treatment (X. Zhou et al., 1996), making this adaptation pertinent to a number of studies 
showing increases in oxygen utilisation (Cruz et al., 2015; Cruz et al., 2016; Angus 
Lindsay et al., 2017; Yoon & Jae, 2018). The low level ROS production during the IR 
cycles induces the binding of nuclear factor E2-related factor (Nrf2) to antioxidant 
response element, initiating the expression of MnSOD alongside a whole family of 
antioxidants (M. Chen et al., 2015; Kaspar, Niture, & Jaiswal, 2009; Nguyen, Nioi, & 
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Pickett, 2009). By increasing antioxidant content within the mitochondria, the function 
of the ETC is maintained in times of relative high energy demands (Bentley et al., 
2015). 
An additional genetic adaptation may the triggering of HIF1α transcription by receptor 
dependant triggers of IPC (bradykinin and opioids) through the phosphoinositide 3-
kinase/protein kinase B pathway (Belaiba et al., 2007). The purpose of HIF1α is to 
signal increases in hypoxic threat defence (Gregg L. Semenza, 1999). Increases in 
HIF1α messenger RNA have been noted in as little as 30 min-post IPC, with increases 
in actual gene concentration seen 1 h-post treatment (Calvani et al., 2012; Chandel et 
al., 2000; Mahfoudh-Boussaid et al., 2012). Whilst activation of HIF1α helps to reduce 
oxidative stress, it also increases vascular endothelial growth factor (VEGF) and 
erythropoietin (EPO) expression (Calvani et al., 2012; Chandel et al., 2000; Fukuda et 
al., 2007; Hoppeler, Vogt, Weibel, & Fluck, 2003). This results in angiogenesis 
(creation of new blood vessels) and erythropoiesis (creation of new blood cells), which 
can contribute greatly to increasing aerobic exercise capacity (Pialoux et al., 2009). 
However, the timeframe of this specific genetic adaptation may be more relevant to 
chronic rather than acute (0-90 min) treatments of IPC, such as the daily treatments 
over 2 weeks seen in Angus Lindsay et al. (2017). Furthermore, although this chronic 
treatment was seen to be effective in increasing whole body oxygen utilisation in an 
unconditioned population, a subsequent replication of this protocol was ineffective 
within a highly conditioned cohort (A. Lindsay et al., 2018). 
 
A number of physiological responses to IPC can take place to increase whole body 
oxygen utilisation. However multiple factors may be contributing to the variability 
within the collective body of research. The timing of the protocol can govern the 
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adaptations possible within the timeframe of the experimental trials whilst the 
conditioning status of the participants can also affect the efficacy of the IPC procedure.  
 
Whole body maximal oxygen consumption is reliant on both the delivery and extraction 
of oxygen to within the muscle (Wagner, 2000). As noted in above sections, IPC 
provides a powerful stimulus for vasodilation through numerous pathways. The results 
of which have been observed during exercise in increases in post-exercise flow 
mediated dilation (FMD) and also reduce pulmonary arterial systolic pressure (Bailey, 
Birk, et al., 2012; Berger et al., 2017; Scott Cocking et al., 2018; Foster et al., 2014; H. 
Jones et al., 2014; Kaur et al., 2017; Seeger et al., 2015; van den Munckhof et al., 2013). 
Notwithstanding, IPC has also been shown to result in functional sympatholysis, 
redirecting arterial blood from splanchnic tissue in order to increase blood volume 
within the exercising muscle (M. Horiuchi, Endo, & Thijssen, 2015; Paradis-Deschênes 
et al., 2017). Increases in circulating NO are central to this effect (Fleming & Busse, 
2003). Not only expressed through the bradykinin and opioids pathways (Downey, 
Davis, & Cohen, 2007), NO is also released as a result of adenosine A1/A3 (and A2b 
receptor activation (Belardinelli et al., 1998; Eckle et al., 2007; Kuno et al., 2007)) and 
via TRPV1 activation downstream of calcitonin gene related peptide (CGRP) release 
(Ay & Tuncer, 2004). However, an increase in NO content may not be sufficient on its 
own to improve performance by increasing blood flow. The oxidation of NO impairs 
its ability to attenuate endothelial inflammation by preventing its inhibition neutrophil 
activation and the expression of adhesion molecules (Gryglewski et al., 1986; Rubanyi 
& Vanhoutte, 1986). Therefore the upregulation of antioxidant defence alongside the 
reduction in damaging ROS production is vital to the vasodilatory function of NO (H. 
Chen et al., 2011; Gryglewski et al., 1986; Mazzoni et al., 1992; Rubanyi & Vanhoutte, 
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1986; T. Zhou et al., 2018). Finally, chronic exposure to IPC results in a reduction of 
inflammatory immune responses through a reduction in leukocyte activation and 
adhesion molecule expression (Kharbanda et al., 2001). In addition, the opening of the 
mKATP channel also assists in the prevention of inflammation by preventing the Na+ 
influx needed for the swelling mechanism. Given the numerous pathways available, it 
is unsurprising that parameter measures of increased vasodilation are the most 
consistent physiological responses reported to IPC in exercise performance.  
 
The extraction of oxygen from arterial blood by the skeletal muscle serves as a 
secondary factor increasing oxygen consumption in this model. Performance studies, 
more commonly in isolated single muscle exercises, have reported lower tissue 
saturation indexes (a ratio of oxygenated to deoxygenated haemoglobin/myoglobin) 
and higher raw concentrations of deoxyhaemoglobin/myoglobin contents in working 
muscles after IPC treatment, signifying a greater extent of skeletal muscle oxygen 
extraction (Barbosa et al., 2014; Kido et al., 2015; Kjeld et al., 2014; Paradis-Deschenes 
et al., 2018; Paradis-Deschênes et al., 2017; Patterson et al., 2015; Richard & Billaut, 
2018c; Tanaka et al., 2016; Turnes et al., 2018; Van Beekvelt, Colier, Wevers, & Van 
Engelen, 2001; Wiggins et al., 2019). Furthermore, accelerated oxygen extraction rates 
have also been reported in a number of studies (Kido et al., 2015; Tanaka et al., 2016). 
A plausible explanation of improved oxygen extraction parameters may be an increased 
mitochondrial oxidative capacity. Increases in muscle oxidative capacity have been 
previously noted in two different plantar flexion models (Andreas et al., 2011; Jeffries 
et al., 2018). The mechanism behind this increase may be related to a preservation of 
ETC function. Hypoxia is known to diminish mitochondrial membrane potential by 
impairing mitochondrial complex I and III function (Babot et al., 2014; Borutaite & 
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Brown, 2006; Quarrie et al., 2011; Thaveau et al., 2007), yet can be circumvented with 
the S-nitrosylation and mKATP activation modulation of these complexes, providing an 
avenue to maintain respiration rates and mitochondrial flux (Garlid & Paucek, 2003; 
Prime et al., 2009; Rostovtseva & Colombini, 1997; Yabe et al., 1997). Furthermore, 
an additional adaptive response to HIF1α expression is the subunit switching of 
cytochrome c oxidase subunit (Fukuda et al., 2007). This switch increases the efficiency 
of electron transfer to complex 4 in the ETC during hypoxia. Not only does this reduce 
ROS production, but also facilitates the pumping of protons from the inner membrane 
space, improving the production of ATP for a given oxygen cost. This specific 
adaptation may be responsible for particularly large ergogenic effects seen in breathing-
restricted performance studies. Whilst Kjeld et al. (2014) found that IPC produced a 
0.4% (0.23) increase in the 1000m time trials performance of elite rowers, the same 
preconditioning stimulus was found to improve the static and dynamic breath holding 
of elite divers by ~8-17% (0.63-0.87). A contrast of these results suggests that the 




The effect of IPC on anaerobic capacity may prove to be a double edged sword in some 
respects. In exercises comprising of repeat short duration sets with restricted recovery 
periods (such as 12 x 6 s cycling sprints or 5 x 5 MVC isokinetic knee extensions), IPC 
may prove a positive effect (Paradis-Deschenes et al., 2016; Patterson et al., 2015). This 
effect is likely due to an enhanced capacity to recover PCr stores between sets. The 
activation of mKATP channels may be responsible for this improved capacity. Activation 
of the mKATP channel induces mitochondrial matrix swelling, which facilitates the 
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functional bridging of the intra membrane space (Schlattner & Wallimann, 2000; 
Wallimann et al., 1998). The octamer, mitochondrial creatine kinase (Mi-Ck), forms 
the bridge that spans between the voltage dependant anion channel (outer membrane) 
and the ATP/ADP translocator (ANT) (inner membrane) (Rostovtseva & Colombini, 
1997; Vyssokikh & Brdiczka, 2003). Dysfunctional Mi-Ck bridging inhibits PCr re-
synthesis rates during ischemia but the mKATP mediated-matrix swelling ensures a rapid 
Mi-Ck reaction (V. Saks et al., 1998; V. A. Saks et al., 1986; V. A. Saks et al., 1994). 
This greatly facilitates the output of PCr as the re-phosphorylation of ADP substrates 
is accelerated within the matrix (V. Saks et al., 1998). Overall, matrix swelling may be 
responsible for increases in repeated anaerobic efforts by improving the recovery 
capacity of PCr stores (Angus Lindsay et al., 2017; Paradis-Deschênes, Joanisse, & 
Billaut, 2016; Patterson et al., 2015). An additional facet of the IPC mechanism that 
may improve anaerobic performance is the phenomenon of PCr super-compensation. 
This has been noted in plantar flexion exercises where following ischemia, PCr content 
was recovered to ~+10% of resting levels (Andreas et al., 2011; Kobara et al., 1996). 
However the performance benefits of super-compensated anaerobic stores has yet to be 
realised in single effort alactic exercises (N. Gibson et al., 2015; Murray, Gibson, 
Fawkner, Mahony, & Tracey, 2014). 
  
In longer duration anaerobic efforts, pro-survival effects of IPC may actually become 
detrimental to performance. Both Paixão et al. (2014) and N. Gibson et al. (2015) 
reported negative effects in anaerobic exercises. This may be due to the function of IPC 
that negates metabolic acidosis during ischemia via the downregulation of anaerobic 
glycolysis (Kobara et al., 1996; Weiss et al., 1996). To do this, multiple glycolytic 
enzymes are inhibited alongside downregulated glycogenolysis, thus reducing 
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glycolytic flux (Masoud et al., 2015; Vogt et al., 2002; Weiss et al., 1996). 
Consequently, exercise performances relying heavily on energy produced via this 
pathway, are likely to be negatively affected. Nevertheless, reduced anaerobic 
glycolysis can also provide some benefits by reducing proton accumulation during 
submaximal exercise (Bailey, Jones, et al., 2012). This specific effect may then lead to 
improved performances in incremental exercise tests by providing better cellular 
conditions to complete the final stages of the maximal tests (Lisboa et al., 2017; Seeger 
et al., 2017).  
 
Neural 
Although the majority of performance research has investigated the capacity for 
humoral end effectors to improve exercise performance, IPC signal transduction 
operates via both humoral and neural pathways. As a result of this, the properties of any 
sort of neurally mediated ergogenic effect is relatively unknown.   
Interest in a neural pathway began when IPC treatment, in the absence of any increases 
in ventilator parameters, increased maximal aerobic power output by 4% (Crisafulli et 
al., 2011). In their explanation, the authors inferred that IPC may have lowered the 
sensitivity of the body to fatigue signals, permitting exercise to a greater degree of 
severity. It was later proposed that IPC may achieve this by interfering with the 
feedback loop between the exercising muscle and the CNS (Cruz et al., 2015). This 
feedback loop helps to maintain homeostasis by terminating exercise effort upon 
sensation of metabolic threats. However, an interference within this loop would 
theoretically prolong exercise effort to a greater severity (Amann et al., 2009). 
Therefore, IPC presents a possible avenue to accessing untapped exercise potential 




Figure 2-3 The potential neural pathway underlying the transfer of the pro-survival end effectors of IPC to the 
betterment of exercise performance. Within the neural pathway, the ischemic tissue triggers the local afferent neural 
pathway, stimulating an efferent pathway into the target tissue, activating extracellular receptor pathways. This 
induces a number of physiological responses which have been observed concomitant to increases. A number of end 
effectors can contribute to these physiological responses and have been listed accordingly next to each physiological 
response. 
 
Function of the Feedback Loop 
As mentioned above, a feedback loop between the CNS and sensory fibres innervating 
exercising tissue exists to help to regulate muscle activity. The sensory fibres are 
metabo/mechano-sensitive, thinly myelinated (group III) and unmyelinated (group IV) 
afferent fibres. Metabolic perturbations are detected by the afferents and are signalled 
to the CNS via increases in spontaneous discharges (Gandevia, 2001; Taylor, Butler, & 
Gandevia, 2000). The metabolic perturbations are detected via specific receptors 
located on the afferents including TRPV 1 and 2 (previously mentioned in section 
2.3.2.2), acid sensing ion channels1, 2, and 3 (ASIC 1-3) and purinergic receptors 
(P2X2, 3 ,4) (Jankowski, Rau, Ekmann, Anderson, & Koerber, 2013). The differential 
expression of these receptors distinguishes differences between subtypes of metabo-
receptive afferents as either ergo-receptors (i.e. freely perfused and predominantly 
aerobic metabolite detection) or nociceptive (noxious levels of metabolite detection 
common to ischemia) (Jankowski et al., 2013; Light et al., 2008). The signalling of 
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these metabolic perturbations to the CNS functions to regulate cardiovascular, 
hemodynamic, ventilatory adjustments (metaboreflex) and neuromuscular function 
required to match exercise intensity. Similarly, the detection of exercise-induced 
metabolic perturbations increases afferent discharge which acts to inhibit efferent 
output (neural drive) from spinal motor neurons. Holistically, the inhibition of neural 
drive leading to reductions in muscle activation is referred to as central fatigue (Amann, 
2011; Amann et al., 2011; Amann et al., 2008; Amann et al., 2009; Amann, Romer, 
Subudhi, Pegelow, & Dempsey, 2007; Amann et al., 2013).  
 
Ergogenic Neural Pathways 
The theory of Crisafulli et al. (2011) essentially implied that IPC could create a 
“functional overshoot” in neural drive. It’s exactly this overshoot that was speculated 
to be responsible for the increased muscle activity and concomitant performance 
enhancements noted in two cycling studies (Cruz et al., 2015; Cruz et al., 2016). Cruz 
et al. (2015) observed that IPC increased time to fatigue of maximal constant load 
cycling concomitant with increased surface electromyography (sEMG) amplitudes, 
VO2peak and VO2 slow component amplitudes. The increases in sEMG activity were 
interpreted as increased type IIb muscle fibre activation. This was deduced from 
increases in end-exercise VO2 slow component amplitudes, as type IIb muscle fibres 
are comparatively less oxygen efficient (Broxterman, Layec, Hureau, Amann, & 
Richardson, 2017). The subsequent observations of the following study (Cruz et al., 
2016), supported those in the original, as power output and sEMG amplitude were once 
again improved during maximal cycling. Moreover, increases in sEMG to power output 
ratios were also observed. This observation corresponded with previous observations 
in where IPC increased sEMG amplitudes and attenuated force output decrements 
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during equivocally electrically stimulated exercise in felines (Phillips, Petrie, Zhou, 
Guanche, & Baratta, 1997). Exactly how this augmented muscle activation is achieved 
though is unclear. Cruz and colleagues have previously speculated that the endogenous 
opioids produced during the initial IR cycles may interacted with the afferents to reduce 
discharge rates, thereby reducing inhibitory discharge signalling (Dragasis et al., 2013; 
Endres-Becker et al., 2007; Shaqura et al., 2014).  This speculation was based on 
similarities to previous research which showed similar physiological responses to the 
blockage of group III and IV fibre innervation via the application of lumbar intrathecal 
fentanyl (Amann et al., 2009). However, in Amann et al. (2009), ventilatory parameters 
were notably depressed by the fentanyl as the metaboreflex was also inhibited. Thus, it 
was speculated that in Cruz et al. (2015); Cruz et al. (2016), the IPC mediated opioid 
afferent interaction may have been limited to the ergo-receptors subtypes of the afferent 
fibres, limiting the sensation of fatiguing exercise (increased EMG amplitudes at end-
exercise) but permitting continued cardiovascular regulation (increased ventilatory 
parameters). The plausibility of this theory has been demonstrated in a recent piece of 
research where cycling performance was improved via the application of intrathecal 
fentanyl whilst breathing 100% O2 to maintain arterial saturation (Hureau et al., 2019). 
In results not dissimilar to Cruz and colleagues, muscle activity increased concomitant 
to power output increases. The use of electrical femoral nerve stimulation in this study 
also showed that peripheral fatigue was substantially exacerbated in the absence of a 
fully functioning feedback loop, as reductions in quadriceps twitch torque were far 
greater following the administration of fentanyl.  
In a requested viewpoint opinion piece, Cruz and colleagues also speculated upon an 
alternative ergogenic neural pathway (Cruz et al., 2017). This theory proposed that 
prolonged TPRV1 activation during the IR cycles can desensitise muscle afferents such 
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that their discharge thresholds are increased during exercise, essentially inhibiting the 
development of central fatigue (Cruz et al., 2017). The activation of the TPRV1 receptor 
has previously been implicated with IPC (Luo et al., 2013; Pollak et al., 2014), and long 
lasting desensitisation after continuous activation has been seen to have an analgesic 
effect (Burns, Chipchase, & Schabrun, 2016; Sharma, Vij, & Sharma, 2013). Thus 
increased thresholds may allow for greater metabolic perturbations throughout exercise, 
allowing for increased muscle activity.  
A desensitisation of afferents could also help to explain increases in squat jump heights 
reported by Beaven et al. (2012) which were concomitant with reductions in eccentric 
power. Although the primarily mechano-receptive type III sensory fibres (muscle 
spindles) are responsible for the detection of muscle stretch, they also possess 
nociceptive properties. Accordingly, hypoxia has previously been shown to acutely 
reduce tonic vibration index, a marker of muscle spindle excitability (Delliaux, Brerro-
Saby, Steinberg, & Jammes, 2009). Therefore, it’s possible that IPC can acutely 
improve elastic power movements via a desensitisation of muscle spindles, increasing 
elastic energy development of the jump but reducing parameters of eccentric power. 
Alternatively, a cross-over between the two theories of TRPV1 involvement and opioid 
production is also plausible. Here, endogenous opioid production may work to directly 
inhibit TRPV1 activity, an effect that has previously been note between μ (mu) specific 
opioid receptors (Endres-Becker et al., 2007). As such, the desensitisation of afferent 
muscle fibres and the resulting overshoot in neural drive that it creates remains the main 
theory of a neurally mediated ergogenic pathway of IPC. 
An alternative avenue of inhibited central fatigue development may also be that of 
reduced afferent stimuli production. Evidently, IPC improves ion cycling (Ca+2, Na+, 
K+) within the mitochondria, reduces glycolytic metabolite accumulation and also 
63 
 
reduces oxidative stress production. All of these by products are known to stimulate 
afferent receptors and subsequently engage feedback mechanisms (Delliaux et al., 
2009). It is then plausible that the simple reduction of stimuli may reduce neural drive 
inhibition during severe intensity exercise, thus improving exercise performance. 
Certainly given the measures of increased power output concomitant to reductions in 
oxidative stress of Angus Lindsay et al. (2017) can support this. Furthermore to this 
point, the increases in both relaxation and contraction times of Barbosa et al. (2014) 
may serve to represent neuromuscular function as a direct result of improved calcium 
handling during exercise to fatigue. 
Whilst these mechanistic pathway of reduced central fatigue development may help to 
explain a number of IPC enhanced performances, it fails to account for the findings of 
Hyngstrom and colleagues. In stroke effected participants, IPC has been seen to acutely 
increase maximal voluntary force output across multiple studies. Here, participants 
were seen to increase knee extension MVC force outputs alongside reduced motor unit 
recruitment thresholds and increased tendon tap reflex responses (Durand et al., 2019; 
A. Hyngstrom et al., 2016; A. S. Hyngstrom et al., 2018). It was proposed that the 
stimulation of the group III/IV afferents actually resulted in the release of 
neuromodulators (norepinephrine and serotonin), increasing the excitability of spinal 
motor neurons and thus increasing muscle activation (Dawson et al., 2016; Hayes et al., 
2014; Linder, Rosenfeldt, Rasanow, & Alberts, 2015). Although this branch of the 
theory remains especially pertinent to stroke survivors as the group III and IV afferents 
are supposed to become hyper-excitable post injury and its effect is expected to lose 
efficacy in healthy participants. Evidentially the premise of this theory works with 
increased motor neuron excitability and its underlying principles may act independently 




Presently, no such study to date has targeted an investigation into the premise of either 
of these avenues of neurological exercise augmentations. Whilst some have used proxy 
measures to complement their research into the ergogenic capacity of IPC, no such 
study has been performed with mechanistic focus solely assessing the neural responses 
to IPC with the required rigor.  
Conclusions 
Ischemic preconditioning is a simple concept with complex mechanisms of action. Its 
proven benefits of cellular protection have been shown to transfer to performance 
enhancement but the ideal application is still unclear. The physiological responses 
relating to oxygen consumption and energy provision can be elucidated by the known 
end effectors of the molecular signalling pathways. However, proposed neuromuscular 










Methods Applied in this Thesis 
This section explores the techniques utilised within this thesis and the rational of each 
measure. Specific methodologies regarding each technique within this thesis can be 
viewed within the Methods section of Chapters 3, 4 and 5. 
 
Neuromuscular Function 
To assess the mechanisms of central and peripheral fatigue development, we utilised a 
combination of the interpolated twitch technique, surface electromyography and also 
dynamometry.  
Interpolated twitch technique 
The interpolated twitch technique was used to assess parameters of central and 
peripheral fatigue. The technique involves the delivery of a supramaximal electrical 
stimulus to the axons of the α-motor neurons that innervate a contracting muscle. This was 
delivered both during a maximal voluntary contraction and also 2-3 s post the MVC. If the 
level of motor unit recruitment is submaximal during the MVC, the electrical stimulus 
will evoke a twitch (involuntary muscle contraction), superimposed on the MVC 
(superimposed twitch). The voluntary activation (VA) of the muscle is then derived 
from the relationship between the superimposed twitch and the corresponding twitch 
evoked from the resting muscle 2-3 s post the MVC (resting twitch). The longitudinal 
changes in VA and parameters of the resting twitch from pre to post exercise can then 
be used as measures of central and peripheral fatigue development respectively. In the 
preparatory phase of the experimental trials, to deliver the stimulation, a 4 x 3 cm 
aluminium foil strip coated with Conductive Adhesive Hydrogel (Ten20; Weaver and 
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Company, Aurora, CO, USA) was first placed on the lateral aspect of the hip, inferior 
to the iliac crest, to provide the site of the anode. Then, to identify the optimal nerve 
location for cathodal stimulation of the femoral nerve (Digitimer model DS7AH 
stimulator, Welwyn Garden City, UK), a rubber-insulated portable cathodal probe was 
used. The probe was moved around the femoral triangle using a stimulus intensity of 
30 mA until the largest muscle compound action potential (M-wave) was elicited from 
both the VL and VM recording sites. For all stimulations, a 200 μs square-wave pulse 
was applied at 400 V, with each stimulation being a doublet (two pulses applied to the 
femoral nerve with a 100 ms inter stimulus interval; 10 Hz stimulation). When the 
optimal nerve location was identified it was marked with a felt-tip pen and a 20 mm 
diameter surface electrode was applied (Kendall 700; Tyco Healthcare Group, 
Mansfield, MA, USA). Thereafter, to determine the optimum stimulus intensity to 
minimise discomfort and ensure 100% motor unit recruitment, a ramp test was 
completed, increasing stimulation current in 10 mA increments with 20 s rests between 
stimuli until plateaus in VL and VM M-wave amplitudes (Mmax) and the size of the 
knee-extensor twitch torque were observed. The maximal stimulus intensity (in 
milliamperes) was recorded and was multiplied by 130% to establish the stimulation 
intensity to be delivered to each individual participant in each experimental trial.  
 
Surface Electromyography 
The use of surface electromyography served two purposes within this study. The first 
was to provide guidance for the level of electrical stimulation required to ensure 
complete motor unit recruitment for the supramaximal twitch stimulations.  The second 
was to provide a measurement for gross nervous system output. Values obtained from 
sEMG could then be used to grossly infer amplitudes and rates of muscle activation for 
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comparison with prior research. Knee extensor sEMG was recorded during the 
experimental trials with Ag–AgCl surface electrodes (Maxsensor; Medimax Global, 
Seven Hills, NSW, Australia) positioned over the vastus medialis (VM) and vastus 
lateralis (VL) on the right thigh. During the preparatory phase of each experimental 
trial, electrodes were placed in the centre of the muscle belly with the inferior VL and 
VM electrodes positioned 8-12 cm and 3-4 cm from the lateral aspect of patella, 
respectively. Electrode placement specific to each participant was recorded to ensure 
consistency within and between testing sessions. A self-adhesive reference electrode 
was attached to the patella on the left leg. All placement sites were shaved, exfoliated 
and cleaned with an alcohol swab, while electrodes and cables were also taped to avoid 
any movement artefact. Raw electrode outputs from both VM and VL were pre-
amplified by a ML138 Octal BioAmp (ADInstruments, Australia), converted to a 
digital signal with a Powerlab (ADI Instruments, Sydney, NSW, Australia) and the 
bandpass filtered within MATLAB software (R2010a; The MathWorks Inc., Natick, 
MA, USA). A bandwidth frequency was applied ranging from 20 to 500 Hz (common 
mode rejection ratio > 90 dB; impedance input = 100 MΩ; gain = 1000).  
 
Dynamometry 
Dynamometry, a Biodex System 4 Pro dynamometer (Biodex Medical Systems, Inc., 
Shirley, New York, USA.), was used in this study to permit the accurate measurement 
of maximal voluntary torque, measures of voluntary and muscle activation and 
performance parameters of each exercise protocol. Participants were positioned upright 
in the dynamometer with thigh/trunk and knee angles of 90 degrees, and the centre of 
rotation of the lever arm aligned with the sagittal plane axis of the knee joint. 
Participants were secured with an adjustable thigh strap and contralateral diagonal 
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shoulder straps securing the trunk. A padded ankle cuff was placed superior (3 cm) to 
the lateral malleolus. Torque output signals were directly sampled from the 
dynamometer at 1000 Hz (Powerlab, ADI Instruments, Sydney, NSW, Australia) and 
low pass filtered at 10 Hz within MATLAB software (R2010a; The MathWorks Inc., 
Natick, MA, USA). Torque signals were calibrated for each participant’s limb weight 
(following positional securing via straps), and a predetermined calibration factor was 
applied for conversion of the recorded voltage to units of torque (Nm).  
 
Near-infrared spectroscopy and Pulse Oximetry 
Skeletal Muscle Oxygenation 
To assess the effect of IPC on skeletal muscle oxygenation, a combination of near-
infrared spectroscopy and pulse oximetry was utilised. 
 
Near-infrared spectroscopy 
Near-infrared spectroscopy (NIRS) was used to measure parameters of tissue 
oxygenation in the lower limb throughout each experimental trial. NIRS data was 
collected for tissue saturation index (TSI) as a percentage of haemoglobin oxygen 
saturation and this was based of fractions of deoxyhaemoglobin (HHb) and 
oxyhaemoglobin (O2Hb) volumes measured in arbitrary units (AU). A total 
haemoglobin (THb) volume, also in AU, was also calculated from these measures and 
used as a proxy measure of blood volume. In Chapter 3, a spatially resolved, dual 
wavelength NIRS apparatus, Portamon (Portamon, Artinis Medical Systems, the 
Netherlands), was used which was then replaced by a moorVMS-NIRS apparatus in 
Chapters 4 & 5 (moorVMS-NIRS; Moor Instruments Ltd, Axminster, Devon, UK). 
During the preparatory phase of each experimental trial, the NIRS device was fixed 
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directly above the belly of the rectus femoris muscle at the mid-point between the 
inguinal fold and the top of the patella on the most anterior aspect after cleaning the 
skin with an alcohol swab. The device was fitted with an adhesive black silicone mould 
to reduce movement artefact and eliminate potentially interfering background noise. 
Skinfold thickness was measured at the site using a Harpenden skinfold calliper (British 
Indicator Ltd., Burgess Hill, West Sussex, UK) during the familiarisation session, and 
in all accounts, was less than half the distance between the emitter and the detector (i.e. 
30 mm). This thickness is adequate to let near infrared light through muscle tissue, and 
coupled with the anatomical location of the NIRS, minimizes measurement variation. 
The position on the participant was noted and replicated in the following trials. A 
modified form of the Beer-Lambert law, using two continuous wavelengths (760 and 
850 nm) and a differential optical path length factor of 4.95, was used to calculate micro 
molar changes in tissue haemoglobin concentrations. NIRS data were acquired at 5 Hz. 
In chapter 5 the use of a NIRS apparatus was complemented by the use of a pulse 
oximeter (Masimo Radical-7 Rainbow SET Pulse Oximeter, Masimo Corporation, 
Switzerland) in order to provide measures for arterial oxygen saturation. This was 
implemented specifically to monitor the differences between environmental conditions 
(hypoxia vs normoxia).  
 
Ischemic Preconditioning 
Ischemic preconditioning protocols followed as per the findings of S. Cocking et al. 
(2018); (Salvador et al., 2016). Blood flow to the lower leg was restricted via the 
inflation of a blood pressure cuff to either 220 mmHg (IPC) or 20 mmHg (SHAM) for 
three 5 min periods on each leg, each interspersed by a 5 min reperfusion. Occlusion 
alternated between contralateral limbs ensuring a total IPC or SHAM time of 30 min 
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whilst the CON protocol consisted of 30 min of passive rest. A 18 cm wide inflatable 
cuff (Hokanson CC17, Bellevue, USA) was pressurised via an automated system 
(Hokanson E20/AG101Rapid Cuff Inflation System, Bellevue, USA). 
 
Hypoxic Air Inspiration 
Hypoxia was administered to participants in Chapter 5 prior to undertaking the exercise 
protocol in order to exacerbate localised tissue deoxygenation. Participants were fitted 
with a custom made facemask connected to a custom built portable normo-baric 
hypoxia generator (New South Wales Institute of Sport/Altitude Training Systems, 
Sydney, AUS). Oxygen fractions of inspired air were monitored by a separate portable 
gas analyser (O2 Analyser, gold edition, VacuMed, Seattle, USA) connected to the 
inspiration hose of the generator. 
 
Exercise Protocols 
All exercise protocols were completed on a dynamometer (Biodex Pro 4, Biodex 
Medical Systems, Inc., Shirley, New York, USA). The use of a dynamometer allowed 
immediate transitions into and from all neuromuscular assessments, enabling adequate 
neuromuscular fatigue profiling (Carroll, Taylor, & Gandevia, 2017). The consistency 
of the exercise modality across all experiments also meant that changes in exercise 
types between the studies would hold high value and any accompanying results could 
be then be attributed to that specific change.  
The 2 min MVC 
To assess any changes in neural drive that IPC may elicit, a sustained 2 min maximal 
isometric voluntary contraction was to induce fatigue. Muscle afferent discharge is 
significantly increased after sustained fatiguing isometric exercise, particularly when 
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high intramuscular pressure impairs muscle perfusion (e.g. ischemia) (Peter G. Martin, 
Janette L. Smith, Jane E. Butler, Simon C. Gandevia, & Janet L. Taylor, 2006; 
Rossman, Garten, Venturelli, Amann, & Richardson, 2014; Rossman, Venturelli, 
McDaniel, Amann, & Richardson, 2012). These conditions optimise reductions in 
voluntary activation and provide an ideal platform to view any influence that IPC may 
have on changes in central and peripheral fatigue development (Light et al., 2008; 
Pollak et al., 2014; Sinoway, Hill, Pickar, & Kaufman, 1993).  
 
The 3 min AOT 
Attempting to optimize the humoral benefits in order to elicit any available neural 
effect, a 3 min dynamic knee extension protocol with naturally normalized muscle 
perfusion was chosen for study. The protocol consisted of 135 isokinetic knee 
extensions (300°/s extension: 500°/s flexion) completed at a frequency of 45 repetitions 
per minute. The regulation of repetition ranges of motion and frequency meant that 
muscle perfusion would be naturally normalized across trials, optimizing conditions to 
assess the beneficial effects of enhanced oxygen. The exercise was completed without 
pacing to ensure that a plateau in power output was achieved prior to the conclusion of 
the test. Ischemic preconditioning has previously been shown to enhance exercise 
modalities over 3 min performed at an all-out intensity (Griffin et al., 2017). 
Furthermore, both knee extension and rhythmic dynamic exercise protocols have been 
shown to elicit substantial humoral benefits of IPC (Barbosa et al., 2014; Kido et al., 




The Hypoxic Repeat Sets 
To combine both severe localised tissue deoxygenation and dynamic contractions, 
hypoxia was added to a repeat anaerobic effort exercise protocol. The consisted of 6 
sets of 11 isokinetic knee extensions (120°/s extension: 300°/s flexion) completed at a 
frequency of 40 repetitions per minute. Each set lasted approximately 17 s with 20 s of 
rest between each set. Hypoxia was administered 10 min prior to the commencement 
of the protocol and concluded with the finishing of the task. Hypoxia has previously 
been shown to exacerbate central and peripheral fatigue development associated with 
repeat sets of knee extension exercises (Christian, Bishop, Billaut, & Girard, 2014). 
This characteristic provides obvious benefits the attempt to observe the influence of 
IPC on neural drive. In addition to this, the humoral benefits of IPC are known to be 
further pronounced in exercises performed in hypoxia (Paradis-Deschenes et al., 2018). 
Subsequently, this effect is likely to benefit the intermittent nature of the protocol due 






Chapter 3 The effect of IPC on central and peripheral fatiguing mechanisms in 
humans following sustained maximal isometric exercise 








Ischemic preconditioning (IPC) is thought to inhibit neural feedback from 
metabolically sensitive muscle afferents during exercise. It was hypothesized that IPC 
could affect the mechanism of centrally mediated fatigue following a maximally 
fatiguing protocol. Eleven resistance trained males completed three 2 min maximal 
voluntary contractions (MVC’s) via an isometric leg extension preceded by treatments 
of IPC (3 × 5 min bilateral leg occlusions at 220 mmHg), SHAM (3 × 5 min at 20 
mmHg) or CON (30 min passive rest). Femoral nerve stimulation was utilised to 
explore central and peripheral fatigue pathways. This was profiled at baseline (BL), 
prior to the 2 min MVC (Pre), and then 10 s post (Post). Tissue oxygenation was 
measured throughout the 2 min MVC’s via near-infrared spectroscopy. P r e  t o  
P o s t  MVC and twitch torque levels declined (-71 ± 56; d = 1.33 ± 0.51, p < 0.007) (-
51 ± 20 Nm; d = 3.76 ± 0.84, p < 0.005) respectively without differences between 
conditions (MVC; p = 0.67, twitch torque, p = 0.39). Voluntary activation was also 
unaffected by condition (p = 0.8). Peak deoxyhaemoglobin concentrations were elevated 
(3.7 ± 3.0 µmol-L; d = 1.02 ± 0.46, p = 0.003) (3.0 ± 3.7 µmol-L; d = 0.82 ± 0.57, p = 
0.03) in the IPC trials relative to CON and SHAM respectively. These findings 
demonstrate that IPC does not affect central or peripherally mediated mechanisms 





Ischemic preconditioning (IPC) was initially developed as a protective technique 
against myocardial ischemia/reperfusion injuries (Murry et al., 1986). It has recently 
been introduced in sporting contexts as an ergogenic aid owing to the metabolic 
similarities shared between high intensity exercise and mild ischemic insults (de Groot 
et al., 2010). Performance trials have demonstrated small to moderate (Cohen’s d > 
0.11) ergogenic effects across a range of modalities including a 2.5% reduction in 5 km 
time trial running (Bailey, Jones, et al., 2012), a 2.2% increase in maximal power (6 s 
cycling sprint; (Patterson et al., 2015), a 1.1% reduction in 100 m time trial swimming 
(Jean-St-Michel et al., 2011) and a 0.4% reduction in 1000 m rowing times (Kjeld et 
al., 2014). The IPC technique generally imposes three of four 5 min cycles of 
contralateral limb occlusion followed by a 5 min reperfusion period, accumulating 30-
40 min of sustained limb ischemia (Masahiro Horiuchi, 2017). This preparatory 
exposure to ischemia prior to exercise presumably induces increased cellular tolerance 
to high levels of metabolic perturbation experienced during high intensity exercise (J. 
C. Quindry & Hamilton, 2013). However, the exact mechanisms responsible for 
performance improvement remain unknown. 
 
Early findings suggested enhanced oxygen delivery to be the primary mechanistic 
change induced by IPC, however recent research has proposed IPC may also affect 
neural drive to working skeletal muscle (Barbosa et al., 2014; Crisafulli et al., 2011; 
Cruz et al., 2016; Cruz et al., 2017; Paradis-Deschênes et al., 2016; Tanaka et al., 2016). 
Barbosa et al. (2014) observed an attenuation in the reduction of rates of force 
development and relaxation times (both contractile characteristics symptomatic of 
altered neural drive) after IPC, without concomitant changes in haemodynamics or 
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deoxygenation during submaximal handgrip exercise to failure. Amplified surface 
electromyography (sEMG) at the point of task failure has also been reported following 
IPC treatment when compared to control conditions (Cruz et al., 2015; Cruz et al., 
2016). However, the indirect measures used to assess neural drive (Barbosa et al., 
2014), and the multitude of unrelated factors that can influence sEMG measures 
(Dimitrova & Dimitrov, 2003; Farina et al., 2010), warrant further investigation with 
more direct measures capable of profiling muscle activation after IPC. 
 
The use of maximal voluntary contractions coupled with supramaximal femoral nerve 
stimulation, in addition to changes in sEMG characteristics, may afford the opportunity 
to more accurately profile muscle activation during fatiguing exercise (Bigland-Ritchie, 
Furbush, & Woods, 1986). Profiling of the evoked twitches in reference to the voluntary 
contractions can also better characterise the pathways associated with neuromuscular 
fatigue (Kent‐Braun & Blanc, 1996; Merton, 1954). To complement this method, a 
fatiguing protocol designed to maximise reductions in central drive (i.e. 2 min isometric 
leg extension) may further elucidate whether IPC indeed influences neural drive to the 
working muscle (S. Goodall, Romer, & Ross, 2009; Place, Maffiuletti, Martin, & 
Lepers, 2007). Furthermore, reductions in central drive have been shown to be more 
pronounced after fatiguing voluntary efforts under blood flow restriction (Rossman et 
al., 2014). The blood flow restricting nature of the sustained, 2 min isometric 
contraction may also present a control for any potential increase in O2 delivery provided 
by IPC.  
 
Therefore, the aim of the present study was to assess the effect of IPC on mechanisms 
associated with neural drive (i.e. voluntary activation) and ultimately neuromuscular 
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fatigue. Specifically, the primary objective was to determine if IPC could preserve 
voluntary activation following a sustained, maximal effort exercise task whilst 
controlling for any humoral effects through the use of the isometric modality. Given 
recent evidence (Cruz et al., 2015; Cruz et al., 2016), it was hypothesised that IPC 





All procedures in this study were approved by the Western Sydney University Human 
Research Ethics Committee (approval code H12114) and were conducted in accordance 
with the Declaration of Helsinki, except for registration in a database. Eleven resistance 
trained men with a minimum training history of at least two resistance training sessions 
per week for the previous 6 months (median ± range) (age 24 ± 10 years, height 178 ± 
17 cm, and weight 79 ± 15 kg) volunteered to participate in this study after providing 
informed written consent. Minimum sample size was calculated from an a priori power 
analysis employing the value of 0.2 as the indication of the smallest worthwhile change 
using a customized spreadsheet (Will G Hopkins, 2006). 
 
Experimental Design 
A study flow diagram is provided in Fig. 3.1 During a preliminary session, participants 
were familiarised with all procedures involved in the study and provided with pre-test 
guidelines in regards to restriction of caffeine (12 h), alcohol (24 h), strenuous lower 
body exercise (48 h) and instructions as to replication of caloric and macro intake (24 
h) prior to the experimental trials. The preliminary session included exposure to the 
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femoral nerve stimulation protocols during a 3-5 s maximal voluntary isometric knee 
extension contraction (MVC), the fatiguing protocol (a sustained 2 min maximal 
isometric voluntary contraction of the knee extensors) and the IPC protocol. All testing 
was performed in a climate controlled laboratory (median ± range) (temperature: 23 ± 
1 °C; humidity: 51 ± 4%), at the same time of day and on the right leg over three days 












Figure 3-1 Study flow diagram 
Upon arrival for the experimental trials, participants were assessed for pre-existing knee 
extensor soreness using a 100 mm long single line visual analogue scale (rating 0-100) 
(Lau, Muthalib, & Nosaka, 2013). Participants were then fitted for sEMG and nerve 
stimulation electrodes as well as a portable near infrared spectrometer (NIRS) 
(PortaMon, Artinis Medical Systems BV, Netherlands). Neuromuscular function was 
then assessed at baseline prior to the intervention (BL), 20 min after the intervention 
(e.g. IPC) and 1 min prior to the 2 min MVC (Pre), and lastly 10 sec post 2 min MVC 
(Post). All participants performed the 2 min MVC under three separate intervention 
protocols; a control (CON), a sham occlusion (SHAM) or the IPC protocol (IPC). The 
interventions were performed with the participant lying in a supine position, and blood 
flow to the lower leg restricted via the inflation of a blood pressure cuff to either 220 
mmHg (IPC) or 20 mmHg (SHAM) for three 5 min periods on each leg, each 
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interspersed by a 5 min reperfusion (Salvador et al., 2016). Occlusion alternated 
between contralateral limbs ensuring a total IPC or SHAM time of 30 min whilst the 
CON protocol consisted of 30 min of passive rest. The participant then completed an 
additional 20 min rest prior to the onset of the 2 min MVC (Salvador et al., 2016). The 
inflatable cuff (Hokanson CC17, Bellevue, WA, US) was positioned on the upper leg 
where the adductor longus muscle attaches to the inguinal ligament and pressurised via 
an automated system (Hokanson E20/AG101Rapid Cuff Inflation System, Bellevue, 
WA, US). The cuff was 18 cm wide with an adjustable length of 108 cm. To minimize 
any placebo effect, participants were told that the purpose of the study was to compare 
the impact of two different cuff pressures that could both alter performance (Paradis-
Deschênes et al., 2016). 
 
Neuromuscular Function 
MVC and central activation were assessed pre- and post- both intervention and exercise 
using a Biodex System 4 Pro dynamometer (Biodex Medical Systems, Inc., Shirley, 
New York, USA.) Participants were positioned upright in the dynamometer with 
thigh/trunk and knee angles of 90 degrees, and the centre of rotation of the lever arm 
aligned with the sagittal plane axis of the knee joint. Participants were secured with an 
adjustable thigh strap and contralateral diagonal shoulder straps securing the trunk. A 
padded ankle cuff was placed superior (3 cm) to the lateral malleolus. Prior to 
performing exercise, participants completed a standardised warm up of 6 submaximal 
2-3 s isometric contractions (2 x 25%, 2 x 50% and 2 x 75% of perceived maximal 
effort). Torque output signals were directly sampled from the dynamometer at 1000 Hz 
(Powerlab, ADI Instruments, Sydney, NSW, Australia) and low pass filtered at 10 Hz. 
Torque signals were calibrated for each participant’s limb weight (following positional 
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securing via straps), and a predetermined calibration factor was applied for conversion 
of the recorded voltage to units of torque (Nm). For baseline measures four MVCs were 
performed, two with supramaximal nerve stimulation and two without, with 1 min rest 
between efforts. The highest of the four MVCs was used as the BL value. Thereafter, 
only 1 MVC was performed pre- and post- the exercise task (e.g. 2 min MVC). Each 
MVC was instructed to be performed as hard and as fast as possible and maintained for 
3-4 s. Strong verbal encouragement was provided during all MVCs. CVs of 4.6% and 
12.5% were recorded for MVCs and RTDs between trials, similar to previously 
published CV values (Buckthorpe, Hannah, Pain, & Folland, 2012; Place et al., 2007). 
A CV of 28.6% was attained for the total work done for the 2 min MVC. 
 
Surface EMG (sEMG) 
Knee extensor sEMG was recorded during the experimental trials with Ag–AgCl 
surface electrodes (Maxsensor; Medimax Global, Seven Hills, NSW, Australia) 
positioned over the vastus medialis (VM) and vastus lateralis (VL) on the right thigh. 
Electrodes were placed in the centre of the muscle belly with the inferior VL and VM 
electrodes positioned 8-12 cm and 3-4 cm from the lateral aspect of patella, 
respectively. A self-adhesive reference electrode was attached to the patella on the left 
leg. All placement sites were shaved, exfoliated and cleaned with an alcohol swab, 
while electrodes and cables were also taped to avoid any movement artefact. Electrode 
placement was recorded to ensure consistency within and between testing sessions. 
Raw electrode output was pre-amplified and bandpass filtered, with a bandwidth 
frequency ranging from 20 to 500 Hz (common mode rejection ratio > 90 dB; 
impedance input = 100 MΩ; gain = 1000). sEMG amplitudes were determined via the 
root mean square (RMS) of the 500 ms following supramaximal stimulation and the 
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MVC offset. Repolarisation of the superimposed M-wave (see Femoral Nerve 
Stimulation) and restoration of voluntary sEMG signals were observed in all data sets 
by 500 ms post stimulation, thus eliminating twitch artefact from contaminating the 
signal. Peak and maximal rate of amplitude development were quantified for both VM 
and VL. Processing of all neuromuscular data was performed using MATLAB software 
(R2010a; The MathWorks Inc., Natick, MA, USA). 
 
Femoral Nerve Stimulation 
A 4 x 3 cm aluminium foil strip coated with Conductive Adhesive Hydrogel (Ten20; 
Weaver and Company, Aurora, CO, USA) was placed on the lateral aspect of the hip, 
inferior to the iliac crest, as the anode. To identify nerve location for cathodal 
stimulation of the femoral nerve (Digitimer model DS7AH stimulator, Welwyn Garden 
City, UK), a rubber-insulated portable cathodal probe was used. The probe was moved 
around the femoral triangle using a stimulus intensity of 30 mA until the largest muscle 
compound action potential (M-wave) was elicited from both the VL and VM recording 
sites. For all stimulations, a 200 μs square-wave pulse was applied at 400 V, with each 
stimulation being a doublet (two pulses applied to the femoral nerve with a 100 ms inter 
stimulus interval; 10 Hz stimulation). When the optimal nerve location was identified, 
this was marked with a felt-tip pen and a 20 mm diameter surface electrode was applied 
(Kendall 700; Tyco Healthcare Group, Mansfield, MA, USA). Thereafter, stimulus 
intensity was increased in 10 mA increments with 20 s rests between stimuli until 
plateaus in VL and VM M-wave amplitudes (Mmax) and the size of the knee-extensor 
twitch torque were observed. The maximal stimulus intensity (in milliamperes) was 
recorded and multiplied by 130% to establish the test intensity (range for participants 
70–290 mA; VL Mmax 10.7 ± 4.1 mV and VM Mmax 15.3 ± 3.5 mV). Twitch torque 
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CVs of 3.9% were recorded across trials, similar to that of previous reliability studies 
(Place et al., 2007). 
 
Near-infrared Spectroscopy (NIRS) 
Oxygenation status of skeletal tissue was assessed using a portable spatially resolved, 
dual wavelength NIRS apparatus (PortaMon, Artinis Medical Systems BV, 
Netherlands). NIRS data was collected for deoxyhaemoglobin (HHb), oxyhaemoglobin 
(HbO2) and total haemoglobin (THb), equal to the sum of HHb and HbO2 and a 
surrogate indicator of changes in blood volume (Van Beekvelt, Colier, et al., 2001). 
After cleaning the skin with an alcohol swab, the NIRS device was fixed directly above 
the distal border of the gastrocnemius belly with a black calf compression sleeve to 
eliminate potentially interfering background light. Skinfold thickness was measured at 
the site of the application of the NIRS (x̅ = 7.32 ± 2.31 mm) using a Harpenden skinfold 
calliper (British Indicator Ltd., Burgess Hill, West Sussex, UK) during the 
familiarisation session, and was less than half the distance between the emitter and the 
detector (i.e. 20 mm). This thickness is adequate to let near infrared light through 
muscle tissue, and coupled with the anatomical location of the NIRS, minimizes 
measurement variation (CV = ~7 - 11%) (Muthalib, Millet, Quaresima, & Nosaka, 
2010). The position on the participant was noted and replicated in the following trials. 
The pressure cuff was positioned above the NIRS device, which did not affect the 
placement of the device during occlusions. A modified form of the Beer-Lambert law, 
using two continuous wavelengths (760 and 850 nm) and a differential optical path 
length factor of 4.95, was used to calculate micro molar changes in tissue haemoglobin 
concentrations. NIRS data were acquired at 10 Hz. At rest, once positioned within the 
dynamometer, the signal was stabilized and 1 min of baseline values was analysed pre 
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intervention. The NIRS signals were recorded throughout the 2 min MVC to obtain 
peak and average rates of change in concentrations of HHb, HbO2 and THb. This data 
was then normalised to the baseline collected prior to the intervention. 
 
Data Processing 
During all MVCs, the following torque variables were recorded: (i) the maximal 
voluntary torque (MVT; in Nm); and (ii) the maximal rate of torque development 
(RTDmax; in Nm.s-1), calculated as the greatest average 10 ms slope of the torque–time 
curve during the initial 100 ms of the contraction. During the 2 min MVC, total work 
done (kJ) was recorded. Voluntary activation (VA) was estimated using the 
superimposed twitch technique (Merton, 1954) according to the following formula 
(Strojnik & Komi, 1998): VA (%) = 100 – [D × (Tsup/MVT)/RT] × 100, where D is 
the difference between the torque level immediately before the superimposed twitch 
(Tsup) and the maximal torque recorded during the twitch, MVT is maximal voluntary 
torque during the entire contraction (not including the twitch response), and RT is the 
maximal amplitude of the resting potentiated twitch. The following variables were 
processed from each MVC for VL and VM sEMG signals: (i) maximal sEMG 
amplitude of VL (VLmax) and VM (VMmax), processed as the greatest average root 
mean square over a 250 ms period; and (ii) maximal rate of sEMG rise (VLRERave 
and VMRERave), calculated from the greatest average 10 ms slope throughout the 
initial 100 ms of the contraction. All sEMG signals were normalised to their respective 
M-wave. The following variables were calculated from the resting potentiated twitch: 
(i) RT amplitude (in newton metres); (ii) time to peak torque production derived from 
the RT (TTP; in milliseconds (ms)); (iii) the half-relaxation time (½ RT; in ms), which 





All statistical analyses were completed using IBM SPSS Statistics version 22 (SPSS 
Inc., Chicago, IL, USA). The Shapiro–Wilk normality test was applied to assess 
normality of distribution. The descriptive data are presented as means ± SD. Pain scores 
were analysed for differences using a one-way ANOVA. BL, Pre and Post 
neuromuscular assessment data (MVT, RTDmax, VA, VLmax and VMmax, 
VLRERave, and VMRERave and RT) and 2 min MVC time profiles for both work and 
NIRS data were analysed at 20% completion intervals using two-way (condition × time) 
ANOVA for repeated measures. Separate paired T-tests analyses were used to assess 
differences in total work capacity of the 2 min MVCs and NIRS variables (peak and 
average rate of change). In the event of a significant F ratio, post hoc comparisons were 
made using a Bonferroni correction. Two-tailed statistical significance was accepted at 
p < 0.05. Mean differences with standard deviations (SD) with Cohen’s effect sizes ± 
90% confidence intervals (CIs) were calculated when significant changes over time or 
when differences between conditions were observed (Will G Hopkins, 2003; W. G. 
Hopkins et al., 2009). The magnitude of effect sizes for  each change was defined as 
small > 0.2, moderate > 0.5 and large > 0.8 (Cohen, 1969).  
 
Results 
Maximal Torque Production  
Maximal torque declined between BL (BL: 262 ± 60 Nm) and Pre (Pre: 237 ± 56 Nm) 
(mean decline of 24 ± 16 Nm, d = 0.41 ± 0.15, p <0.05; Table 3.1). Maximal torque 
decreased following the 2 min MVC (mean decline of 71 ± 56 Nm, d = 1.33 ± 0.51, p 





Table 3.1 The MVC data for max toque output (MVC) and the maximal rate of torque production (RTD) for each MVC performed at baseline (BL) (n = 11), pre 2 min MVC (Pre) (n = 11) and 
post 2 min MVC (Post) (n = 11). Data are presented as mean ± SD (range: min - max). *Significantly different from BL (p < 0.05). †Significantly different from Pre (p < 0.05). 
 MVC (Nm) RTD (Nm.s-1) 
 CON SHAM IPC CON SHAM IPC 
BL 261 ± 62.2 (227.5) 
261 ± 63.9 
(223.1) 
263 ± 55.5 
(190.7) 
1431 ± 469.8 
(1453.7) 
1410 ± 393.2 
(1232.6) 
1499 ± 388.1 
(1156.8) 
PRE 237 ± 62.2* (207.7) 
245 ± 63.6* 
(207.5) 
231 ± 42.0* 
(144.3) 
1251 ± 451.1* 
(1361.1) 
1221 ± 339.9* 
(1170.5) 
1254 ± 349.6* 
(1017.9) 
POST 169 ± 46.7*† (151.4) 
167 ± 41.3*† 
(130.8) 
168 ± 32.2*† 
(94.6) 
699 ± 311.6*† 
(945.3) 
673 ± 236.0*† 
(767.4) 





Descending Central Drive 
Voluntary activation was unchanged throughout the experimental trials (p = 0.29; Table 
3.3, Fig. 3.2). No changes in max sEMG amplitude or RERave for VL or VM were 




Table 3.2 The sEMG/M data for VL (VLmax), VM (VMmax), VLRERmax and VMRERmax (all expressed as percentages of respective M-waves) for each MVC performed at baseline (BL) (n 
= 11), pre 2 min MVC (Pre) (n = 11) and post 2 min MVC (Post) (n = 11). Abbreviations: sEMG/M, surface electromyograms normalized to M-waves; VL, vastus lateralis; VM, vastus medialis; 
RERave, average rate of sEMG rise. Data are presented as mean ± SD (range: min - max). 
 VM VL 
 Max (%) RERave (%) Max (%) RERave (%) 
 CON SHAM IPC CON SHAM IPC CON SHAM IPC CON SHAM IPC 
BL 8.9 ± 4.3 (15.0) 
9.4 ± 4.3 
(14.0) 
7.2 ± 1.3 
(14.0) 
260 ± 195 
(732.0) 
331 ± 194 
(651.0) 
351 ± 178 
(523.0) 
7.2 ± 1.3 
(12.0) 
7.2 ± 3.0 
(12.0) 
6.2 ± 2.7 
(10.0) 
248 ± 159 
(579.0) 
240 ± 76 
(240.0) 
190 ± 77 
(241.0) 
PRE 7.7 ± 2.7 (8.0) 
9.7 ± 4.6 
(16.0) 
7.7 ± 2.0 
(13.0) 
242 ± 92 
(279.0) 
303 ± 148 
(486.0) 
300 ± 151 
(477.0) 
7.7 ± 2.0 
(7.0) 
7.4 ± 3.0 
(11.0) 
5.8 ± 2.0 
(7.0) 
244 ± 115 
(396.0) 
260 ± 130 
(449.0) 
204 ± 75 
(274.0) 
POST 13.7 ± 15.3 (53.0) 
11.7 ± 5.6 
(18.0) 
10.3 ± 8.0 
(24.0) 
385 ± 351 
(1223.0) 
357 ± 229 
(796.0) 
306 ± 193 
(733.0) 
10.3 ± 8.0 
(28.0) 
7.8 ± 3.0 
(10.0) 
9.0 ± 6.0 
(18.0) 
338 ± 216 
(730.0) 
260 ± 121 
(392.0) 




Resting Twitch Characteristics 
The resting twitch torque declined between BL and Pre measures (mean decline of 11 
± 8 Nm; d = 0.93 ± 0.26, p < 0.01; Table 3.3) before further declining at Post (mean 
decline of 51 ± 20 Nm; d = 3.76 ± 0.84, p < 0.01, Table 3.3). The ½ RT was not different 
between BL and Pre measures however it increased at Post (mean increase of 48 ± 13 
ms; d = 10.7 ± 2.57, p < 0.05, Table 3.3). Time to peak twitch did not change throughout 




Table 3.3 The amplitude of the peak resting twitch force (RT), the time-to-peak twitch (TPT), the half-relaxation time (½ RT) after MVCs at baseline (BL) (n = 11), pre 2 min MVC (Pre) (n = 
11) and post 2 min MVC (Post) (n = 11). Data are presented as mean ± SD (range: min - max). *Significantly different from BL (p < 0.05). †Significantly different from Pre (p < 0.05). 
 RT (Nm) ½ RT (ms) TTP (ms) VA (%) 
 CON SHAM IPC CON SHAM IPC CON SHAM IPC CON SHAM IPC 
BL 
96 ± 58.0 
(58.6) 
95 ± 47.1 
(54.9) 
97 ± 49.7 
(47.1) 
79 ± 15.9 
(32.0) 
81 ± 21.2 
(33.3) 
80 ± 22.9 
(35.5) 
173 ± 12 
(13.0) 
174 ± 14 
(12.0) 
174 ± 28 
(30.0) 
95 ± 3.0 
(8.4) 
93 ± 5.8 
(15.8) 
94 ± 2.9 
(12.8) 
PRE 86 ± 40.1* 
(46.2) 
86 ± 42.5* 
(47.3) 
86 ± 36.5* 
(38.7) 
78 ± 16.6 
(29.2) 
79 ± 17.9 
(15.3) 
77 ± 24.2 
(32.2) 
170 ± 16 
(15.0) 
187 ± 152 
(149.7) 
171 ± 11 
(11.3) 
93 ± 4.6 
(11.6) 
94 ± 4.1 
(10.9) 
93 ± 5.7 
(14.4) 
POST 34 ± 78.9*† (61.0) 
34 ± 71.3*† 
(63.6) 
34 ± 68*† 
(66.7) 
121 ± 55.1† 
(44.0) 
130 ± 36.5† 
(91.3) 
126 ± 69.0† 
(102.7) 
194 ± 256 
(240.3) 
153 ± 92 
(90.0) 
169 ± 55 
(62.0) 
85 ± 17.6 
(48.6) 
89 ± 16.3 
(44.0) 






Peak deoxyhaemoglobin (HHb) concentrations following the 2 min MVC were elevated in IPC 
(15.1 ± 2.8 µmol-L) relative to CON (11.3 ± 3.6 µmol-L) (mean increase of 3.7 ± 3.0 µmol-L; d 
= 1.02 ± 0.46, p < 0.01; Fig. 3.3A) and SHAM (12.1 ± 3.0 µmol-L) (mean increase of 3.0 ± 3.7 
µmol-L; d = 0.82 ± 0.57, p < 0.05; Fig. 3.3A). When time was profiled at 20% completion 
intervals throughout the 2 min MVC, there were significant increases in HHb concentrations 
in IPC relative to CON (d = 1.47 ± 0.6, p < 0.01) and SHAM (d = 1.44 ± 0.69, p < 0.05) (Fig. 
3.3A). There was no significant difference between conditions in the rate of HHb accumulation 
(p = 0.91). In HbO2 measures, neither peak (p = 0.69), rate (p = 0.44) or time profiled (p = 
0.71) levels were significantly different between conditions (Fig. 3.3B). Peak total 
haemoglobin (THb) concentrations were elevated in IPC (10.3 ± 5.5 µmol-L) relative to CON 
(4.9 ± 4.4 µmol-L) (mean increase of 5.4 ± 6.43 µmol-L, d = 1.16 ± 0.81, p < 0.05) but not 
SHAM (8.1 ± 5.8 µmol-L) (mean increase of 2.1 ± 8.6 µmol-L, d = 0.46 ± 1.08, p = 0.45; Fig. 
3.3C). There were no significant differences in the time profiled concentrations of THb (p = 














Figure 3-3 Time course of relative change in haemoglobin species concentration (µmol-L) (A, B and C) throughout the 2 min 
MVC in 20% completion increments. A: [HHb], Deoxyhaemoglobin, B: [HbO2], Oxyhaemoglobin, C: [THb], Total 
haemoglobin. Data are presented as means ± SD. * denotes significant increases in IPC relative to both Con and Sham (p < 
0.05). 
 
Total Work Done 
The total work done during the 2 min MVC was not different between conditions (p = 0.28), 
nor was the time profiling of the 2 min effort (p = 0.28). When analysed in 20% completion 
segments between 0-20, 20-40, 40-60, 60-80 and 80-100 there were no differences between 





Pain scores recorded on the visual analogue scale did not change throughout testing (1.0 ± 1.3, 
p = 0.91). 
 
Discussion 
The novel aspect of this study was the use of supramaximal femoral nerve stimulation to assess 
the effect of IPC on neural drive following sustained isometric exercise. In contrast to our 
hypothesis, the main finding demonstrated that three, 5 min periods of bilateral IPC at an 
inflation pressure of 220 mmHg does not affect neural drive during or after 2 minutes of 
maximal, sustained isometric knee extensor exercise. IPC did, however, result in an increase 
in localised oxygenation within the contracting muscle, albeit without any evidence of 
performance improvement (e.g. total work done). 
 
Ischemic preconditioning did not demonstrate any influence on measurements commensurate 
with neuromuscular fatigue in the present study. There were no treatment effects of IPC on 
VA, nor any indication IPC influenced muscle recruitment (e.g. no ∆ in sEMG variables; Table 
3.2). It has been suggested IPC may interfere with group III and IV afferent feedback, resulting 
in attenuated central fatigue and compromised work output (Amann et al., 2009; Crisafulli et 
al., 2011). Although not a measure of afferent feedback, presumably any imposition on these 
fibres (e.g. IPC) would be evidenced by changes in the superimposed twitch responses during 
an MVC. However, this did not occur in the present study, and as similar reductions in 
peripheral twitch amplitudes were evident across trials (Table 3.3), no meaningful changes 
were observed in VA (Fig. 3.2, Table 3.3). Elevated sEMG activity has also provided indirect 
evidence that IPC can preserve neural drive (Cruz et al., 2015; Cruz et al., 2016). Again, this 
increase in muscle recruitment was not present in the current study (Table 3.2). However, 
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sEMG measures are influenced by multiple factors, rendering comparisons between electrical 
activity within the muscle and neural drive inappropriate (Dimitrova & Dimitrov, 2003; Farina 
et al., 2010). Alternatively, these increases in sEMG signals may in fact be related to humoral 
benefits induced by IPC enabling an increase in skeletal muscle performance (Bailey, Birk, et 
al., 2012; Angus Lindsay et al., 2017; Paradis-Deschênes et al., 2016, 2017). As such, prior 
observations of increased sEMG activity may have been a by-product of IPC augmented 
humoral pathways, rather than a direct neural response.  
 
A secondary finding of this study was the influence of IPC on blood oxygenation. Across all 
trials, consistent increases in blood volume and deoxygenation were observed throughout the 
exercise task. However, under the influence of IPC there was a ~ 37% relative increase in the 
magnitude of blood deoxygenation with a trend for an increase in blood volume relative to the 
changes observed in CON and SHAM (Fig. 3.3). This would suggest that IPC induced an 
increase in oxygen delivery to the exercising muscle. This finding is similar to that of Paradis-
Deschênes et al. (2017), whereupon IPC increased oxygenation throughout a repeated, 
maximal voluntary knee extension task (16% increase in oxygen delivery; d = 0.36 ± 0.86). 
This consistent effect of increased oxygen delivery may in part be due to improved endothelial 
function resulting from the release of blood born chemical vasodilators induced by IPC 
(Downey et al., 2007; Steven P. Jones & Bolli, 2006; Kimura et al., 2007). However, as yet the 
mechanism underpinning any observed increase in the deoxygenated haemoglobin species 
remains unclear. 
 
The seemingly disparate relationship between performance and oxygen delivery serves to 
reinforce the study design aimed to isolate any neural effect of IPC. Isometric contractions have 
previously been shown to impede arterial blood flow to the muscle through sustained increases 
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in intramuscular pressure (Sadamoto, Bonde-Petersen, & Suzuki, 1983). As such, total blood 
volume supplied to the static contracting muscle is significantly reduced compared to that of a 
dynamically contracting muscle over similar time duration (Laaksonen et al., 2003). 
Theoretically, the constant intramuscular pressure induced by the sustained isometric 
contraction would also provide a level of control over blood supply, further isolating any neural 
effect (if any) of IPC. As neural drive was not affected in the present study, presumably any 
performance gain induced by IPC would not be a result of improved neuromuscular function. 
However, future research is required to confirm whether a more dynamic exercise modality 
(e.g. where perfusion is not limited) would confer the same neuromuscular responses observed 
in the present study. 
 
One limitation inherent in any IPC study design is that participants are fully aware of the 
significant pressure differences between IPC, sham and control conditions. To account for this 
limitation in the present study, participants were informed that both IPC and SHAM may 
influence performance (Paradis-Deschênes et al., 2016), but were naïve to the hypothesis that 
IPC would improve neural drive. The similar reductions in MVC (~ 30%; Table 3.1), work 
completed and peripheral twitch characteristics (~ 68%; Table 3.3) would suggest no placebo 
effect was present. Even the differences observed in peak deoxygenation between IPC (d = 
1.02 ± 0.46) and SHAM (d = 0.2 ± 0.57) relative to CON did not influence the performance 
measures.  
 
In conclusion, this experiment was designed to utilise a prolonged isometric contraction to 
restrict perfusion and mitigate any potential humoral effects of IPC, thereby better isolating 
any potential changes in neural drive to the working muscle. The findings demonstrate that IPC 
did not affect neural drive or performance despite inducing an elevation in blood volume and 
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oxygen delivery. Furthermore, these findings suggest that mechanisms related to improved 
perfusion may predominant over any changes in neuromuscular function induced by IPC. 
Further research is required to establish to what extent, if any, IPC may have on neuromuscular 




Chapter 4 The effect of IPC on central and peripheral fatiguing mechanisms in humans 
following maximal single limb isokinetic exercise 







Ischemic preconditioning (IPC) is thought to enhance neural drive in dynamic exercise 
however it is unaffected in static exercise. We hypothesized that the muscle oxygenation 
induced by a dynamic exercise task would allow IPC to attenuate post-exercise reductions in 
voluntary activation. Ten resistance trained males completed three 3 min maximal all-out 
tests (AOTs) via 135 isokinetic leg extensions preceded by treatments of IPC (3 × 5 min 
bilateral leg occlusions at 220 mmHg), SHAM (3 × 5 min at 20 mmHg) or CON (30 min 
passive rest). Femoral nerve stimulation was utilised to explore central and peripheral fatigue 
pathways. This was profiled at baseline (BL), prior to the AOT (Pre), and then 10 s post (Post). 
Tissue oxygenation was measured throughout the AOT via near-infrared spectroscopy. 
MVC torque levels declined (-87 ± 23 Nm, 95% CI = -67 to -107 Nm; p < 0.001) between Pre 
and Post without differences between conditions (p = 0.75). This Pre to Post decline coincided 
with decreases in twitch torque (-30 ± 13 Nm; 95% CI = -25 to -35 Nm; p < 0.001) but not 
voluntary activation (p = 0.72) and neither were affected by condition (twitch torque, p = 0.55; 
voluntary activation, p = 0.74). There were no differences in tissue saturation index (p = 0.27) 
or deoxyhaemoglobin (p = 0.86) measures. These findings demonstrate that IPC does not 
affect central or peripherally mediated mechanisms of fatigue during an all-out 3 min 





Ischemic preconditioning (IPC) was initially developed as a protective technique against 
myocardial ischemia/reperfusion injuries (Murry et al., 1986). It has recently been introduced 
in sporting contexts as an ergogenic aid due to the similar metabolic perturbation profile 
between high intensity exercise and mild ischemic insults (de Groot et al., 2010; Marongiu & 
Crisafulli, 2014; John C. Quindry, 2017; J. C. Quindry & Hamilton, 2013). The IPC technique 
generally imposes 3-4 x 5 min cycles of contralateral limb occlusion followed by a 5 min 
reperfusion period, accumulating 30 to 40 min of sustained limb ischemia (Masahiro Horiuchi, 
2017). Performance trials have demonstrated small albeit inconsistent ergogenic effects, 
ranging across modalities (running, rowing, cycling, swimming), time domains (<1 min to 30 
min) and intensities (sub-maximal, sustained high intensity and all-out effort) (Bailey, Jones, 
et al., 2012) (Angus Lindsay et al., 2017; Patterson et al., 2015), (Ferreira et al., 2016; Jean-St-
Michel et al., 2011; Lisboa et al., 2017) (Kjeld et al., 2014). These performance effects have 
often been attributed to a combination of peripheral vasodilation and increases in mitochondrial 
efficiency (Andreas et al., 2011; M. Horiuchi et al., 2015; Angus Lindsay et al., 2017; Paradis-
Deschênes et al., 2016, 2017; G. L. Semenza, 2011; Tanaka et al., 2016). However, a growing 
body of research has suggested that IPC may also augment neural mechanisms concomitant to 
the preservation of skeletal muscle function (Cruz et al., 2015; Cruz et al., 2016; A. S. 
Hyngstrom et al., 2018). 
  
Recent clinical research has demonstrated acute improvements in maximal strength 
corresponding with increases in surface electromyography (sEMG) signal amplitude after IPC 
(A. S. Hyngstrom et al., 2018). Similarly, enhanced sEMG signals have been seen in both 
aerobic and sprint cycling, where increased sEMG to power output ratios have suggested that 
IPC increases skeletal muscle activation (Cruz et al., 2015; Cruz et al., 2016). Based on these 
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findings, it was suggested neural drive was augmented through a disruption to the central 
feedback loop via the interference of signalling from group III and IV afferent sensory fibres 
(Amann et al., 2013; Blain et al., 2016). However, whilst sEMG can provide an estimate of 
gross nervous system output, the multitude of unrelated factors contributing to the signal 
amplitude confounds any mechanistic insight as to where within the neural circuitry IPC may 
be conferring its effect (Farina et al., 2010). In light of this, we recently used the interpolated 
twitch technique during a maximal, 2-min isometric leg extension task to better clarify whether 
IPC influences centrally mediated factors (e.g. neural drive) associated with maintaining task 
performance (S. L. Halley, Marshall, & Siegler, 2018). Contrary to previous reports (Cruz et 
al., 2015; Cruz et al., 2016), we did not observe an effect of IPC on sEMG amplitude nor did 
we see any improvement in the additional measures of neural drive (e.g. voluntary activation) 
(S. L. Halley et al., 2018). 
 
A notable point of difference between these studies, however, was our use of a static, prolonged 
maximal voluntary contraction (S. L. Halley et al., 2018) while the cycling tasks were more 
dynamic in nature (Cruz et al., 2015; Cruz et al., 2016). Although we hypothesised the 
sustained maximal effort would provide a favourable environment for IPC to influence neural 
drive (P. G. Martin, J. L. Smith, J. E. Butler, S. C. Gandevia, & J. L. Taylor, 2006; Taylor et 
al., 2000), the isometric task may have restricted skeletal muscle oxygen delivery through 
augmented intramuscular pressures (McNeil, Allen, Olympico, Shoemaker, & Rice, 2015). 
Moreover, the increased neural activity observed in both cycling studies was associated with 
IPC-mediated improvements in aerobic energy provision (as inferred via augmented 
haemoglobin kinetics) and therefore endurance capacity (Cruz et al., 2015; Cruz et al., 2016). 
More recently, Griffin and colleagues have also demonstrated significant improvements in the 
ability to sustain maximal rates of aerobic metabolism (e.g. critical power) after IPC, but 
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conversely, did not observe a differential effect on skeletal muscle oxygenation (Griffin et al., 
2017). As these authors did not measure neural activity, we cannot discern whether IPC-
mediated preservation of neural signalling compensated for the negligible change in aerobic 
energy provision. 
 
Therefore, the aim of the present study was to determine whether IPC, coupled with a dynamic 
exercise task designed to optimise oxygen delivery to skeletal muscle, augments neural drive 
during fatiguing exercising. Specifically, we examined whether a standard bout of IPC (3 x 5 
min cycles) better preserves voluntary activation following a 3-min maximal power test 
comprised of rhythmic dynamic single-leg extensions (Griffin et al., 2017). Given recent 
evidence (Cruz et al., 2015; Cruz et al., 2016; Tanaka et al., 2016), it was hypothesised that 
IPC would improve performance of the test through an attenuation of centrally mediated 




All procedures in this study were approved by the Western Sydney University Human Research 
Ethics Committee (approval code H12114) and were conducted in accordance with the 
Declaration of Helsinki, except for registration in a database. Ten resistance trained men with 
a minimum training history of at least two resistance training sessions per week for the previous 
6 months (mean ± SD) (age: 24.1 ± 3, weight: 80.5 ± 7) volunteered to participate in this study 
after providing informed written consent. Minimum sample size was calculated from an a 
priori power analysis employing the small effect size threshold value of d = 0.2 as the 





A study flow diagram is provided in Fig. 4.1 During a preliminary session, participants were 
familiarised with all procedures involved in the study and provided with pre-test guidelines in 
regards to restriction of caffeine (12 h), alcohol (24 h), strenuous lower body exercise (48 h) 
and instructions as to replication of caloric and macro intake (24 h) prior to the experimental 
trials. The preliminary session included exposure to the femoral nerve stimulation protocols 
during a 3-5 s maximal voluntary isometric knee extension contraction (MVC), the fatiguing 
protocol (a 3-min all out maximal power dynamic single-leg extension test (AOT)) and the IPC 
protocol. All testing was performed in a climate controlled laboratory (mean ± SD) 
(temperature: 23 ± 1°C; humidity: 50 ± 3%), at the same time of day and on the right leg over 





interspersed by a 5 min reperfusion (Salvador et al., 2016). Occlusion alternated between 
contralateral limbs ensuring a total IPC or SHAM time of 30 min whilst the CON protocol 
consisted of 30 min of passive rest. A plateau in the NIRS-derived deoxyhaemoglobin 
concentration signal was observed in every participant at the end of each 5-min cycle, and was 
taken as a sign of occlusion.  The inflatable cuff (Hokanson CC17, Bellevue, WA, US) was 
positioned on the upper leg where the adductor longus muscle attaches to the inguinal ligament 
and pressurised via an automated system (Hokanson E20/AG101Rapid Cuff Inflation System, 
Bellevue, WA, USA). The cuff was 18 cm wide with an adjustable length of 108 cm. To 
minimize any placebo effect, participants were told that the purpose of the study was to 
compare the impact of two different cuff pressures that could both alter performance (Paradis-
Deschênes et al., 2016). The participant then completed an additional 20 min rest prior to the 
onset of the AOT  (Salvador et al., 2016). 
 
After the 20 min rest, the AOT was performed on a dynamometer (Biodex Pro 4, Biodex 
Medical Systems, Inc., Shirley, New York, USA) as a 3-min all out maximal power test. The 
task was comprised of 135 repetitions of an isokinetic (300°/s extension: 500°/s flexion), knee 
extension movement with the range of motion set to 75° (from the start position, 90°knee 
flexion) and performed at a frequency of 45 repetitions per minute (Griffin et al., 2017). Each 
contraction was performed maximally with no pacing to ensure that a plateau in power output 
was achieved prior to the conclusion of the test. No knowledge of work rates or timing was 
given to the participants during the test. Coefficient of variation (CV’s) of the performance 





Maximal voluntary torque and measures of voluntary and muscle activation were assessed 
using the same dynamometer (Biodex Pro 4). Participants were positioned upright in the 
dynamometer with thigh/trunk and knee angles of 90 degrees, and the centre of rotation of the 
lever arm aligned with the sagittal plane axis of the knee joint. Participants were secured with 
an adjustable thigh strap and contralateral diagonal shoulder straps securing the trunk. A 
padded ankle cuff was placed superior (3 cm) to the lateral malleolus. Prior to performing 
exercise, participants completed a standardised warm up of six submaximal, 2 to 3 s isometric 
contractions (2 x 25%, 2 x 50% and 2 x 75% of perceived maximal effort). Torque output 
signals were directly sampled from the dynamometer at 1000 Hz (Powerlab, ADI Instruments, 
Sydney, NSW, Australia) and low pass filtered at 10 Hz. Torque signals were calibrated for 
each participant’s limb weight (following positional securing via straps), and a predetermined 
calibration factor was applied for conversion of the recorded voltage to units of torque (Nm). 
For baseline measures four MVCs were performed; two with supramaximal nerve stimulation 
(see Femoral Nerve Stimulation) and two without, with one-minute rest between each effort. 
The highest of the four MVCs was used as the BL value. Thereafter, only 1 MVC was 
performed pre- and post- the exercise task (e.g. AOT). Each MVC was instructed to be 
performed as hard and as fast as possible and maintained for 3-4 s. Strong verbal 
encouragement was provided during all MVCs. The maximal torque measure recorded for each 
MVC was taken as the highest torque value achieved during the contraction prior to the nerve 
stimulation. CVs of 5% and 9% were recorded for MVCs and rates of torque development 
(RTD) between trials, similar to previously published CV values (Buckthorpe et al., 2012; 
Place et al., 2007). 
 
Femoral Nerve Stimulation 
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A 4 x 3 cm aluminium foil strip coated with Conductive Adhesive Hydrogel (Ten20; Weaver 
and Company, Aurora, CO, USA) was placed on the lateral aspect of the hip, inferior to the 
iliac crest, as the anode. To identify nerve location for cathodal stimulation of the femoral nerve 
(Digitimer model DS7AH stimulator, Welwyn Garden City, UK), a rubber-insulated portable 
cathodal probe was used. The probe was moved around the femoral triangle using a stimulus 
intensity of 30 mA until the largest muscle compound action potential (M-wave) was elicited 
from both the VL and VM recording sites. For all stimulations, a 200 μs square-wave pulse 
was applied at 400 V, with each stimulation being a doublet (two pulses applied to the femoral 
nerve with a 100 ms inter stimulus interval; 10 Hz stimulation). When the optimal nerve 
location was identified it was marked with a felt-tip pen and a 20 mm diameter surface electrode 
was applied (Kendall 700; Tyco Healthcare Group, Mansfield, MA, USA). Thereafter, stimulus 
intensity was increased in 10 mA increments with 20 s rests between stimuli until plateaus in 
VL and VM M-wave amplitudes (Mmax) and the size of the knee-extensor twitch torque were 
observed. The maximal stimulus intensity (in milliamperes) was recorded and multiplied by 
130% to establish the test intensity (range for participants 70–290 mA; VL Mmax 13.1 ± 6.8 
mV and VM Mmax 12.1 ± 3.7 mV). Twitch torque CVs of 2.2% were recorded across trials, 
similar to that of previous reliability studies (Place et al., 2007). 
 
Surface EMG (sEMG) 
Knee extensor sEMG was recorded during the experimental trials with Ag–AgCl surface 
electrodes (Maxsensor; Medimax Global, Seven Hills, NSW, Australia) positioned over the 
vastus medialis (VM) and vastus lateralis (VL) on the right thigh. Electrodes were placed in 
the centre of the muscle belly with the inferior VL and VM electrodes positioned 8-12 cm and 
3-4 cm from the lateral aspect of patella, respectively. A self-adhesive reference electrode was 
attached to the patella on the left leg. All placement sites were shaved, exfoliated and cleaned 
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with an alcohol swab, while electrodes and cables were also taped to avoid any movement 
artefact. Electrode placement was recorded to ensure consistency within and between testing 
sessions. Raw electrode output was pre-amplified and bandpass filtered, with a bandwidth 
frequency ranging from 20 to 500 Hz (common mode rejection ratio > 90 dB; impedance input 
= 100 MΩ; gain = 1000). Peak and maximal rate of amplitude development were quantified 
for both VM and VL. Processing of all neuromuscular data was performed using MATLAB 
software (R2010a; The MathWorks Inc., Natick, MA, USA). 
 
Near-infrared Spectroscopy (NIRS) 
Oxygenation status of skeletal tissue was assessed using a spatially resolved, dual wavelength 
NIRS apparatus (moorVMS-NIRS; Moor Instruments Ltd, Axminster, Devon, UK). NIRS data 
was collected for tissue saturation index (TSI) as a percentage of haemoglobin oxygen 
saturation (%) and deoxyhaemoglobin concentrations (HHb) in arbitrary units (AU). After 
cleaning the skin with an alcohol swab, the NIRS device was fixed directly above the belly of 
the rectus femoris muscle at the mid-point between the inguinal fold and the top of the patella 
on the most anterior aspect. The device was fitted with an adhesive black silicone mould to 
reduce movement artefact and eliminate potentially interfering background noise. Skinfold 
thickness was measured at the site of the application of the NIRS (x̅ = 12.8 mm) using a 
Harpenden skinfold calliper (British Indicator Ltd., Burgess Hill, West Sussex, UK) during the 
familiarisation session, and was less than half the distance between the emitter and the detector 
(i.e. 30 mm). This thickness is adequate to let near infrared light through muscle tissue, and 
coupled with the anatomical location of the NIRS, minimizes measurement variation. The 
position on the participant was noted and replicated in the following trials. The pressure cuff 
was positioned above the NIRS device, which did not affect the placement of the device during 
occlusions. A modified form of the Beer-Lambert law, using two continuous wavelengths (760 
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and 850 nm) and a differential optical path length factor of 4.95, was used to calculate micro 
molar changes in tissue haemoglobin concentrations. NIRS data were acquired at 5 Hz. At rest, 
once positioned within the dynamometer, the signal was stabilized and 1 min of baseline values 
was analysed pre intervention. The NIRS signals were recorded throughout the experimental 
trials with average values reported at baseline, during the intervention and throughout the AOT. 
Peak values were also reported during the intervention and throughout the AOT. The time to 
peak HHb concentrations, measured from the start of the AOT, were also reported. 
 
Data Processing 
During all MVCs, the following torque variables were recorded: (i) the maximal voluntary 
torque (MVT; in Nm), calculated as the highest torque value throughout the entire MVC; and 
(ii) the maximal rate of torque development (RTDmax; in Nm.s-1), calculated as the greatest 
average 10 ms slope of the torque–time curve during the initial 100 ms of the contraction.  
Voluntary activation (VA) was estimated using the superimposed twitch technique (Merton, 
1954) according to the following formula (Strojnik & Komi, 1998): VA (%) = 100 – [D × 
(Tsup/MVT)/RT] × 100, where D is the difference between the torque level immediately before 
the superimposed twitch (Tsup) and the maximal torque recorded during the twitch, MVT is 
maximal voluntary torque during the entire contraction (not including the twitch response), and 
RT is the maximal amplitude of the resting potentiated twitch. The following variables were 
calculated from the resting potentiated twitch: (i) RT amplitude (in newton metres (Nm)); (ii) 
time to peak torque production derived from the RT (TTP; in milliseconds (ms)); (iii) the half-
relaxation time (½ RT; in ms), which was defined as the time elapsed from the peak twitch 




The following variables were processed from each MVC for VL and VM sEMG signals: (i) 
maximal sEMG amplitude of VL (VLmax) and VM (VMmax), processed as the greatest 
average root mean square over a 250 ms period from the beginning of the contraction to prior 
to the supramaximal stimulation; and (ii) maximal rate of sEMG rise (VLRERmax and 
VMRERmax), calculated from the greatest average 10 ms slope throughout the initial 100 ms 
of the contraction. All sEMG signals were normalised to their respective M-wave. 
From the AOT the following performance variables were recorded: (i) end test power (ETP); 
calculated as the average peak power output from the repetitions performed in the last 30 s of 
the test, (ii) work above end test power (W^ETP); calculated as the sum of work completed 
above ETP, (iii) peak power output (PPO); calculated as the highest 5-point running average 
of power output and (iv) total work done (TWD). 
 
Statistical Analyses 
Descriptive data are presented as mean ± SD. All statistical analyses were completed using 
IBM SPSS Statistics version 25 (SPSS Inc., Chicago, IL, USA). The Shapiro–Wilk test was 
applied to assess normality of distribution. ETP, W^ETP, PPO, TWD and NIRS data were 
analysed for differences using a one-way ANOVA for repeated measures. BL, Pre and Post 
neuromuscular assessment data (MVT, RTDmax, VA, VLmax and VMmax, VLRERmax, and 
VMRERmax and RT) were analysed using a two-way (condition × time) ANOVA for repeated 
measures. In the event of a significant F ratio, post hoc comparisons were made using a 
Bonferroni correction. Two-tailed statistical significance was accepted at p < 0.05. Mean 
differences with standard deviations (SD) were calculated when significant changes over time 





Maximal Torque Production  
Maximal torque output was not different between BL (252 ± 46 Nm) and Pre (238 ± 44 Nm), 
but decreased at Post (151 ± 28 Nm) following the AOT (mean decline of 87 ± 23 Nm, 95% 
CI = -67 to -107 Nm; p < 0.001; Table 4.1). There were no differences between conditions (p 
= 0.75). Similarly, RTDmax did not change between BL (1709 ± 328 Nm.s-1) and Pre (1575 ± 
376 Nm.s-1) but decreased at Post (mean declines of 572 ± 124 Nm.s-1, 95% CI = -353 to -792 
Nm.s-1; p < 0.001). There were no differences between conditions (p = 0.70).  
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Table 4.1 The sEMG data for VM (VMmax, VMRERmax) and VL (VLmax, VLRERmax), (all expressed as percentages of respective M-waves) for each MVC performed at baseline (BL), prior 
to the 3-min AOT (Pre) and post-3 min AOT (Post) for control (CON) (n = 10), sham (SHAM) (n = 10) and IPC (n = 10). Abbreviations: sEMG/M, surface electromyograms normalized to M-
waves; VL, vastus lateralis; VM, vastus medialis; RERmax, maximum rate of sEMG rise. Data are presented as mean ± SD. 
 
 VM VL 
 Max (%) RERmax (%) Max (%) RERmax (%) 
 CON SHAM IPC CON SHAM IPC CON SHAM IPC CON SHAM IPC 
BL 15 ± 4 16 ± 8 15 ± 6 763 ± 343 732 ± 388 850 ± 585 11 ± 5 11 ± 5 12 ± 6 567 ± 295 585 ± 300 396 ± 169 
PRE 12 ± 4 15 ± 4 16 ± 5 653 ± 345 524 ± 341 844 ± 604 12 ± 6 10 ± 5 13 ± 6 585 ± 384 365 ± 142 469 ± 193 





Descending Central Drive 
Voluntary activation was unchanged throughout the experimental trials (BL: 87 ± 7%, Pre: 85 
± 8%, Post: 88 ± 5%; p = 0.72). There were no changes in peak sEMG amplitude or RERmax 
throughout the trials or between conditions for VL (Table 4.1). For VM, there was a main effect 
of time for peak sEMG amplitude (p = 0.05), however post-hoc analysis revealed no pairwise 
differences (Table 4.1). 
 
Resting Twitch Characteristics 
The resting twitch torque declined from Pre after the AOT (mean decline of 30 ± 13 Nm; 95% 
CI = -25 to -35 Nm; p < 0.001; Table 4.2). The ½ RT (mean increase of 33 ± 26 ms; 95% CI = 
14 to 51 ms; p < 0.01; Table 4.2) and TTP (mean increase of 16 ± 13 ms; 95% CI = 6 to 26 ms; 
p < 0.01; Table 4.2) both increased after the AOT. There were no differences between 





Table 4.2 Data for amplitude of the peak resting twitch force (RT), the time-to-peak twitch (TTP), the half-relaxation time (½ RT) after maximal voluntary contractions at baseline (BL), prior to 
the 3-min AOT (Pre) and post 3-min AOT (Post) for control (CON) (n = 10), sham (SHAM) (n = 10) and IPC (n = 10). Data are presented as mean ± SD. *Significantly different from BL (p < 
0.05) 
 
 RT (Nm) TTP (ms) ½ RT (ms) 
 CON SHAM IPC CON SHAM IPC CON SHAM IPC 
BL 94 ± 17 92 ± 17 95 ± 15 103 ± 8 95 ± 7 103 ± 8 100 ± 25 106 ± 6 111 ± 30 
PRE 90 ± 15 91 ± 14 91 ± 13 99 ± 7 101 ± 9 100 ± 10 103 ± 9 102 ± 10 100 ± 9 






At BL there were no differences between conditions in TSI (CON: 68.7 ± 5.1%, SHAM: 67.5 
± 4.7%, IPC: 67.7 ± 5.9%) or HHb (CON: 96 ± 31 AU, SHAM: 104 ± 36 AU, IPC: 113 ± 41 
AU). During the intervention, in the IPC condition peak HHb was elevated vs CON but not 
SHAM (mean increase vs CON of 99 ± 95 AU; 95% CI = 4 to 195 AU; p < 0.05, vs SHAM 85 
± 92 AU; p = 0.07; Table 4.3) and average TSI was lower vs both CON and SHAM (mean 
decrease vs CON of 10.6 ± 5.9; 95% CI = -5 to -16%; p < 0.001, vs SHAM 8.0 ± 6.3%; 95% 
CI = -2 to -14%; p < 0.05; Table 4.3). During the AOT, there were no differences between 
conditions for either W^ETP or ETP in average or minimal tissue saturation (TSI) (Fig.4.2) or 
maximal or average deoxyhaemoglobin (HHb). There was no difference between conditions in 
the time to peak HHb concentrations
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Table 4.3. Average and peak data for tissue saturation index (TSI) and deoxyhaemoglobin (HHb) during the intervention, the window of power output above the plateau reached at the end of the 
test (W^ETP), the plateau reached at the end of the test (ETP) and the last 10s of the test (End) for control (CON) (n = 10), sham (SHAM) (n = 10) and IPC (n = 10). Time to peak represents the 
time to minimum TSI and maximum HHb levels. Data are presented as mean ± SD. Significantly different from  CON and SHAM (p < 0.05).
 TSI (%) HHb (AU) 
Average CON SHAM IPC CON SHAM IPC 
Intervention 76.0 ± 3.0 73.3 ± 5.7 65.4 ± 6.1* 67 ± 17 71 ± 28 100 ± 44 
W^ETP 55.5 ± 11.1 58.9 ± 10.4 58.2 ± 8.7 139 ± 71 137 ± 71 140 ± 75 
ETP 59.3 ± 10.0 61.8 ± 9.5 60.4 ± 8.6 152 ± 82 134 ± 69 140 ± 67 
End 59.2 ± 9.9 61.3 ± 9.7 60.1 ± 8.7 152 ± 81 134 ± 68 140 ± 67 
Peak  CON SHAM IPC CON SHAM IPC 
Intervention 74.2 ± 3.7 70.2 ± 3.8 40.9 ± 13.2* 73 ± 19 86 ± 33 171 ± 102* 
W^ETP 52.0 ± 14.3 54.6 ± 13.9 54.6 ± 12.3 175 ± 97 157 ± 80 162 ± 87 




Table 4.4 The performance data for the 3 min all out test (AOT) with the end test power (ETP), work done above the rate of 
end test power (W^ETP), total work done (TWD) and peak power output (PPO) for control (CON) (n = 10), sham (SHAM) 



















 AOT Physical Characteristics 
 CON SHAM IPC 
ETP 
(W) 260 ± 66 271 ± 78 251 ± 64 
W^ETP 
(J) 2997 ± 978 3051 ± 1158 3158  ± 917 
TWD 
(J) 8817 ± 2089 9211 ± 2020 8770 ± 2050 
PPO 




The primary aim of this study was to determine whether IPC would attenuate the decline in 
neural drive following a dynamic, 3-min leg extension protocol designed to optimise skeletal 
muscle oxygen delivery. Contrary to our hypothesis, IPC did not affect voluntary activation 
nor did it influence other measures of neural activity (e.g. sEMG amplitude) or peripheral 
fatigue characteristics. Furthermore, IPC did not attenuate the decline in functional measures 
of performance (MVC, RTD, PPO, etc.), nor did it alter tissue oxygenation during the 3-min 
exercise. 
 
In contrast to other reports (Griffin et al., 2017), IPC had a nominal effect on neuromuscular 
fatigue following the maximal effort knee extension task (e.g. AOT). Our hypothesis was based 
on previous studies theorizing that IPC may preserve skeletal muscle activation throughout 
exercise as a result of an overshoot in central motor drive induced via a disruption to the central 
feedback loop mechanism (Amann et al., 2011; Blain et al., 2016; Crisafulli et al., 2011; Cruz 
et al., 2017). This disruption is thought to occur through an inhibition of afferent signalling 
from metabolically sensitive group III and IV fibres resulting via a) the desensitisation of the 
muscle afferents due to over stimulation during the IPC procedure (Burns et al., 2016) and/or 
b) a reduced excitability of the muscle afferents due to opioid receptor activation by circulating 
endogenous opioids released during the IPC stimulus (Amann et al., 2009; Downey et al., 
2007). Regardless of mechanistic pathway, in theory, any influence IPC might have on these 
sensory fibres would manifest in changes to measures of central drive (e.g. voluntary 
activation) and/or peripheral fatigue characteristics (Amann et al., 2009; Babault, Desbrosses, 
Fabre, Michaut, & Pousson, 2006; Place et al., 2007). However, and consistent with our 
previous observations, IPC did not affect central or peripheral fatigue indices (Table 4.1). 
Collectively, this raises the possibility that the increased sEMG activity observed in previous 
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studies (Cruz et al., 2015; Cruz et al., 2016; A. S. Hyngstrom et al., 2018) may be unrelated to 
central factors associated with neural drive. Alternatively, the increased sEMG signals may be 
a result of changes in the velocity of the contractions e.g. cycling cadence. Contraction velocity 
is known to confound sEMG measures (Luca, 1997), and despite prior reports of IPC 
improving contraction and relaxation times, it was unaccounted for in the previous studies 
reporting increased sEMG activity. Modulated contraction velocities may stem directly from 
the IPC attenuation of post-ischemic oxidative stress generation, as excessive levels of 
oxidative stress are known to impair muscle contractility (Crestanello, Lingle, Kamelgard, 
Millili, & Whitman, 1996; Angus Lindsay et al., 2017; Quarrie et al., 2011; Quarrie et al., 2012; 
G. L. Semenza, 2011). Consequently, it may be plausible that previous observations of 
increased sEMG activity were reflective of altered contraction velocities driven by metabolic 
responses to IPC rather than enhanced efferent drive. 
 
A dynamic fatiguing protocol was used in the present study to ensure adequate muscle 
perfusion during exercise (Bailey, Birk, et al., 2012; S. L. Halley et al., 2018; Paradis-
Deschênes et al., 2016; Tanaka et al., 2016), and theoretically allow the IPC to promote the 
acute upregulation of vasodilatory factors such as adenosine and nitric oxide (Horimoto, 
Gaudette, Saltman, & Krukenkamp, 2000; Kimura et al., 2007; Kontos, 2001) and preserve 
muscle function similar to previous reports (Cruz et al., 2015; Cruz et al., 2016). However, 
there was no notable preservation of muscle function throughout (Table 4.4) or following 
(Table 4.2) the dynamic protocol. Additionally, and in contrast to our previous findings under 
isometric conditions (S. L. Halley et al., 2018), IPC did not increase haemoglobin volume or 
accelerate oxygen dissociation (Table 4.3). We believe this disparate outcome in tissue 
saturation kinetics may be related to the severity of peripheral fatigue induced by the isometric 
protocol. Despite the shorter duration of the isometric protocol (2 vs. 3 minutes) (S. L. Halley 
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et al., 2018), declines in muscle contractility were far greater than in the dynamic leg extension 
protocol (RT ~ 32% lower and ½ RT ~ 33% longer) (S. L. Halley et al., 2018). The task demand 
(e.g. 100% MVC), coupled with the restricted muscle perfusion, may also explain the increase 
in localised O2 delivery after IPC (~35%) observed only in the 2-min isometric protocol (S. L. 
Halley et al., 2018). Interestingly, others reporting comparable humoral effects after IPC have 
observed performance improvements during lower intensity efforts (e.g. 20% MVC to task 
failure), albeit without a sham condition (Tanaka et al., 2016). The substantial difference in 
contraction intensity between these studies (20% vs. 100% MVC (S. L. Halley et al., 2018)) 
may further suggest that the ergogenic effects of IPC are dependent on a combination of task 
demand and the extent of localised fatigue in the muscle (Marshall, Finn, & Siegler, 2015). 
 
IPC failed to elicit an ergogenic effect over any of the performance characteristics of the AOT, 
which is in direct contrast to the increase in critical power reported by Griffin and colleagues 
during a 3-min maximal cycling effort (Griffin et al., 2017). However, a closer inspection of 
the difference between critical power these authors report (IPC: 241 ± 65 W; SHAM: 234 ± 67 
W) would suggest the magnitude to be trivial (d < 0.11) (Griffin et al., 2017). Nonetheless, 
neither Griffin’s nor the current study observed any effect of IPC on TSI during the exercise 
task, with both reporting around a 20 to 25% reduction regardless of condition from the start 
to the end of the three minutes (Fig. 4.2). This again may be a function of task demand, as 
others showing improvements during exercise to failure after IPC consistently demonstrate 
amplified and accelerated deoxyhaemoglobin dynamics (Griffin et al., 2017; S. L. Halley et 
al., 2018). A recent meta-analysis gives further support, reporting the likelihood of IPC 
providing an ergogenic benefit in time to failure tasks at nearly 6%, whereas only a 0.5% 
improvement persists in those incorporating fixed end-points (Salvador et al., 2016). In many 
of the fixed-endpoint tasks (excluding repeat sprints), there have also been incidences of 
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improved oxygen delivery in the absence of any performance (S. L. Halley et al., 2018; Turnes 
et al., 2018; Zinner et al., 2017). Whilst it is well established that IPC induces the production 
of vasodilatory factors (nitric oxide, adenosine, etc.) (Kimura et al., 2007), the attenuation of 
oxidative stress and preserved mitochondrial function may play a greater role in improving 
performance (G. L. Semenza, 2011). In relation to task demand, tasks to failure may benefit to 
a greater extent from attenuations in oxidative stress than in fixed-endpoint tasks. The 
exception to this might be when additional stressors are imposed during the fixed-endpoint 
tasks to induce a comparable oxidative stress, such as exercising in hypoxia (Kjeld et al., 2014; 
Paradis-Deschenes et al., 2018). For example, the ergogenic effect of IPC on 5km cycling time 
trial (fixed-end point) performance has been shown to increase under progressively hypoxic 
conditions (FIO2 0.18: +1.1%; FIO2 0.15: +1.7%) (Paradis-Deschenes et al., 2018).  
A consistent limitation of IPC research is the inability to truly blind participants to the 
significant pressure differences between the SHAM and IPC protocols. To account for this in 
the present study, participants were informed that both conditions may influence performance; 
however, they were naïve to the expected outcome. The efficacy of this control measure was 
evidenced in the lack of difference between performance responses, consistent MVC and RT 
reductions (~ 36%, ~ 32%) and the similar magnitude and timing of peak deoxygenation levels 
(~139 AU, ~35 s) across all IPC and SHAM trials. 
 
Conclusion 
This experiment used a dynamic, 3-min leg extension protocol to promote muscle oxygenation 
in order to assess the effect of IPC on sEMG amplitudes and exercise-induced reductions in 
voluntary activation. Our findings suggest that IPC does not influence voluntary activation to 
the muscle during such a task, nor does it affect tissue oxygenation or functional measures of 
performance. Future research investigating the influence of task demand and exercise severity 
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Chapter 5 The influence of tissue oxygenation on the capacity for IPC to mediate effects 
on neuromuscular function in humans during maximal intermittent single limb isokinetic 
exercise 






Ischemic preconditioning (IPC) has been proposed to preserve neural drive during fatiguing 
exercise, however this may be dependent on tissue oxygenation. Therefore, we investigated the 
effect of hypoxia on the capacity of IPC to preserve neural drive during an intermittent single 
limb exercise protocol (EP). In a randomised, crossover design, eleven resistance trained males 
completed four EPs (6 sets of 11 isokinetic leg extensions) in either normoxic (FiO2:0.21) or 
hypoxic (FiO2:0.14) conditions which were preceded by treatments of either IPC (3 x 5 min 
bilateral leg occlusions at 220 mmHg) or a SHAM (3 x 5 min at 20 mmHg). Femoral nerve 
stimulation was utilized to assess voluntary activation and potentiated twitch torque during 
maximal voluntary contractions (MVCs) performed at baseline (BL), prior to the EP (Pre), and 
after each set (1,2,3,4,5, Post). Tissue oxygenation (via near-infrared spectroscopy) and sEMG 
activity was measured throughout the EP. MVC and twitch torque levels declined (MVC: 96.2 
± 24 Nm; 95% CI = 73 to 119 Nm; p < 0.001, twitch: 37 ± 11 Nm; 95% CI = 26 to 48 Nm; p 
< 0.001) between Pre and Post without reductions in voluntary activation (P = 0.99); there were 
no differences between conditions. In hypoxia, IPC reduced TSI% (1.8 ± 2.2%; 95% CI = 0.5 
to 3.5%; p < 0.05) and HbO2 (15 ± 10; 95% CI = 7 to 23; p < 0.001) compared to Sham. There 
was no IPC effect in normoxia. These results suggest that the neuromuscular fatigue 
modulations of IPC are not dependent on tissue saturation. Induced reductions of tissue 





Ischemic preconditioning (IPC) was initially developed as a protective technique against 
ischemia/reperfusion injuries (Murry et al., 1986), however has since been considered as an 
ergogenic aid to improve exercise performance (de Groot et al., 2010). The technique generally 
imposes 3-4 x 5 min cycles of blood flow occlusion and reperfusion, accumulating 30 to 40 
min of sustained limb ischemia (Salvador et al., 2016). Exercise performance trials have 
demonstrated small, albeit inconsistent, ergogenic effects during aerobic and exhaustive tasks 
(Caru et al., 2019). Presumably, increased peripheral vasodilation and improved mitochondrial 
efficiency have contributed to these performance improvements (Kimura et al., 2007; G. L. 
Semenza, 2011).  However a number of recent studies have also speculated that a neurological 
response to the reperfusion may increase muscle activation and attenuate neuromuscular 
fatigue (Cruz et al., 2017; A. Hyngstrom et al., 2016).  
 
Recent research has demonstrated that IPC can acutely increase maximal voluntary strength, 
which has been attributed to increased neural activity (as measured by surface 
electromyography (sEMG)) and lowered submaximal motor unit recruitment thresholds 
(Durand et al., 2019; A. Hyngstrom et al., 2016; A. S. Hyngstrom et al., 2018). Exercise 
performance trials have also reported increased sEMG activity concomitant with extended 
times to task failure and elevated power output during aerobic and anaerobic cycling tasks 
(Cruz et al., 2015; Cruz et al., 2016), leading to the conclusion that IPC increases skeletal 
muscle activation (Cruz et al., 2015; Cruz et al., 2016; A. S. Hyngstrom et al., 2018). 
Furthermore, these authors have suggested the increased neural activity may be reflective of 
IPC-mediated inhibition of metabolically sensitive group III and IV afferents, ultimately 
prolonging neural drive in the severe exercise intensity domain (Cruz et al., 2017; A. S. 
Hyngstrom et al., 2018). However, whilst sEMG can provide an estimate of gross nervous 
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system output, a multitude of unrelated factors contribute to the sEMG signal (Dimitrova & 
Dimitrov, 2003; Farina, 2006). In an attempt to address these limitations, we incorporated the 
interpolated twitch technique into two separate studies (S. L. Halley et al., 2018; Samuel L. 
Halley, Marshall, & Siegler, 2019), however failed to observe any influence of IPC over sEMG 
amplitudes, voluntary activation or any other additional central or peripheral measures of 
neural drive. 
 
There are a few plausible explanations for the discrepancies between studies for the effect of 
IPC on neuromuscular measures (e.g. sEMG, voluntary activation). The efficacy of IPC in 
terms of exercise performance appears to improve in a task-dependent manner, whereby 
extended durations at high intensities (e.g. to task failure) may better facilitate an ergogenic 
benefit from the reperfusion technique (Caru et al., 2019; Kjeld et al., 2014; Salvador et al., 
2016; Tanaka et al., 2016). The disparity between studies thereafter often lies in the mechanistic 
contributions (e.g. systemic, humoral or neural) purportedly responsible for attenuating fatigue. 
As fatigue is multi-factorial, the proportional contribution of these mechanisms is difficult to 
discern and may themselves be influenced by a multitude of contributing factors (e.g. subject 
phenotype, task demand, etc.). For example, although the task performance benefit is consistent 
across a variety of study populations (e.g. trained, recreationally trained, clinical), the 
mechanistic contribution of the neuromuscular system is far less conclusive (Carvalho & 
Barroso, 2019; Cruz et al., 2015; Cruz et al., 2016; Durand et al., 2019; A. Hyngstrom et al., 
2016; A. S. Hyngstrom et al., 2018; Tanaka et al., 2016). Moreover, these IPC-mediated neural 
contributions are also influenced by task demand, as only dynamic tasks within the studies of 
healthy populations have reported increased sEMG activity (Cruz et al., 2015; Cruz et al., 
2016). Interestingly, although we observed no influence on the neuromuscular system, we did 
observe increased muscle O2 extraction in the 2-min isometric leg extension model (S. L. 
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Halley et al., 2018) but not in the 3-min dynamic model (Samuel L. Halley et al., 2019), which 
we believe further highlights a trend for IPC to favour exercise tasks that may impair localised 
tissue oxygenation. As such, it is possible our previous exercise protocols did not impose a 
sufficient level of localised perturbation relative to the subject cohort (e.g. resistance trained) 
in order to replicate the neural responses observed in previous studies (Cruz et al., 2015; Cruz 
et al., 2016; Durand et al., 2019; A. Hyngstrom et al., 2016; A. S. Hyngstrom et al., 2018).  
Therefore, the aim of the present study was to determine whether the IPC mediated effects on 
neuromuscular function in resistance-trained individuals are dependent on the degree of 
exercising tissue oxygenation. To further reduce tissue oxygenation in our subject cohort we 
incorporated an additional hypoxic challenge (Foster et al., 2014; Paradis-Deschenes et al., 
2018) into a dynamic, intermittent exercise protocol comprised of 6 x 11 maximal, repeated 
effort single-leg extensions. We examined whether the intense dynamic exercise, either alone 
or in combination with the hypoxic challenge, would influence the efficacy of a standard bout 
of IPC (3 x 5 min cycles) in preserving neuromuscular function or central drive. We 
hypothesised that IPC would improve performance outcomes central to neuromuscular 
function in both environmental conditions (e.g. normoxia and hypoxia) through an attenuation 
of centrally mediated declines in neural drive (e.g. voluntary activation), with the magnitude 




All procedures in this study were approved by the Western Sydney University Human Research 
Ethics Committee (approval code H12114) and were conducted in accordance with the 
Declaration of Helsinki, except for registration in a database. Eleven resistance trained men 
with a minimum training history of at least two resistance training sessions per week for the 
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previous 6 months (mean ± SD) (age: 23.1 ± 2, weight: 78.6 ± 7) volunteered to participate in 
this study after providing informed written consent. Minimum sample size was calculated from 
an a priori power analysis employing the small effect size threshold value of d = 0.2 as the 




A study flow diagram is provided in Fig. 5.1. During a preliminary session, participants were 
familiarised with all procedures involved in the study and provided with pre-test guidelines in 
regards to restriction of caffeine (12 h), alcohol (24 h), strenuous lower body exercise (48 h) 
and instructions as to replication of caloric and macro intake (24 h) prior to the experimental 
trials. The preliminary session included exposure to the femoral nerve stimulation protocols 
during a 3-5 s maximal voluntary isometric knee extension contraction (MVC), the exercise 
protocol (6 sets of 11 repetitions of maximal all out dynamic leg extensions) and the IPC 
protocol. The experimental trials consisted of four separate intervention protocols; normoxic 
sham (NormSham (FiO2 20.9 ± 0.05%)), normoxic IPC (NormIPC (FiO2 20.9 ± 0.05%)), 
hypoxic sham (HypSham (FiO2 14.0 ± 0.07%)) and hypoxic IPC (HypIPC (FiO2 14.0 ± 
0.07%)). All testing was performed in a climate controlled laboratory (mean ± SD) 
(temperature: 23 ± 1°C; humidity: 51 ± 2%), at the same time of day and on the right leg over 




Upon arrival to the laboratory, participants were fitted for sEMG (see Surface EMG) and nerve 
stimulation (see Femoral Nerve Stimulation) electrodes as well as a near infrared spectrometer 
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(NIRS) (moorVMS-NIRS; Moor Instruments Ltd, Axminster, Devon, UK) and also a pulse 
oximeter (Maximo Radical-7 Rainbow SET Pulse Oximeter, Masimo Corporation, 
Switzerland). Neuromuscular function (see Neuromuscular Function) was then assessed for 
baseline measurements prior to the intervention (BL). Thereafter, participants underwent either 
IPC or SHAM treatments depending on the trial. The IPC interventions were performed under 
ambient conditions with the participant lying in a supine position, and blood flow to the lower 
leg restricted via the inflation of a blood pressure cuff to either 220 mmHg (IPC) or 20 mmHg 
(SHAM) for three 5 min periods on each leg, each interspersed by a 5 min reperfusion 
(Salvador et al., 2016). Occlusion alternated between contralateral limbs ensuring a total IPC 
or SHAM time of 30 min whilst the CON protocol consisted of 30 min of passive rest. A plateau 
in the NIRS-derived deoxyhaemoglobin concentration signal was observed in every participant 
at the end of each 5-min cycle, and was taken as a sign of occlusion. The inflatable cuff 
(Hokanson CC17, Bellevue, USA) was positioned on the upper leg where the adductor longus 
muscle attaches to the inguinal ligament and pressurised via an automated system (Hokanson 
E20/AG101Rapid Cuff Inflation System, Bellevue, USA). The cuff was 18 cm wide with an 
adjustable length of 108 cm. To minimize any placebo effect, participants were told that the 
purpose of the study was to compare the impact of two different cuff pressures that could both 
alter performance (Paradis-Deschênes et al., 2016).  
 
Approximately ten minutes after the treatment, participants were exposed to the environmental 
condition of that particular trial via a fitted facemask connected to a custom built portable 
normo-baric hypoxia generator (New South Wales Institute of Sport/Altitude Training 
Systems, Sydney, AUS). Oxygen fractions of inspired air were monitored by a separate 
portable gas analyser (O2 Analyser, gold edition, VacuMed, Seattle, USA) connected to the 
inspiration hose of the generator. Three minutes prior to the conclusion of the 10-min wash-in 
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period, participants began a standardised dynamic warm up consisting of 1 set of the exercise 
protocol performed in ramped increments of effort (100% being maximal effort) for each rep 
(2 x 60%, 2 x 70%, 2 x 80%, 2 x 90% 3 x 100%). Finally, a pre-exercise (Pre) neuromuscular 
function assessment was conducted prior to commencing the exercise protocol. The total time 
period following the IPC/SHAM intervention before the exercise protocol summated to 20 min 
(Salvador et al., 2016). 
 
The exercise protocol was performed on a dynamometer (Biodex Pro 4, Biodex Medical 
Systems, Inc., Shirley, New York, USA) as repeat maximal power leg extension test. The task 
was comprised of 6 sets of 11 repetitions of an isokinetic (120°/s extension: 300°/s flexion), 
knee extension movement with the range of motion set to 70° (from the start position, 90°knee 
flexion) and performed at a frequency of 40 repetitions per minute. Each set lasted 
approximately 17 s with 20 s of rest between each set. Neuromuscular assessments were 
completed ~3 s post each set (six in total). Each contraction was performed maximally with no 
pacing strategies permitted. No knowledge of work rates or timing was given to the participants 
during the test. Coefficient of variation (CV’s) of average set power output and work completed 
of the exercise protocol were between 12% to 18%, respectively. Upon completion of the 













Maximal voluntary torque and measures of voluntary and muscle activation were assessed 
using the same dynamometer (Biodex Pro 4). Participants were positioned upright in the 
dynamometer with thigh/trunk and knee angles of 90 degrees, and the centre of rotation of the 
lever arm aligned with the sagittal plane axis of the knee joint. Participants were secured with 
an adjustable thigh strap and contralateral diagonal shoulder straps securing the trunk. A 
padded ankle cuff was placed superior (3 cm) to the lateral malleolus. Prior to performing 
exercise, participants completed a standardised warm up of six submaximal, 2 to 3 s isometric 
contractions (2 x 25%, 2 x 50% and 2 x 75% of perceived maximal effort). Torque output 
signals were directly sampled from the dynamometer at 1000 Hz (Powerlab, ADI Instruments, 
Sydney, NSW, Australia) and low pass filtered at 10 Hz. Torque signals were calibrated for 
each participant’s limb weight (following positional securing via straps), and a predetermined 
calibration factor was applied for conversion of the recorded voltage to units of torque (Nm). 
For baseline measures four MVCs were performed; two with supramaximal nerve stimulation 
(see Femoral Nerve Stimulation) and two without, with one-minute rest between each effort. 
The highest of the four MVCs was used as the BL value. Thereafter, only 1 MVC was 
performed pre, during and post the exercise protocol. Each MVC was instructed to be 
performed as hard and as fast as possible and maintained for 3-4 s. Strong verbal 
encouragement was provided during all MVCs. The maximal torque measure recorded for each 
MVC was taken as the highest torque value achieved during the contraction prior to the nerve 
stimulation. CVs of 5% and 9% were recorded for MVCs and rates of torque development 
(RTD) between trials, similar to previously published CV values (Buckthorpe et al., 2012; 
Place et al., 2007). 
 
Femoral Nerve Stimulation 
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A 4 x 3 cm aluminium foil strip coated with Conductive Adhesive Hydrogel (Ten20; Weaver 
and Company, Aurora, CO, USA) was placed on the lateral aspect of the hip, inferior to the 
iliac crest, as the anode. To identify nerve location for cathodal stimulation of the femoral nerve 
(Digitimer model DS7AH stimulator, Welwyn Garden City, UK), a rubber-insulated portable 
cathodal probe was used. The probe was moved around the femoral triangle using a stimulus 
intensity of 30 mA until the largest muscle compound action potential (M-wave) was elicited 
from both the VL and VM recording sites. For all stimulations, a 200 μs square-wave pulse 
was applied at 400 V, with each stimulation being a doublet (two pulses applied to the femoral 
nerve with a 100 ms inter stimulus interval; 10 Hz stimulation). When the optimal nerve 
location was identified it was marked with a felt-tip pen and a 20 mm diameter surface electrode 
was applied (Kendall 700; Tyco Healthcare Group, Mansfield, MA, USA). Thereafter, stimulus 
intensity was increased in 10 mA increments with 20 s rests between stimuli until plateaus in 
VL and VM M-wave amplitudes (Mmax) and the size of the knee-extensor twitch torque were 
observed. The maximal stimulus intensity (in milliamperes) was recorded and multiplied by 
130% to establish the test intensity (range for participants 70–290 mA; VL Mmax 22.9 ± 5.1 
mV and VM Mmax 22.5 ± 6.0 mV). Twitch torque CVs of 7% were recorded across trials, 
similar to that of previous reliability studies (Place et al., 2007). 
 
Surface EMG (sEMG) 
Knee extensor sEMG was recorded during the experimental trials with Ag–AgCl surface 
electrodes (Maxsensor; Medimax Global, Seven Hills, NSW, Australia) positioned over the 
vastus medialis (VM) and vastus lateralis (VL) on the right thigh. Electrodes were placed in 
the centre of the muscle belly with the inferior VL and VM electrodes positioned 8-12 cm and 
3-4 cm from the lateral aspect of patella, respectively. A self-adhesive reference electrode was 
attached to the patella on the left leg. All placement sites were shaved, exfoliated and cleaned 
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with an alcohol swab, while electrodes and cables were also taped to avoid any movement 
artefact. Electrode placement was recorded to ensure consistency within and between testing 
sessions. Raw electrode output was pre-amplified and bandpass filtered, with a bandwidth 
frequency ranging from 20 to 500 Hz (common mode rejection ratio > 90 dB; impedance input 
= 100 MΩ; gain = 1000). Peak and maximal rate of amplitude development were quantified 
for both VM and VL. Processing of all neuromuscular data was performed using MATLAB 
software (R2010a; The MathWorks Inc., Natick, MA, USA). 
 
Near-infrared Spectroscopy (NIRS) 
Oxygenation status of skeletal tissue was assessed using a spatially resolved, dual wavelength 
NIRS apparatus (moorVMS-NIRS; Moor Instruments Ltd, Axminster, Devon, UK). NIRS data 
was collected for tissue saturation index (TSI) as a percentage of haemoglobin oxygen 
saturation (%) and this was based of fractions of deoxyhaemoglobin (HHb) and 
oxyhaemoglobin (HbO2) volumes measured in arbitrary units (AU). A total haemoglobin 
(THb) volume, also in AU, was also calculated from these measures and used as a proxy 
measure of blood volume (Van Beekvelt, Shoemaker, Tschakovsky, Hopman, & Hughson, 
2001). After cleaning the skin with an alcohol swab, the NIRS device was fixed directly above 
the belly of the rectus femoris muscle at the mid-point between the inguinal fold and the top of 
the patella on the most anterior aspect. The device was fitted with an adhesive black silicone 
mould to reduce movement artefact and eliminate potentially interfering background noise. 
Skinfold thickness was measured at the site of the application of the NIRS (x̅ = 14.7 mm) using 
a Harpenden skinfold calliper (British Indicator Ltd., Burgess Hill, West Sussex, UK) during 
the familiarisation session, and was less than half the distance between the emitter and the 
detector (i.e. 30 mm). This thickness is adequate to let near infrared light through muscle tissue, 
and coupled with the anatomical location of the NIRS, minimizes measurement variation. The 
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position on the participant was noted and replicated in the following trials. The pressure cuff 
was positioned above the NIRS device, which did not affect the placement of the device during 
occlusions. A modified form of the Beer-Lambert law, using two continuous wavelengths (760 
and 850 nm) and a differential optical path length factor of 4.95, was used to calculate micro 
molar changes in tissue haemoglobin concentrations. NIRS data were acquired at 5 Hz. The 
NIRS signals were recorded throughout the experimental trials with values reported at BL 
(average of 30 s of data prior of baseline neuromuscular measures), during the intervention 
(averaged across the 30 min of IPC/Sham), before (average of 30 s data prior to PRE) and 
throughout each set of the EP. During the EP, data was collected with each leg extension 
repetition of the set. 
 
Data Processing 
During all MVCs, the following torque variables were recorded: (i) the maximal voluntary 
torque (MVT; in Nm), calculated as the highest torque value throughout the entire MVC; and 
(ii) the maximal rate of torque development (RTDmax; in Nm.s-1), calculated as the greatest 
average 10 ms slope of the torque–time curve during the initial 100 ms of the contraction.  
Voluntary activation (VA) was estimated using the superimposed twitch technique (Merton, 
1954) according to the following formula (Strojnik & Komi, 1998): VA (%) = 100 – [D × 
(Tsup/MVT)/RT] × 100, where D is the difference between the torque level immediately before 
the superimposed twitch (Tsup) and the maximal torque recorded during the twitch, MVT is 
maximal voluntary torque during the entire contraction (not including the twitch response), and 
RT is the maximal amplitude of the resting potentiated twitch. The following variables were 
calculated from the resting potentiated twitch: (i) RT amplitude (in newton metres (Nm)); (ii) 
time to peak torque production derived from the RT (TTP; in milliseconds (ms)); (iii) the half-
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relaxation time (½ RT; in ms), which was defined as the time elapsed from the peak twitch 
torque to 50% peak twitch torque. 
 
The following variables were processed from each MVC for VL and VM sEMG signals: (i) 
maximal sEMG amplitude of VL (VLmax) and VM (VMmax), processed as the greatest 
average root mean square over a 250 ms period from the beginning of the contraction to prior 
to the supramaximal stimulation (normalised to their respective M-wave) ; and (ii) maximal 
rate of sEMG rise (VLRERmax and VMRERmax), calculated from the greatest average 10 ms 
slope throughout the initial 100 ms of the contraction (normalised to their respective M-wave) 
(iii) VL (VLMmax) and VM (VMMmax) peak-to-peak amplitudes of the M-Wave.  
For each repetition of the EP, the following performance variables were recorded: (i) peak 
power (power), (ii) a summation of the work completed within the set (work). Peak VL and 
VM signals were also collected for each rep of EP. The signals were normalised to the 
respective M-waves recorded during the neuromuscular assessment following each set.  
Statistical Analyses 
 
Descriptive data are presented as mean ± SD. Statistical analyses were completed using IBM 
SPSS Statistics version 25 (SPSS Inc., Chicago, IL, USA). The Shapiro–Wilk test was applied 
to assess normality of distribution. A general linear model was used to analyse for differences 
between conditions in performance (power and work), sEMG and NIRS variables collected 
during the EP, with repetition and set numbers as fixed effects. In the event of a significant F 
ratio, post hoc comparisons were performed using an adjusted Bonferroni correction. 
Neuromuscular assessment data (MVT, RTDmax, VA, VLmax and VMmax, VLRERmax, 
VMRERmax, VLMmax, VMMmax, RT, RT TTP and ½RT) and resting NIRS data (BL, 
Treatment and Pre) were analysed for differences using a two-way (condition × time) repeated 
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measures ANOVA. In the event of a significant F ratio, post hoc comparisons were made using 
a Bonferroni correction. Two-tailed statistical significance was accepted at p < 0.05. Mean 





Maximal Torque Output 
MVC maximal torque was maintained between BL and Pre before progressively decreasing 
throughout the exercise protocol (mean Pre to Post decline of 96 ± 24 Nm; 95% CI = 73 to 119 
Nm; p < 0.001; Fig. 5.2), however without differences between conditions (p = 0.59). MVC 
rates of torque development followed a similar pattern (Fig. 5.2), with no changes between 
conditions (p = 0.73). 
 
 
Figure 5-2 Maximal torque output (Nm) values derived during the maximal voluntary contractions performed prior to the 
exercise task (Pre) and after completion of each set within the exercise task. A significant decline from Pre was evident in all 








Resting Twitch Characteristics 
The resting twitch torque was not different between BL and Pre, but declined progressively 
following the first set of the exercise protocol in all conditions (mean Pre to Post decline of 37 
± 11 Nm; 95% CI = 26 to 48 Nm; p < 0.001; Table 5.1). There were also main effects for time 
for both ½ RT (mean Pre to Post increase of 34 ± 20 ms; 95% CI = 17 to 52 ms; p < 0.001; 
Table 5.1) and RT TTP (mean Pre to Post increase of 12 ± 20 ms; 95% CI = 8 to 33 ms; p < 





Table 5.1 Resting twitch characteristics (maximal resting twitch torque (RT), half-relaxation time (1/2 RT) and time to peak torque (TTP)) derived from femoral stimulation during the maximal 
voluntary contractions at baseline (BL), pre-exercise (Pre) and after each set (1, 2, 3, 4, 5) until completion (Post). Data are presented as mean ± SD. 
   Time 
RT Tmax (Nm)  BL Pre 1 2 3 4 5 Post 
 NormSham 102 ± 16 99 ± 12 93 ± 15 84 ± 18 74 ± 18 69 ± 18 67 ± 19 66 ± 20 
 NormIPC 105 ± 15 99 ± 14 95 ± 15 85 ± 16 76 ± 15 68 ± 17 63 ± 17 63 ± 16 
 HypSham 103 ± 11 99 ± 15 93 ± 14 82 ± 17 73 ± 15 66 ± 14 62 ± 13 58 ± 15 
 HypIPC 101 ± 10 97 ± 11 95 ± 20 84 ± 18 77 ± 19 69 ± 20 64 ± 18 60 ± 19 
  Time 
RT TTP (ms)  BL Pre 1 2 3 4 5 Post 
 NormSham 11 ± 3 11 ± 3 11 ± 3 12 ± 2 12 ± 3 12 ± 3 12 ± 3 12 ± 3 
 NormIPC 11 ± 2 11 ± 2 10 ± 3 11 ± 3 12 ± 3 12 ± 3 11 ± 3 12 ± 3 
 HypSham 10 ± 2 11 ± 3 11 ± 3 12 ± 3 13 ± 3 13 ± 2 13 ± 2 13 ± 3 
 HypIPC 10 ± 1 11 ± 3 11 ± 4 12 ± 4 12 ± 4 12 ± 3 12 ± 4 12 ± 4 
  Time 
½ RT (ms)  BL Pre 1 2 3 4 5 Post 
 NormSham 11 ± 1 10 ± 2 11 ± 1 12 ± 3 13 ± 3 13 ± 3 13 ± 3 14 ± 4 
 NormIPC 11 ± 2 10 ± 1 11 ± 2 12 ± 3 12 ± 3 13 ± 3 14 ± 4 13 ± 3 
 HypSham 11 ± 1 10 ± 1 10 ± 1 11 ± 2 12 ± 3 12 ± 3 13 ± 3 13 ± 3 




Descending Central Drive 
Voluntary activation (average VA: 90 ± 1.5%) was unchanged between conditions during the 
IPC treatment (p = 0.15) and experimental protocol (p = 0.99). There were no main effects of 
condition or time for VL Peak, VL M Wave, VM M Wave (Table 5.2) during the MVCs. There 
was, however, a main effect of condition (p < 0.05) and time (p < 0.001) for VM Peak, although 




Table 5.2 Surface EMG signals (peak amplitude for vastus lateralis and medialis normalised to the M-wave (VL Peak, VM Peak) and M-wave for VL and VM, respectively) derived during the 
maximal voluntary contractions at baseline (BL), pre-exercise (Pre) and after each set (1, 2, 3, 4, 5) until completion (Post). Data are presented as mean ± SD. 
   Time 
VL Peak (% M Wave)   BL Pre 1 2 3 4 5 Post 
 NormSham 6 ± 2 6 ± 2 7 ± 3 6 ± 2 7 ± 3 7 ± 5 6 ± 2 5 ± 2 
 NormIPC 7 ± 3 7 ± 1 7 ± 3 6 ± 2 5 ± 1 6 ± 3 5 ± 3 5 ± 2 
 HypSham 7 ± 2 6 ± 2 6 ± 2 7 ± 4 7 ± 3 7 ± 3 7 ± 2 7 ± 4 
 HypIPC 6 ± 1 6 ± 1 6 ± 2 6 ± 2 6 ± 3 6 ± 2 6 ± 2 6 ± 3 
   Time 
VM Peak (% M Wave)   BL Pre 1 2 3 4 5 Post 
 NormSham 5 ± 1 6 ± 1 5 ± 1 6 ± 1 5 ± 1 5 ± 1 5 ± 1 4 ± 1 
 NormIPC 5 ± 2 5 ± 1 5 ± 1 5 ± 1 4 ± 1 4 ± 1 4 ± 1 5 ± 1 
 HypSham 6 ± 1 5 ± 1 5 ± 2 5 ± 2 5 ± 1 5 ± 2 5 ± 1 5 ± 1 
 HypIPC 5 ± 1 5 ± 1 5 ± 1 5 ± 1 5 ± 1 5 ± 1 4 ± 1 4 ± 2 
   Time 
VL M Wave (mV)   BL Pre 1 2 3 4 5 Post 
 NormSham 23 ± 6 23 ± 5 22 ± 7 23 ± 5 22 ± 7 22 ± 7 23 ± 6 23 ± 4 
 NormIPC 24 ± 4 24 ± 5 24 ± 5 24 ± 5 25 ± 5 23 ± 6 23 ± 6 25 ± 4 
 HypSham 23 ± 5 25 ± 3 25 ± 3 23 ± 6 23 ± 6 24 ± 6 24 ± 6 23 ± 7 
 HypIPC 22 ± 4 23 ± 4 22 ± 5 23 ± 5 23 ± 5 22 ± 5 23 ± 4 22 ± 6 
   Time 
VM M Wave (mV)   BL Pre 1 2 3 4 5 Post 
 NormSham 23 ± 7 22 ± 7 23 ± 7 23 ± 7 23 ± 7 23 ± 7 23 ± 6 23 ± 6 
 NormIPC 23 ± 6 22 ± 6 23 ± 7 23 ± 7 23 ± 7 23 ± 7 23 ± 7 24 ± 7 
 HypSham 21 ± 7 21 ± 6 22 ± 7 22 ± 7 22 ± 6 22 ± 6 22 ± 6 22 ± 6 




VL Peak increased throughout the exercise protocol (p < 0.001), and there was also a main 
effect of condition (p< 0.001), however post hoc analyses indicated these differences to be less 
than 0.5% (NormSham: 3.7± 0.1%, 95% CI 3.6 to 3.9%; NormIPC: 3.5 ± 0.1%, 95% CI 3.4 to 
3.6%; HypSham: 4.0 ± 0.1%, 95% CI 3.9 to 4.1%; HypIPC: 3.6 ± 0.1%, 95% CI 3.5 to 3.7% 
(Table 5.3). Although VM Peak increased over the 11 repetitions (p < 0.001), there were no 
significant differences between sets 1 – 6 (p = 0.33) (Table 5.3). Similar to VL Peak there were 
also main effects of condition (p < 0.001),however post hoc analyses indicated these 
differences to also be less than 0.5% (NormSham: 3.9 ±0.1%, 95% CI 3.7 to 4.0%; NormIPC: 
4.2 ± 0.1%, 95% CI 4.0 to 4.3%; HypSham: 4.3 ± 0.1%, 95% CI 4.2 to 4.5%; HypIPC: 4.1 ± 




Table 5.3 Surface EMG signals (peak amplitude for vastus lateralis and medialis normalised to the M-wave (VL %, VM %) derived from the average signal collected from each repetition of each 
set (1, 2, 3, 4, 5, 6). Data are presented as mean ± SD.  
 
   Set 
VL (%)  1 2 3 4 5 6 
 NormSham 4 ± 2 4 ± 1 4 ± 1 4 ± 1 4 ± 1 4 ± 2 
 NormIPC 4 ± 2 4 ± 2 4 ± 1 4 ± 3 3± 3 3 ± 1 
 HypSham 4 ± 2 4 ± 2 4 ± 2 4 ± 2 4 ± 2 4 ± 3 
 HypIPC 4 ± 2 4 ± 2 4 ± 3 4 ± 2 3 ± 1 4 ± 3 
  Set 
VM (%)  1 2 3 4 5 6 
 NormSham 4 ± 2 4 ± 2 4 ± 1 4 ± 1 4 ± 1 4 ± 1 
 NormIPC 4 ± 2 4 ± 2 4 ± 2 5 ± 2 4 ± 1 4 ± 1 
 HypSham 4 ± 2 5 ± 2 4 ± 2 4 ± 2 4 ± 1 5 ± 2 





Baseline, IPC Treatment and Pre 
There were no differences between conditions at baseline for any variables. During the 
treatment period, TSI% was lowered in NormIPC relative to NormSham (mean decrease of 7 
± 8%; 95% CI = 0.4 to 13%; p = 0.03) and there was also a non-significant difference between 
HypIPC and HypSham (mean difference of 5.5 ± 7.6%, 95% CI = 0.9 to 11.8%; p = 0.14). 
During the pre-exercise measurement period, SaO2 was lower in the hypoxic conditions (~ 94 
to 95%) when compared to normoxic conditions (> 99%) (p < 0.001).  
 
Exercise Protocol 
TSI% decreased in all conditions throughout the exercise protocol (p < 0.001) (Fig. 5.3). TSI% 
was significantly reduced in the hypoxic conditions compared to the normoxic conditions (p < 
0.001), with further post hoc analyses indicating HypIPC to be lower than HypSham (mean 
decrease of 1.8 ± 2.2%; 95% CI 0.5 to 3.5%; p < 0.05). HHb increased throughout the exercise 
protocol in all conditions (p < 0.001) (Table 5.4). There was a main effect of condition, where 
HHb was significantly reduced in the hypoxic conditions compared to the normoxic conditions 
(p < 0.001) (Table 5.4). HbO2 increased in all conditions throughout the exercise protocol (p < 
0.001) (Table 5.4), with HypSham elevated to a greater extent compared to HypIPC (mean 
increase of 15 ± 10 AU; 95% CI 7 to 23 AU; p < 0.001) and both normoxic conditions 
(NormSham: mean increase of 18 ± 10 AU; 95% CI 10 to 26 AU; p < 0.001; HypIPC: mean 
increase of 16 ± 10 AU; 95% CI 8 to 24 AU; p < 0.001). THb increased throughout the exercise 
protocol (p < 0.005), with THb elevated to a greater extent in the hypoxic conditions compared 
to normoxic conditions (p < 0.001; Table 5.4). Differences between SaO2 were consistent 
throughout the exercise protocol, with the normoxic (97 to 98%) higher than hypoxic 




Figure 5-3 Tissue saturation index (TSI%) changes recorded prior to the exercise task (Pre) (average of 30 s of data prior of 
the start of exercise) and throughout each set of the exercise task (data collected with each leg extension repetition of the set 
and averaged across the set). A significant decline in TSI% from Pre was evident after Set 1 (main effect of time (*p < 0.001); 
two-way repeated measures ANOVA)). Hypoxic sham (HypSham) and hypoxic IPC (HypIPC) conditions were also 
significantly different, with HypIPC significantly lower than HypSham throughout the exercise task (main effect of condition 






Table 5.4 Tissue oxygenation measurements (deoxyhaemoglobin (HHb), oxyhaemoglobin (HbO2) and total haemoglobin (THb)) for each repetition and averaged across each set (1, 2, 3, 4, 5, 6) 
until completion. Data are presented as mean ± SD. 
 
  Set 
HbO2 (AU)  1 2 3 4 5 6 
 NormSham 158 ± 70 147 ± 64 148 ± 57 154 ± 55 157 ± 53 157 ± 50 
 NormIPC 151 ± 41 148 ± 41 154 ± 42 157 ± 45 160 ± 48 160 ± 48 
 HypSham 176 ± 69 162 ± 61 166 ± 60 172 ± 62 176 ± 64 176 ± 66 
 HypIPC 156 ± 55 148 ± 52 152 ± 52 158 ± 55 163 ± 57 163 ± 57 
  Set 
HHb (AU)  1 2 3 4 5 6 
 NormSham 87 ± 47 105 ± 55 104 ± 55 103 ± 55 103 ± 54 103 ± 54 
 NormIPC 90 ± 50 107 ± 63 107 ± 63 108 ± 66 106 ± 65 104 ± 64 
 HypSham 107 ± 51 129 ± 65 131 ± 68 130 ± 66 131 ± 68 132 ± 68 
 HypIPC 117 ± 74 138 ± 88 137 ± 88 139 ± 91 140 ± 92 141 ± 92 
   Set 
THb (AU)  1 2 3 4 5 6 
 NormSham 246 ± 86 254 ± 85 255 ± 82 259 ± 82 262 ± 81 262 ± 80 
 NormIPC 243 ± 72 257 ± 83 263 ± 89 267 ± 95 268 ± 99 268 ± 100 
 HypSham 285 ± 95 292 ± 96 298 ± 101 304 ± 105 308 ± 109 309 ± 111 





Performance Variables  
Both power output and work declined from set 1 to set 6 of the exercise protocol (Power: mean 
decline of 146 ± 13 W; 95% CI 134 to 158 W; p < 0.001; Work: mean decline of 264 ± 22 kJ; 
95% CI 244 to 283 kJ; p < 0.001), however with no differences between conditions (p = 0.84). 
 
Discussion 
The primary aim of this study was to determine whether the IPC mediated effects on 
neuromuscular fatigue in resistance-trained individuals are dependent on exercising tissue 
oxygenation. Contrary to our hypothesis, IPC did not affect any facet of neuromuscular fatigue 
regardless of exercise task or oxygen availability. IPC did however, lead to increased muscle 
O2 extraction in hypoxic exercise although this failed to manifest into any improvement in 
exercise performance.  
Previous studies have suggested any increase in skeletal muscle activation and subsequent 
attenuation of neuromuscular fatigue induced by IPC may be related to the chemo/metabo-
receptive group III and IV muscle afferents (Cruz et al., 2015; Cruz et al., 2016; Durand et al., 
2019; A. Hyngstrom et al., 2016; A. S. Hyngstrom et al., 2018). Specifically, Cruz and 
colleagues  proposed that IPC evokes a desensitization of group III/IV muscle afferents (via 
overstimulation and/or opioid receptor activation of metabo-receptors) that facilitates a 
reduction in motor drive inhibition (Cruz et al., 2015; Cruz et al., 2016; Cruz et al., 2017). 
Alternatively, Hyngstrom and colleagues propose IPC-mediated increases in muscle activation 
are achieved via the release of neuromodulators (norepinephrine and serotonin) as a result of 
afferent fibre stimulation, thereby increasing the excitability of spinal motor neurons (A. S. 
Hyngstrom et al., 2018). Regardless of mechanism, presumably any influence of IPC should 
have surfaced in acute changes in voluntary activation or potentiated twitch characteristics. 
However, consistent with our previous observations, IPC did not influence any of the 
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neuromuscular properties measured in the present study (S. L. Halley et al., 2018; Samuel L. 
Halley et al., 2019). Consequently, our collective results suggest that a number of confounding 
variables may have contributed to prior observations of increased sEMG activity. 
The contractions velocities of dynamic movements are known to reduce the stability of skin-
muscle interactions and confound sEMG signals recorded by surface electrodes (Farina et al., 
2010). Despite prior reports of IPC improving contraction and relaxation rates (Barbosa et al., 
2014), contraction velocity was uncontrolled in the aforementioned cycling studies, presenting 
an unaccounted variable for explaining the increase sEMG activity. We utilised an isokinetic 
dynamometer in to control for this variable in each of our studies, dynamic and isometric, with 
no observable differences in sEMG amplitude. Consequently, it is plausible that Cruz and 
colleagues may have observed augmented contractions velocities similar to Barbosa et al. 
(2014), rather than altered efferent signalling. The only other reports of increased sEMG 
activity have come in clinical populations, where Hyngstrom and colleagues observed acute 
increases in average RMS of the sEMG signals after IPC during MVCs (A. S. Hyngstrom et 
al., 2018). However, differences in participant characteristics (resistance trained vs stroke 
patients) may explain these discrepancies as stroke patients may exhibit hyper-excitability in 
group III and IV afferents (Hidler & Schmit, 2004) which could have amplified the IPC 
modulated increases in neural drive. Without this hyper-excitability present in a healthy 
population, the IPC effect may be too small to detect. 
In the current study, the use of hypoxia was unable to invoke neural responses to IPC. In 
contrast however, the introduction of hypoxia to the exercise protocol appeared to induce a 
humoral response, in the form of enhanced peripheral haemoglobin kinetics. During hypoxic 
exercise, TSI% was reduced by ~ 3% while HHb content was increased by nearly 7%, relative 
to the respective sham condition (Fig. 5.2). As IPC decreased TSI% without changes in THb 
levels, this suggests enhanced muscle O2 extraction and increased muscle oxidative capacity 
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(De Blasi et al., 1994; Grassi et al., 2003). We’ve previously shown IPC to induce similar 
increases in muscle O2 extraction during isometric, but not dynamic, maximal leg extension 
protocols (S. L. Halley et al., 2018; Samuel L. Halley et al., 2019). These similar humoral 
responses intuitively suggest a common trigger for IPC. The subsequent non-effects within the 
normoxic and dynamic trials indicates that tissue deoxygenation may be responsible for the 
triggering. The reduction of FiO2 in the current study invoked a humoral response by inhibiting 
haemoglobin-myoglobin O2 offload and ameliorating exercise induced muscle ischemia 
(Russell S. Richardson et al., 2006; R. S. Richardson, Noyszewski, Kendrick, Leigh, & 
Wagner, 1995; Takakura et al., 2017). It’s plausible that a similar humoral response was 
triggered by exacerbated exercise-induced ischemia in the isometric study. The sustained high 
levels of intramuscular pressures likely restricted arterial inflow to the working muscle thereby 
increasing tissue deoxygenation (R. Broxterman et al., 2015; R. M. Broxterman et al., 2015; 
Dempsey & Wagner, 1999; McNeil et al., 2015). As the dynamic protocol permitted consistent 
perfusion, the exercising muscle was unlikely to become sufficiently deoxygenated and similar 
to the normoxic trial, failed to trigger a humoral IPC response. Consequently, it can be inferred 
that exercising tissue deoxygenation may can act as trigger for the humoral responses to IPC.  
Although the purpose of this thesis was centred on the mechanism of IPC rather than the 
performance effect, the negligible effects on performance were somewhat unexpected. We 
hypothesised that the effects of IPC would be proportional to the stress imposed by the exercise 
protocol. Specifically, in study 3, we anticipated our model to show a negligible performance 
effect in normoxia and a relative increase in performance in the hypoxia. This was based on 
the work of Paradis-Deschenes et al. (2018) showing that the relative ergogenic effect of IPC 
increased when the imposed hypoxic stress increased during a 5km cycling time trial (FIO2: 
0.180, +1.1±1.1%; FIO2: 0.154, +1.5±0.7%). Conversely, our model found that IPC had a 
negligible impact on performance (no change in work or average power) in both normoxic and 
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hypoxic conditions. A plausible explanation for the lack of performance effect is that the 
hypoxic dosage was insufficient to significantly impair performance for the given exercise 
modality. Although moderate hypoxia (13-17% FIO2) preferentially impairs exercises with 
large aerobic energy contributions (Deb et al., 2018; Girard, Brocherie, & Millet, 2017), repeat 
sprint exercises (~5-10 reps of ~5-10s) are nonetheless effected (~5-10% mechanical work) 
(Balsom, Gaitanos, Ekblom, & Sjodin, 1994; Billaut & Buchheit, 2013; Brosnan, Martin, 
Hahn, Gore, & Hawley, 2000; K. J. Smith & Billaut, 2010). This research (in addition to our 
pilot testing) suggested that our model should have been sufficient in impairing repeated sets 
of maximal leg extensions. However, these findings were sourced from whole body exercises, 
not single limb. Within the sham trials of our single limb exercise model, there appeared to be 
no detrimental effects of moderate hypoxia (14% FIO2) on performance (ΔAve Power Output 
NormSham vs HypSham: 2.9%). In comparison, hypoxia impaired average power output in 
the 5km cycling TT by -14.1% (Paradis-Deschenes et al., 2018). Moreover , whilst both studies 
observed similar baseline TSI% values of ~70%, the average TSI% value in HypIPC was 
57.2% compared to that of 34.6% in Paradis-Deschenes et al. (2018). This is despite the fact 
that the fractional inspired O2 of our hypoxic conditions (FIO2: 0.14) were comparatively 
greater than that of Paradis-Deschenes and colleagues (FIO2: 0.154). Consequently, a more 
severe dosage of hypoxia (FIO2: ~0.10) may have proved more effective in impairing exercise 
performance in our single limb exercise protocol, thus creating a larger spectrum for the 
physiological benefits of IPC to manifest into performance benefits (Alhammoud et al., 2018; 
Christian et al., 2014; Stuart Goodall, Twomey, & Amann, 2014; Kawahara, Saito, Kashimura, 
& Muraoka, 2008). Nevertheless, although the moderate hypoxia provided a platform to 
observe physiological changes, it may have been inadequate to sufficiently impair exercise in 




This study primarily focussed on the mechanisms of IPC, rather than the performance effects. 
Accordingly, an intermittent isokinetic exercise protocol was used in order to comprehensively 
profile factors of muscle fatigue throughout the exercise with the aid of regular intermissions, 
akin to Christian et al. (2014). Although the subsequent fatigue profiles remained unaffected, 
the hypoxia-specific humoral response confirmed the presence of an IPC effect. This 
combination of findings validated the use of our study design to elicit and observe the 
mechanisms of IPC. However, the mechanistic focus of the intermittent exercise protocol then 
most likely inhibited the transfer of physiological effects to performance enhancements. The 
Salvador et al. (2016) meta-analysis found IPC more likely to improve aerobic tasks (vs 
anaerobic) with larger enhancements observed in tasks to failure (vs fixed-endpoint tasks e.g. 
time trials and fixed repetition tasks). Perhaps unsurprisingly, these parameters also run parallel 
with our proposal of tissue oxygenation as a trigger for IPC. As such, any respite from muscle 
deoxygenation throughout exercise would oppose the inaction of the humoral responses. 
Consequently, the intermittent nature (6 set x 11 reps: 20 s rest between sets) of our exercise 
protocol, whilst permitting concurrent fatigue profiling, was unlikely to benefit from a 
performance effect. Future studies replicating our study design may look to extend the final set 
of the EP to a point of failure similar to Tanaka et al. (2016). This would further promote tissue 
deoxygenation to trigger humoral effects more likely to lead to performance effects. 
Alternatively, the use of greater hypoxic dosages may also contribute similar alterations to 
tissue oxygenation. We utilised a more severe hypoxic dosage (FiO2: 0.14) than previous IPC 
research (FiO2: 0.154) (Paradis-Deschenes et al., 2018) in anticipation of the differential effects 
of hypoxia between exercise modalities (Deb et al., 2018). However, an increase in hypoxic 
severity could provide an alternative pathway to observe the performance effects of IPC 
(Amann et al., 2007; Christian et al., 2014). 
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A consistent limitation of IPC research is the inability to provide a convincing blinding for 
participants due to the significant pressure differences between the sham and IPC protocols. 
To account for this in the present study, participants were confounded with information that 
both low and high pressure treatments may influence performance and furthermore, they were 
naïve to the environmental condition that they were exposed to in each trial. The efficacy of 
this measure to control for any placebo effect is apparent in similarities between all 
performance outcomes and strengthened by the clear differences in muscle oxygenation 
measures between the sham and IPC conditions. Coupled with the indifferences in Pre-Post 
MVC and RT reductions (~ 36%, ~ 32%) across all conditions, it’s clear that no placebo effect 
was present.  
 
This experiment utilised hypoxia to investigate the influence of tissue oxygenation on the 
purported IPC mediated effects on neuromuscular fatigue in resistance-trained individuals. 
Contrary to our hypothesis, IPC did not affect any facet of neuromuscular fatigue regardless of 
environmental conditions. The introduction of hypoxia did however invoke a humoral 
response, improving muscle O2 extraction during exercise. Further research into the influence 










Summary of Findings 
The purpose of this thesis was to investigate the capacity for IPC to elicit neurally mediated 
ergogenic benefits during exercise performance. To address this purpose, three specific 
research aims were implemented with three independent experimental studies. 
 
The first aim of this series of investigations was to assess the influence of IPC on central and 
peripheral fatiguing mechanisms during sustained maximal isometric exercise. The results of 
study 1 found that IPC posed no influence over parameters of neural drive. In spite of IPC 
enhancing both skeletal muscle oxygen delivery and extraction, there were no concomitant 
increases in exercise performance. The lack of a performance effect in spite of improved 
muscle oxygenation suggested that the prevention of adequate muscle perfusion by the 
sustained isometric contraction limited the transfer of physiological responses into enhanced 
performance. It was interpreted that this may have also impaired the observation of any neural 
effect. 
 
Subsequently, in light of these preliminary findings, study 2 modified the exercise protocol to 
a dynamic contraction to continue to investigate the capacity for IPC to modulate neural drive. 
In spite of this modification, IPC failed to influence parameters neural drive once more. In 
addition, the modification to a dynamic exercise protocol reduced the level of imposed exercise 
stress and in doing so, may have failed to evoke the humoral benefits of IPC. The failure to 
evoke humoral physiological responses may have also impaired the proposed neuromuscular 
modulation leading to increased muscle activation. 
 
As in inferred by the findings from Chapters 3 & 4, the final study of this series continued the 
investigation into capacity for IPC to increase muscle activation. The exercise protocol once 
again increased in complexity by combining dynamic contractions with manipulations to 
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increase the level of exercise stress. Hypoxia was introduced to a modified version of the 
existing protocol, in the attempt to induce IPC mediated neuromuscular modulations leading 
to increased muscle activation. Keeping with prior findings, IPC posed no influence over 
measures of central or peripheral fatigue development. Although, the use of hypoxia did induce 
the humoral benefits from IPC, supporting the hypothesis of a task-dependant induction of 
physiological responses, this was again without concomitant increases in performance. 
 
Collectively, this thesis provides evidence that IPC is unable to elicit neuromuscular benefits 
pertaining to increased neural drive in single limb maximal exercise. It is however, indicative 
that the humoral response to IPC is relative to the level of exercise stress imposed. 
 
Insights on the effect of IPC on neural drive  
Previous studies have demonstrated potential for IPC to modulate neural drive during maximal 
intensity exercise. However, the measures used to quantify these neural effects possess 
drawbacks that limit the validity of prior inferences. Therefore, this thesis aimed to use 
measures of central (voluntary activation) and peripheral (resting twitch) fatigue to assess the 
capacity of IPC to modulate of neural drive with more precision and specificity than previous 
investigations. 
 
Indirect measures have suggested that IPC can modulate the function of type III and IV muscle 
afferents, leading to enhanced skeletal muscle activation during intense exercise (Crisafulli et 
al., 2011). Progressions of this theory has since outlined a number of viable pathways that IPC 
could employ to interfere with type III and IV muscle afferent feedback in order to attenuate 
the development of central fatigue (Amann et al., 2009; Cruz et al., 2015; Dragasis et al., 2013; 
Endres-Becker et al., 2007). Regardless of the exact mechanism of any of these pathways, any 
imposition on afferent function should have impacted parameters of central and peripheral 
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fatigue development (Hureau et al., 2019). However, such an impact was not observed in any 
of the three studies. Consequently, in the context of single limb maximal isokinetic exercise, 
IPC did not facilitate an overshoot of neural drive (via afferent discharge modulation) resulting 
in the preservation of muscle activation. 
 
The findings of this thesis contradict prior interpretations of IPC increasing skeletal muscle 
activation during intense exercise. Furthermore they also concur with recent research, which 
found IPC to be ineffective in influencing the metaboreflex action of type III and IV afferent 
fibres (Incognito, Doherty, Lee, Burns, & Millar, 2017; Mulliri et al., 2016). In combination 
with this research, it appears more likely that prior observations of increased muscle activation 
during maximal cycling exercises may have instead reflected increased work capacity of the 
muscle enabled by humoral responses. 
 
An alternative neural avenue of IPC proposes that increased muscle excitability may lead to 
enhanced muscle activation. Hyngstrom and colleagues reported that rather than impairing 
central fatigue development, IPC could actually increase the excitability spinal motor neurons 
in order to acutely increase neuromuscular output (Durand et al., 2019; A. Hyngstrom et al., 
2016; A. S. Hyngstrom et al., 2018). However, no acute increases in neuromuscular output 
were observed during any experiment of this theses. An explanation to this contrast in findings 
may have already been provided by Hyngstrom and colleagues. An afferent fibre hyper-
excitability compensation phenomenon specific to stroke afflicted participants has been 
suggesting to be an integral component to engage this pathway. As such, our findings may 
confirm that the absence of such a phenomenon can preclude healthy participants from the 





The relationship between the humoral benefits of IPC and the ischemic exercise threat 
A trend within existing literature shows that IPC may be more efficacious in exercises 
exhibiting degrees of muscle ischemia (swimming, apnoeic and hypoxic exercises). This trend 
has been supported in cycling time trials where the efficacy of IPC was shown to be 
proportional to the degree of hypoxic exposure. The physiological but not performance findings 
of this thesis have concurred with these observations. The exercise protocols used in Chapters 
3 and 5* (*hypoxic condition only) posed greater ischemic threats than the protocol of Chapter 
4. Accordingly, only oxygenation measures in Chapters 3 and 5* demonstrated any humoral 
benefits of IPC.  
 
As per previous discussions, it was proposed that the humoral effects in Chapters 3 and 5* were 
evoked by similar ischemic threats. Throughout the isometric protocol, high intramuscular 
pressures presumably impeded arterial inflow and perfusion of the exercising muscle. In 
Chapter 5, during hypoxic exercise, reduced fractional inspired oxygen similarly inhibited the 
delivery of oxygen to the working muscle. It was then presumed that in the absence of either 
sustained high intramuscular pressures or hypoxic breathing, the 3 min AOT protocol failed to 
engage any humoral benefits of IPC. It’s unknown what aspect of the ischemic threat triggered 
the increase in oxygen delivery and extraction in Chapters 3 and 5*. Clinical research has 
identified the upregulated ROS concentrations present in sub-lethal myocardial as significant 
contributors for myocardial protection (Costa & Garlid, 2008; D. J. Hausenloy & Yellon, 2008; 
Kalogeris et al., 2014). However, comparative extents of ischemia may not occur within 
exercising skeletal muscle. As such, it may be the case that upregulated ROS within exercising 
muscle may be achieved through the combination of tissue deoxygenation and also a significant 
increase in the demand for ATP synthesis. This combination would be sufficient to 
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substantially increase proton motive forces to the extent of disrupting mitochondrial function 
resulting in increased oxidative stress (B. Kadenbach, 2003). The degree of exercise induced 
oxidative stress produced during these activities could have effected both endothelial and 
mitochondrial function to a greater extent than during the 3 min AOT. Nevertheless, the results 
of this thesis support a positive relationship between severity of exercise-induced muscle 
ischemia and the engagement of the humoral benefits of IPC. 
Limitations 
 
The purpose of this thesis was to investigate the capacity for IPC to influence the development 
of central and peripheral fatigue. In the context of this thesis, the development of central fatigue 
was assessed through interactions between measures of voluntary activation and 
neuromuscular function throughout the experimental trials. However, in all three studies of this 
experiment, the pre-to-post exercise changes in voluntary activation were minimal. This 
provided a narrow scope in which to observe any influence of IPC on central fatigue 
development, potentially increasing the chances of a type II error. Although no measures 
relating to central fatigue (VA, sEMG parameters) were found to be influenced by IPC, 
exercise protocols inducing greater decrements in voluntary activation may have reduced the 
probability of type II errors. 
 
Previous work from Crisafulli and colleagues has utilized Doppler imaging to determine 
whether or not sufficient pressure was applied to achieve arterial occlusion. This work found 
that occlusion pressures varied between individuals and this subsequently resulted in the 
development of personalized occlusion pressures consisting of SBP + 50mmHg. The 
experiments within this thesis did not replicate the use of Doppler imaging to guarantee arterial 
occlusion. Furthermore, all experiments employed standardized pressures of 220mmHg across 
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all individuals, as per the majority of studies within IPC literature. Nonetheless, live analyses 
of TSI and THb NIRS parameters during limb occlusion revealed that in every individual, the 
use of 220mmHg pressures was sufficient to prevent arterial inflow and positive changes in 
tissue oxygenation.  
 
 
IPC research is plagued with the limitation of the inability to provide a convincing blinding for 
participants due to the significant pressure differences between the SHAM and IPC protocols. 
To account for this, in this thesis, participants were given information that both low and high 
pressure treatments may influence performance. Furthermore, in study 3, participants were 
naïve to the environmental condition that they were exposed to in each trial. The efficacy of 
this measure to control for any placebo effect is evidenced in similarities throughout all studies 
between all performance outcomes. Additionally, the clear changes in oxygenation measures 
were observed in studies 1 and 3, independent of performance outcomes. This rules out any 
motivational aspect that may have affected oxygenation measures as a result of influenced 
participant effort. This was also particularly important in small number of participants that 
participated in multiple experiments. Coupled with the indifferences in parameters of 
neuromuscular assessments across all conditions throughout all studies, it sufficed to suggest 
that no placebo effect was present. 
 
Future Directions  
The experiments of this thesis suggests that IPC does not elicit neuromuscular modulations 
during maximal intensity single limb exercise. However, these findings may be limited to the 
context of the single limb exercise modality/objective though. Fixed end-point tasks were used 
throughout all experimental protocols in this thesis in order to control for even amounts of 
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mechanical work. However, exercise tasks to failure have been shown to elicit greater effects 
from IPC. As such, the use of an extended protocol to fatigue in conjunction with the 
interpolated twitch technique may reveal different findings to a fixed end-point task. 
Furthermore, the production of specific ROS subtypes and locations vary between exercise 
modalities (aerobic whole body vs single limb isometric). Therefore, the use of single limb 
exercise may restrict the array of exercise-induced ROS species subtype. An avenue of IPC 
neural augmentation has been proposed to operate through the depravation of muscle afferent 
stimuli (including different forms of ROS). Therefore, in conjunction with the interpolated 
twitch technique, future research should also employ different exercise modalities. Thus, the 
manipulation of both exercise modalities and objectives could increase the understandings of 
the neural capabilities of IPC. 
 
Given the prominent role that oxidative stress plays within the IPC mechanism, all future 
performance research should endeavour to include assessments of oxidative stress and 
antioxidant function. In order to truly implicate the reduction of oxidative stress as a contributor 
to the ergogenic effects of IPC, future studies should attempt to accurately assess both ROS 
production and levels of antioxidant defence with regard to the guidelines of Nikolaidis et al. 
(2012). This is particularly pertinent to the continued investigations of the effect of IPC on 
exercises inducing muscle ischemia including hypoxic or apnoeic exercise. 
 
A methodological consideration for future studies may be the provision of a better strategy to 
overcome any sort of concern over placebo effects. The use of a low pressure treatment as a 
sham is currently the most common strategy to overcome placebo effects in IPC research. 
However recently, the inclusion of additional confounders has improved the quality of the 
experimental designs. McIlvenna et al. (2019) and Sabino-Carvalho et al. (2017) circumvented 
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the issues associated with low pressure sham protocols via the use of sham nitric oxide 
supplements and fake ultrasound therapy respectively. Where it is possible, experimental 
designs should endeavour to prevent participants from experiencing directly comparable 
pressure differentials in real and fake IPC treatments. The use of such creative alternative can 
improve the quality of study design. 
Conclusions 
This thesis suggests that IPC was unable to influence parameters of neural drive during and 
following maximal single limb isokinetic exercise in moderately trained male athletes. 
However, the findings do suggest a positive correlation between the hypoxic threat of the 
exercise protocol and the magnitude of humoral benefits elicited, a trend observed in review of 
the literature. Overall these findings provide novel insights into the mechanisms of the 
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preservation of skeletal muscle function (Cruz et al. 
2015, 2016; Hyngstrom et al. 2018). 
Recent clinical research has demonstrated acute 
improvements in maximal strength corresponding with 
increases in surface electromyography (sEMG) signal 
amplitude after IPC (Hyngstrom et al. 2018). Similarly, 
enhanced sEMG signals have been seen in both aerobic 
and sprint cycling, where increased sEMG to power out- 
put ratios have suggested that IPC increases skeletal mus- 
cle activation (Cruz et al. 2015, 2016). Based on these 
findings, it was suggested that IPC facilitated increased 
muscle activity via a disruption to the central feedback 
loop (Cruz et al. 2017). This disruption is proposed to 
arise through inhibited signaling from metabolically sensi- 
tive group III and IV afferent sensory fibers as a conse- 
quence of the metabolic autacoids produced during the 
IPC cycles (Downey et al. 2007; Redington et al. 2012; 
Amann et al. 2013; Blain et al. 2016; Burns et al. 2016; 
Cruz et al. 2017). However, whilst sEMG can provide an 
estimate of gross nervous system output, the multitude of 
unrelated factors contributing to the signal amplitude 
confounds any mechanistic insight as to where within the 
neural circuitry IPC may be conferring its effect (Farina 
et al. 2010). In light of this, we recently used the interpo- 
lated twitch technique during a maximal, 2-min isometric 
leg extension task to better clarify whether IPC influences 
centrally mediated factors (e.g. neural drive) associated 
with maintaining task performance (Halley et al. 2018). 
Contrary to previous reports (Cruz et al. 2015, 2016), we 
did not observe an effect of IPC on sEMG amplitude nor 
did we see any improvement in the additional measures 
of neural drive (e.g. voluntary activation) (Halley et al. 
2018). 
A notable point of difference between these studies, 
however, was our use of a static, prolonged maximal vol- 
untary contraction (Halley et al. 2018) while the cycling 
tasks were more dynamic in nature (Cruz et al. 2015, 
2016). Although we hypothesized the sustained maximal 
effort would provide a favorable environment for IPC to 
influence neural drive (Taylor et al. 2000; Martin et al. 
2006), the isometric task may have restricted skeletal 
muscle oxygen delivery through augmented intramuscular 
pressures (McNeil et al. 2015). Moreover, the increased 
neural activity observed in both cycling studies was asso- 
ciated with IPC-mediated improvements in aerobic energy 
provision (as inferred via augmented hemoglobin kinet- 
ics) and therefore endurance capacity (Cruz et al. 2015, 
2016). More recently, Griffin and colleagues have also 
demonstrated significant improvements in the ability to 
sustain maximal rates of aerobic metabolism (e.g. critical 
power) after IPC, but conversely, did not observe a differ- 
ential effect on skeletal muscle oxygenation (Griffin et al. 
2018). As these authors did not measure neural activity, 
we cannot discern whether IPC-mediated preservation of 
neural signaling compensated for the negligible change in 
aerobic energy provision. 
Therefore, the aim of this study was to determine 
whether IPC, coupled with a dynamic exercise task 
designed to optimize oxygen delivery to skeletal muscle, 
augments neural drive during fatiguing exercising. Specifi- 
cally, we examined whether a standard bout of IPC   
(3 9 5 min cycles) better preserves muscle activity dur- 
ing, and voluntary activation following a 3-min maximal 
power test comprised of rhythmic dynamic single-leg 
extensions. Given recent evidence (Cruz et al. 2015, 2016; 
Tanaka et al. 2016), it was hypothesized that IPC would 
improve performance of the test through an attenuation 
of centrally mediated declines in neural drive (e.g. volun- 





All procedures in this study were approved by the Wes- 
tern Sydney University Human Research Ethics Commit- 
tee (approval code H12114) and were conducted in 
accordance with the Declaration of Helsinki, except for 
registration in a database. Ten resistance trained men 
with a minimum training history of at least two resistance 
training sessions per week for the previous 6 months 
(mean ± SD) (age: 24.1 ± 3, weight: 80.5 ± 7 kg) volun- 
teered to participate in this study after providing 
informed written consent. Minimum sample size was cal- 
culated from an a priori power analysis employing the 
small effect size threshold value of d = 0.2 as the indica- 
tion of the smallest worthwhile change using a cus- 
tomized spreadsheet (Hopkins 2006). 
 
Experimental design 
A study flow diagram is provided in Figure 1. During a 
preliminary session, participants were familiarized with all 
procedures involved in the study and provided with pret- 
est guidelines in regards to restriction of caffeine (12 h), 
alcohol (24 h), strenuous lower body exercise (48 h), and 
instructions as to replication of caloric and macro intake 
(24 h) prior to the experimental trials. The preliminary 
session included exposure to the femoral nerve stimula- 
tion protocols during a 3–5 sec maximal voluntary iso- 
metric knee extension contraction (MVC), the fatiguing 
protocol (a 3-min all out maximal power dynamic single- 
leg extension test (AOT)) and the IPC protocol. All test- 
ing was performed in a climate controlled laboratory 
(mean ± SD)  (temperature:  23 ± 1°C;  humidity: 
50 ± 3%), at the same time of day and on the right leg 
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dynamometer (Biodex Pro 4). Participants were posi- 
tioned upright in the dynamometer with thigh/trunk and 
knee angles of 90°, and the centre of rotation of the lever 
arm aligned with the sagittal plane axis of the knee joint. 
Participants were secured with an adjustable thigh strap 
and contralateral diagonal shoulder straps securing the 
trunk. A padded ankle cuff was placed superior (3 cm) to 
the lateral malleolus. Prior to performing exercise, partici- 
pants completed a standardized warm up of six submaxi- 
mal, 2–3 sec isometric contractions (2 9 25%, 2 9 50%, 
and 2 9 75% of perceived maximal effort). Torque out- 
put signals were directly sampled from the dynamometer 
at 1000 Hz (Powerlab, ADI Instruments, Sydney, NSW, 
Australia) and low pass filtered at 10 Hz. Torque signals 
were calibrated for each participant’s limb weight (follow- 
ing positional securing via straps), and a predetermined 
calibration factor was applied for conversion of the 
recorded voltage to units of torque (Nm). For baseline 
measures four MVCs were performed; two with supra- 
maximal nerve stimulation (see Femoral Nerve Stimula- 
tion) and two without, with one minute rest between 
each effort. The highest of the four MVCs was used as 
the BL value. Thereafter, only 1 MVC was performed pre 
and post the exercise task (e.g. AOT). Each MVC was 
instructed to be performed as hard and as fast as possible 
and maintained for 3–4 sec. Strong verbal encouragement 
was provided during all MVCs. The maximal torque mea- 
sure recorded for each MVC was taken as the highest tor- 
que value achieved during the contraction prior to the 
nerve stimulation. CVs of 5% and 9% were recorded for 
MVCs and rates of torque development (RTD) between 
trials, similar to previously published CV values (Place 
et al. 2007; Buckthorpe et al. 2012). 
 
Femoral nerve stimulation 
A 4 9 3 cm aluminium foil strip coated with Conductive 
Adhesive Hydrogel (Ten20; Weaver and Company, Aur- 
ora, CO) was placed on the lateral aspect of the hip, infe- 
rior to the iliac crest, as the anode. To identify nerve 
location for cathodal stimulation of the femoral nerve 
(Digitimer model DS7AH stimulator, Welwyn Garden 
City, UK), a rubber-insulated portable cathodal probe 
was used. The probe was moved around the femoral tri- 
angle using a stimulus intensity of 30 mA until the largest 
muscle compound action potential (M-wave) was elicited 
from both the VL and VM recording sites. For all stimu- 
lations,  a  200 lsec  square-wave  pulse  was  applied  at 
400 V, with each stimulation being a doublet (two pulses 
applied to the femoral nerve with a 100 msec inter stimu- 
lus interval; 10 Hz stimulation). When the optimal nerve 
location was identified it was marked with a felt-tip pen 
and a 20 mm diameter surface electrode was applied 
(Kendall 700; Tyco Healthcare Group, Mansfield, MA). 
Thereafter, stimulus intensity was increased in 10 mA 
increments with 20 sec rests between stimuli until pla- 
teaus in VL and VM M-wave amplitudes (Mmax) and the 
size of the knee-extensor twitch torque were observed. 
The maximal stimulus intensity (in milliamperes) was 
recorded and multiplied by 130% to establish the test 
intensity (range for participants 70–290 mA; VL Mmax 
13.1 ± 6.8 mV and VM Mmax 12.1 ± 3.7 mV). Twitch 
torque CVs of 2.2% were recorded across trials, similar to 
that of previous reliability studies (Place et al. 2007). 
 
Surface EMG (sEMG) 
Knee extensor sEMG was recorded during the experimen- 
tal trials with Ag–AgCl surface electrodes (Maxsensor; 
Medimax Global, Seven Hills, NSW, Australia) positioned 
over the vastus medialis (VM) and vastus lateralis (VL) 
on the right thigh. Electrodes were placed in the centre of 
the muscle belly with the inferior VL and VM electrodes 
positioned 8–12 cm and 3–4 cm from the lateral aspect 
of patella, respectively. A self-adhesive reference electrode 
was attached to the patella on the left leg. All placement 
sites were shaved, exfoliated and cleaned with an alcohol 
swab, while electrodes and cables were also taped to avoid 
any movement artefact. Electrode placement was recorded 
to ensure consistency within and between testing sessions. 
Raw electrode output was preamplified and bandpass fil- 
tered, with a bandwidth frequency ranging from 20 to 
500 Hz (common mode rejection ratio > 90 dB; impe- 
dance input = 100 MO; gain = 1000). Peak and maximal 
rate of amplitude development were quantified for both 
VM and VL. Processing of all neuromuscular data was 
performed using MATLAB software (R2010a; The Math- 
Works Inc., Natick, MA). 
 
Near-infrared spectroscopy (NIRS) 
Oxygenation status of skeletal tissue was assessed using a 
spatially resolved, dual wavelength NIRS apparatus 
(moorVMS-NIRS; Moor Instruments Ltd, Axminster, 
Devon, UK). NIRS data were collected for tissue satura- 
tion index (TSI) as a percentage of haemoglobin oxygen 
saturation (%) and deoxyhemoglobin concentrations 
(HHb) in arbitrary units (AU). After cleaning the skin 
with an alcohol swab, the NIRS device was fixed directly 
above the belly of the rectus femoris muscle at the mid- 
point between the inguinal fold and the top of the patella 
on the most anterior aspect. The device was fitted with 
an adhesive black silicone mould to reduce movement 
artefact and eliminate potentially interfering background 
noise. Skinfold thickness was measured at the site of the 
application   of   the   NIRS   (Cx ¼ 12:8 mmÞ    using   a 
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Harpenden skinfold calliper (British Indicator Ltd., Bur- 
gess Hill, West Sussex, UK) during the familiarization ses- 
sion, and was less than half the distance between the 
emitter and the detector (i.e. 30 mm). This thickness is 
adequate to let near infrared light through muscle tissue, 
and coupled with the anatomical location of the NIRS, 
minimizes measurement variation. The position on the 
participant was noted and replicated in the following tri- 
als. The pressure cuff was positioned above the NIRS 
device, which did not affect the placement of the device 
during occlusions. A modified form of the Beer-Lambert 
law, using two continuous wavelengths (760 and 850 nm) 
and a differential optical path length factor of 4.95, was 
used to calculate micro molar changes in tissue hemoglo- 
bin concentrations. NIRS data were acquired at 5 Hz. At 
rest, once positioned within the dynamometer, the signal 
was stabilized and 1 min of baseline values was analyzed 
pre intervention. The NIRS signals were recorded 
throughout the experimental trials with average values 
reported at baseline, during the intervention and 
throughout the AOT. Peak values were also reported dur- 
ing the intervention and throughout the AOT. The times 
to peak HHb concentrations, measured from the start of 
the AOT, were also reported. 
 
Data processing 
During all MVCs, the following torque variables were 
recorded: (i) the maximal voluntary torque (MVT; in 
Nm), calculated as the highest torque value throughout 
the entire MVC; and (ii) the maximal rate of torque 
development  (RTDmax;  in  Nm sec-1),  calculated  as  the 
greatest average 10 msec slope of the torque–time curve 
during the initial 100 msec of the contraction. 
Voluntary activation (VA) was estimated using the 
superimposed twitch technique (Merton 1954) according 
to the following formula (Strojnik and Komi 1998): VA 
(%) = 100 - [D 9 (Tsup/MVT)/RT] 9 100, where D is 
the difference between the torque level immediately before 
the superimposed twitch (Tsup) and the maximal torque 
recorded during the twitch, MVT is maximal voluntary 
torque during the entire contraction (not including the 
twitch response), and RT is the maximal amplitude of the 
resting potentiated twitch. The following variables were 
calculated from the resting potentiated twitch: (i) RT 
amplitude (in newton metres (Nm)); (ii) time to peak 
torque production derived from the RT (TTP; in millisec- 
onds (msec)); (iii) the half-relaxation time (½ RT; in 
msec), which was defined as the time elapsed from the 
peak twitch torque to 50% peak twitch torque. 
The following variables were processed from each MVC 
for VL and VM sEMG signals: (i) maximal sEMG ampli- 
tude of VL (VLmax) and VM (VMmax), processed as the 
greatest average root mean square over a 250 msec period 
from the beginning of the contraction to prior to the 
supramaximal stimulation; and (ii) maximal rate of 
sEMG rise (VLRERmax and VMRERmax), calculated 
from the greatest average 10 msec slope throughout the 
initial 100 msec of the contraction. All sEMG signals were 
normalized to their respective M-wave. 
From the AOT the following performance variables 
were recorded: (i) end test power (ETP); calculated as 
the average peak power output from the repetitions per- 
formed in the last 30 sec of the test, (ii) work above end 
test power (W^ETP); calculated as the sum of work 
completed above ETP, (iii) peak power output (PPO); 
calculated as the highest five point running average of 
power output and (iv) total work done (TWD). Peak VL 
and VM signals were also collected for each repetition of 
the AOT and analyzed as an average signal amplitude 
during the ETP, W^ETP, and PPO periods of the test. 




Descriptive data are presented as mean ± SD. All statisti- 
cal analyses were completed using IBM SPSS Statistics 
version 25 (SPSS Inc., Chicago, IL). The Shapiro–Wilk 
test was applied to assess normality of distribution. ETP, 
W^ETP, PPO, TWD, and NIRS data were analyzed for 
differences using a one-way ANOVA for repeated mea- 
sures. BL, Pre, and Post neuromuscular assessment data 
(MVT, RTDmax, VA, VLmax and VMmax, VLRERmax, 
and VMRERmax and RT) were analyzed using a two-way 
(condition 9 time) ANOVA for repeated measures. In 
the event of a significant F ratio, post hoc comparisons 
were made using a Bonferroni correction. Two-tailed sta- 
tistical significance was accepted at P < 0.05. Mean differ- 
ences with standard deviations (SD) were calculated when 
significant changes over time or when differences between 




Maximal torque production 
Maximal torque output was not different between BL 
(252 ± 46 Nm) and Pre (238 ± 44 Nm), but decreased at 
Post (151 ± 28 Nm) following the AOT (mean decline of 
87 ± 23 Nm,  95%  CI = -67  to  -107 Nm;  P < 0.001). 
There were no differences between conditions (P 0.75). 
Similarly, RTDmax did not change between BL 
(1709 ± 328 Nm-sec-1)  and  Pre  (1575 ± 376 Nm-sec-1) 
but decreased at Post (mean declines of 572 ± 124 
Nm-sec-1, 95% CI = -353 to -792 Nm-sec-1; 
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P < 0.001). There were no differences between conditions 
(P = 0.70). 
 
Descending central drive 
Voluntary activation was unchanged throughout the 
experimental trials (BL: 87 ± 7%, Pre: 85 ± 8%, Post: 
88 ± 5%; P = 0.72). There were no changes in peak 
sEMG amplitude or RERmax throughout the trials or 
between conditions for VL (Table 1). For VM, there was 
a main effect  of time  for peak sEMG  amplitude  
(P = 0.05), however, post hoc analysis revealed no pair- 
wise differences (Table 1). There were no differences 
between conditions in VM or VL sEMG measures in any 
variable throughout the AOT (Table 2.) 
 
Resting twitch characteristics 
The resting twitch torque declined from Pre after the 
AOT  (mean  decline  of  30 ± 13 Nm;  95%  CI = -25  to 
-35 Nm; P < 0.001; Table 3). The ½ RT (mean increase 
in 33 ± 26 msec; 95% CI = 14–51 msec; P < 0.01; 
Table 3) and TTP (mean increase in 16 13 msec; 95% 
CI = 6–26 msec; P < 0.01; Table 3) both increased after 
the AOT. There were no differences between conditions 




At BL there were no differences between conditions in 
TSI (CON: 68.7 ± 5.1%, SHAM: 67.5 ± 4.7%, IPC: 
67.7 ± 5.9%) or HHb (CON: 96 ± 31 AU, SHAM: 
104 ± 36 AU, IPC: 113 ± 41 AU). During the interven- 
tion, in the IPC condition peak HHb was elevated versus 
CON but not SHAM (mean increase vs. CON of 99 95 
AU; 95% CI = 4 to 195 AU; P < 0.05, vs. SHAM  
85 ± 92 AU; P = 0.07; Table 4) and average TSI was 
lower versus both CON and SHAM (mean decrease vs. 
CON of 10.6 ± 5.9; 95% CI = -5 to -16%; P < 0.001, 
vs. SHAM 8.0 ± 6.3%; 95% CI = -2 to -14%; P < 0.05; 
Table 4). During the AOT, there were no differences 
between conditions for either W^ETP or ETP in average 
or minimal tissue saturation (TSI) or maximal or average 
deoxyhemoglobin (HHb). There was no difference 




There were no differences between conditions in ETP, 
Ave Power W^ETP, W^ETP, TWD, or PPO (Table 5). 
 
Discussion 
The primary aim of this study was to determine whether 
IPC would attenuate the decline in neural drive following 




365 ± 142 469 ± 193 
585 ± 300 396 ± 169 
13 ± 6 585 ± 384 
12 ± 6 567 ± 295 
844 ± 604 12 ± 6 10 ± 5 
850 ± 585 11 ± 5 11 ± 5 
524 ± 341 
732 ± 388 
16 ± 5 653 ± 345 
15 ± 6 763 ± 343 
12 ± 4 15 ± 4 
POST 12 ± 3 13 ± 4 14 ± 5 656 ± 444 815 ± 722 756 ± 401 10 ± 4 10 ± 5 12 ± 7 530 ± 349 424 ± 178 638 ± 335 
 
The sEMG data for VM (VMmax, VMRERmax) and VL (VLmax, VLRERmax), (all expressed as percentages of respective M-waves) for each MVC 
performed at baseline (BL), prior to the 3-min AOT (Pre) and post-3 min AOT (Post) for control (CON) (n = 10), sham (SHAM) (n = 10) and 
IPC (n = 10). Abbreviations: sEMG, surface electromyograms normalized to M-waves; VL, vastus lateralis; VM, vastus medialis; RERmax, maxi- 
mum rate of sEMG rise. 
BL 15 ± 4 16 ± 8 
PRE 
IPC SHAM IPC CON SHAM IPC CON SHAM CON SHAM IPC CON 
RERmax (%) Max (%) RERmax (%) Max (%) 
Table 1. Data are presented as mean ± SD.  
VM VL 
12 ± 6    8 ± 2    8 ± 3 8 ± 3 
ETP 13 ± 11 9 ± 2     10 ± 5     7 ± 2     7  ± 2 7 ± 3 
The sEMG data for VM and VL during the 3 min all out test 
(AOT), (all expressed as percentages of respective M-waves) aver- 
aged across during the time window of peak power output (PPO), 
power output above the plateau reached at the end of the test 
(W^ETP) and the plateau reached at the end of the test (ETP) for 
control (CON) (n = 10), sham (SHAM) (n = 10) and IPC (n = 10). 
Abbreviations: sEMG, surface electromyograms normalized to M- 
waves; VL, vastus lateralis; VM, vastus medialis. 
13 ± 7    9 ± 2    9 ± 3 8 ± 3 
W^ETP 15 ± 14 10 ± 2 
PPO 14 ± 15 10 ± 2 
Table 2. Data are presented as mean ± SD.  
VM (%) VL (%) 
 
CON SHAM IPC CON SHAM IPC 
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afferents due to opioid receptor activation by circulating 
endogenous opioids released during the IPC stimulus 
(Downey et al. 2007; Amann et al. 2009). Regardless of 
mechanistic pathway, any influence IPC might have on 
these sensory fibers should manifest in changes to measures 
of central drive (e.g. voluntary activation) (Babault et al. 
2006; Place et al. 2007; Amann et al. 2009). However, and 
consistent with our previous observations, IPC did not 
affect any measures of central fatigue used in this study 
(Table 3). Collectively, this raises the possibility that the 
increased sEMG activity observed in previous studies (Cruz 
et al. 2015, 2016; Hyngstrom et al. 2018) may be unrelated 
to central factors associated with neural drive. Alterna- 
tively, the increased sEMG signals reported in previous 
studies may be a result of the lack of control for contrac- 
tion velocity. Contraction velocity is known to confound 
sEMG measures because of the effect dynamic contractions 
have on the stability of the skin-muscle interaction and 
therefore the action potentials recorded by the surface elec- 
trodes (Luca 1997). Despite prior reports of IPC improving 
contraction and relaxation times, contraction velocity has 
not been controlled in previous studies and therefore is an 
unaccounted variable for explaining the increased sEMG 
activity (Barbosa et al. 2014). However, an isokinetic 
dynamometer was used to control and account for the 
contraction velocities in this study with no observable dif- 
ferences in sEMG amplitudes (Table 2). Consequently, it 
may be plausible that previous observations of increased 
sEMG activity were reflective of variations in contraction 
velocities rather than enhanced efferent drive. 
A dynamic fatiguing protocol was used in this study to 
ensure adequate muscle perfusion during exercise (Bailey 
et al., 2012a; Paradis-Deschênes et al. 2016; Tanaka et al. 
2016; Halley et al. 2018), and theoretically allow the IPC 
to promote the acute upregulation of vasodilatory factors 
such as adenosine and nitric oxide (Horimoto et al. 2000; 
Kontos 2001; Kimura et al. 2007) and preserve muscle 
function similar to previous reports (Cruz et al. 2015, 
2016). However, there was no notable preservation of 
muscle function throughout (Table 5) or following 
(Table 3) the dynamic protocol. Additionally, and in con- 
trast to our previous findings under isometric conditions 
(Halley et al. 2018), IPC did not increase hemoglobin vol- 
ume or accelerate oxygen dissociation (Table 4). We 
believe this disparate outcome in tissue saturation kinetics 
may be related to the severity of peripheral fatigue 
induced by the isometric protocol. Despite the shorter 
duration of the isometric protocol (2 vs. 3 min) (Halley 
et al. 2018), declines in muscle contractility were far 
greater than in the dynamic leg extension protocol (RT ~ 
32% lower and ½ RT ~ 33% longer) (Halley et al. 2018). 
The task demand (e.g. 100% MVC), coupled with the 
restricted muscle perfusion, may also explain the increase 
in localized O2 delivery after IPC (~35%) observed only 
in the 2-min isometric protocol (Halley et al. 2018). 
Interestingly, others reporting comparable humoral effects 
after IPC have observed performance improvements dur- 
ing lower intensity efforts (e.g. 20% MVC to task failure), 
albeit without a sham condition (Tanaka et al. 2016). The 
substantial difference in contraction intensity between 
these studies (20% vs. 100% MVC (Halley et al. 2018; 
Kraus et al. 2015)) may further suggest that the ergogenic 
effects of IPC are dependent on a combination of task 
demand and the extent of localized fatigue in the muscle 
(Marshall et al. 2015). 
IPC failed to elicit an ergogenic effect over any of the 
performance characteristics of the AOT, which is in direct 
contrast to the increase in critical power reported by Grif- 
fin and colleagues during a 3-min maximal cycling effort 
(Griffin et al. 2018). However, a closer inspection of the 
difference between critical power these authors report 
(IPC: 241 ± 65 W; SHAM: 234 ± 67 W) would suggest 




Figure 2. Data are presented as means ± SD. (A) Average power 
production at 10 sec increments throughout the AOT for control 
(CON) (n = 10), sham (SHAM) (n = 10) and IPC (n = 10). (B) 
Average tissue saturation index at 10s increments throughout the 
AOT for CON, SHAM and IPC. Abbreviations: the end test power 
(ETP), work done above the rate of end test power (W^ETP), total 
work done (TWD). 
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2018). Nonetheless, neither Griffin’s nor this study 
observed any effect of IPC on TSI during the exercise task, 
with both reporting around a 20–25% reduction regardless 
of condition from the start to the end of the 3 min (Fig. 2). 
This again may be a function of task demand, as others 
showing improvements during exercise to failure after IPC 
consistently demonstrate amplified and accelerated deoxy- 
hemoglobin dynamics (Griffin et al. 2018; Halley et al. 
2018). A recent meta-analysis gives further support, report- 
ing the likelihood of IPC providing an ergogenic benefit in 
time to failure tasks at nearly 6%, whereas only a 0.5% 
improvement persists in those incorporating fixed end- 
points (Salvador et al. 2016). In many of the fixed-end- 
point tasks (excluding repeat sprints), there have also been 
incidences of improved oxygen delivery in the absence of 
any performance (Zinner et al. 2017; Halley et al. 2018; 
Turnes et al. 2018). Whilst it is well established that IPC 
induces the production of vasodilatory factors (nitric 
oxide, adenosine, etc.) (Kimura et al. 2007), the attenua- 
tion of oxidative stress and preserved mitochondrial func- 
tion may play a greater role in improving performance 
(Semenza 2011). In relation to task demand, tasks to failure 
may benefit to a greater extent from attenuations in oxida- 
tive stress than in fixed-endpoint tasks. The exception to 
this might be when additional stressors are imposed during 
the fixed-endpoint tasks to induce a comparable oxidative 
stress, such as exercising in hypoxia (Kjeld et al. 2014; Par- 
adis-Deschenes et al. 2018). For example, the ergogenic 
effect of IPC on 5 km cycling time trial (fixed-end point) 
performance has been shown to increase under progres- 
sively hypoxic conditions (FIO2 0.18: +1.1%; FIO2 0.15: 
+1.7%) (Paradis-Deschenes et al. 2018). 
A consistent limitation of IPC research is the inability 
to truly blind participants to the significant pressure dif- 
ferences between the SHAM and IPC protocols. To 
account for this in this study, participants were informed 
that both conditions may influence performance; how- 
ever, they were na€ıve to the expected outcome. The effi- 
cacy of this control measure was evidenced in the lack of 
difference between performance responses, consistent 
MVC and RT reductions (~ 36%, ~ 32%) and the similar 
magnitude and timing of peak deoxygenation levels (~139 
AU, ~35 s) across all IPC and SHAM trials. 
 
Conclusion 
This experiment used a dynamic, 3-min leg extension 
protocol to promote muscle oxygenation in order to 
assess the effect of IPC on exercise-induced reductions in 
voluntary activation and sEMG amplitudes. Our findings 
suggest that IPC does not influence voluntary activation 
to the muscle during such a task, nor does it affect tissue 
oxygenation or functional measures of performance. 
Future research investigating the influence of task demand 
and exercise severity is warranted to further explore the 
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